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ABSTRACT 
 
 
  
 II 
Analysis of biased signaling in the chemokine system. 
Chemokines constitute a family of almost 50 small secreted cytokines, recognized by about 20 
different 7TM spanning G protein coupled receptors (GPCRs), that activating pertussis toxin sensitive G 
proteins induce cell migration. These receptor are abundantly expressed by leukocytes and, controlling 
cell migration, they dictate leukocyte positioning during homeostatic patrolling within peripheral 
tissues, their maintenance in bone marrow during maturation and in addition mediate their recruitment 
to inflamed tissues. Upon inflammation in fact a number of chemokines are produced or activated by 
inflammatory mediators and diffuse within the tissue, generating a chemical gradient along which 
leukocytes migrate to reach the center of inflammation to contain and remove the insulting factor. This 
system needs an extremely tight control, since its dysregulation has been demonstrated to be at the 
basis of different inflammatory diseases, auto-immunity and has also been linked to cancer 
development. In particular, in this thesis we focused our attention on two regulatory system: post-
translational modifications of chemokines, mediated by enzymes specifically released upon 
inflammation also by immune cells, and on the activity of atypical chemokine receptors, a subfamily of 
chemokine receptors that despite high structural homology and similar binding properties compared to 
conventional chemokine receptors, are unable to drive chemotaxis but act instead as key regulators of 
the chemokine system activity. In detail we looked at the ability of these regulatory mechanisms to 
modulate chemokine signaling properties generating a biased signaling, an emerging feature of GPCR 
pharmacology that describes the ability of a given receptor to elicit different or even opposite functional 
activities depending on the ability of different agonists to stabilize different receptor’s active structural 
conformation, resulting in different phenotypes mediated by the same receptor. In the chemokine 
system biased signaling has already been described to occur on different receptors upon binding of their 
different ligands, therefore during our investigation on chemokine regulatory system signaling we 
maintained our focus on the ability of these systems to bias chemokine signaling properties in order to 
better understand how this regulation occurs. 
To this point we assessed the ability of differently post-translationally modified chemokines to 
elicit signaling activities on different receptors by measuring in HEK293 cells their potential in inhibiting 
adenylyl cyclase, a proximal downstream signal of Gα inhibitory proteins activation, and in inducing β-
arrestin recruitment to the receptors in energy transfer-based assays. We also compared signaling 
properties of an atypical chemokine receptor to the ones elicited by a conventional receptor analyzing 
the phosphoproteome modifications occurring constitutively and after stimulation with the same 
agonist.  
Our results indicate that regulation of CXCL5 and CXCL8 chemokine activity by post-translational 
modifications is more prone to regulate chemokine activity modifying chemokine potency, rather than 
generating a bias in their signaling properties. Truncation of chemokine NH2-terminus increases both 
 III 
CXCL5 and CXCL8 activity, while citrullination of the most NH2-terminal arginine results in opposite 
effects on the two agonists since on CXCL8 increases chemokine potency, while it reduces CXCL5 
activity. We investigated the properties of ACKR2 in recruiting β-arrestins, demonstrating that this 
receptor is able to associate both β-arrestin 1 and 2 in basal conditions while upon agonist stimulation 
preferentially increases its association with β-arrestin 1, resulting in a completely different agonist-
induced outcome of proteome phosphorylation, compared to CCR5, in terms of kinetics, protein 
phosphorylation modifications, biological function of the regulated proteins and signal mediators 
activated. Taken together, these results indicate that chemokine system regulation is based not only on 
chemokine post-translational modifications that modulate chemokine potency, but also on the activity 
of structurally biased atypical chemokine receptors, as in the case of ACKR2 that interacts with different 
effectors and kinetics to generate distinct functional outcomes, compared to the conventional 
chemokine receptor CCR5. 
In this thesis it has also been attempted to translate the investigation of chemokine signaling to 
a clinical intervention for inflammatory diseases. We assessed the modulation of CXCR1 signaling 
activity exerted by Reparixin, a leukocyte migration inhibitor that blocks cell recruitment to inflamed 
tissues, that binds to its target receptors in an allosteric binding site, without inhibiting chemokine 
binding to the receptor. In our assays performed on HEK293 cells we could not detect any inhibition of 
the signaling pathways assayed, possibly indicating that HEK293 cells are not the best model to assay 
the activity of this molecule, with the need to assess in this cellular model drug inhibitory activity on 
read-outs already evaluated in literature on other cell types. 
In conclusion, we can say that observations described in this thesis allow to better understand 
chemokine system regulation, that occurs by biased signaling activity in the case of atypical chemokine 
receptors that by selected interaction with signaling mediators induce opposite biological outcomes 
compared to conventional chemokine receptors, while post-translational modifications regulate 
chemokines activity modulating their potency, rather than biasing their signaling properties. 
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1.1-CHEMOKINES AND THE CHEMOKINE SYSTEM 
Chemokines constitute a family of about 50 low molecular weight (8-12 kDa) proteins that 
regulate directional cell migration acting on about 20 dedicated seven transmembrane (7TM) G protein 
coupled receptors (GPCRs) [1]. The migratory events chemokines drive are fundamental to correctly 
regulate physiological processes such as cell development and leukocyte homing in homeostatic 
conditions, but also in pathological processes are the main responsible for directed leukocyte migration 
to inflamed tissues, together with other inflammation-related molecules such as bacterial-derived 
peptides and activated complement components [1-4]. In adult vertebrates, these small proteins can be 
distinguished between homeostatic or inflammatory chemokines, based on their constitutive and tissue-
restricted expression or their inducible and widespread diffusion, respectively [5]. Chemokine receptors 
expressed on target cells mediate cell response regulating several signaling pathways responsible for cell 
activation, adhesion, polarization towards chemokine gradient and finally migration [6]. These activities 
enable chemokines to orchestrate leukocyte migration, whether that could be during homeostasis 
maintaining immune cells precursors in the bone marrow or mature leukocyte patrolling in peripheral 
tissues or during inflammation recruiting leukocytes to inflamed tissues [7]. Regulation of the 
chemokine system occurs with controlled expression of both chemokines and receptors that determines 
the specificity of the migratory signal, modifying ligands activity by post-translational modifications 
affecting chemokine activity and solubility, and by activity of atypical chemokine receptors (ACKRs), that 
are GPCRs similar to chemokine receptors in terms of structural and binding features, but are devoid of 
chemotactic activity and instead regulate chemokine activity transporting, presenting or scavenging 
their ligands [8]. Leukocytes recruitment to sites of infection and inflammation is a fundamental 
component of host immune defense, and as it needs to be activated only in the case of necessity it also 
needs to be contained to prevent excessive immune response and to redirect it to tissue repair 
functions once the inflammatory cause has been removed. To this point dysregulation of the chemokine 
system has been reported to be involved in several immune diseases [9], spanning from immune 
deficiency, autoimmunity and inflammation-related diseases [1, 9-11]. Therefore, to selectively regulate 
leukocyte recruitment within tissues, drug development focused its attention also on chemokine 
receptors to tackle immune disease, since as GPCRs chemokine receptors are particularly suited to be 
targeted with small molecules inhibitors, easily synthesizable and deliverable drugs [11]. Unfortunately, 
drug development for chemokine receptors recorded a high rate of unsuccessful attempts due to the 
complexity of chemokine system, determined by its redundancy and interplay between different ligands 
and receptors. Therefore now research in this field is looking forward to understand autonomous 
chemokine system regulation in order to design drugs mimicking chemokine system’s own regulation 
methods [11]. 
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1.2-CHEMOKINES 
Chemokine family has been defined to group almost 50 low molecular weight (8-12 kDa), 
secreted cytokines with cell migratory activity that share a common structure characterized by the 
presence of four conserved cysteines [5]. These cysteines form disulfide bonds between them, and in 
particular the first cysteine interacts with the third and the second with the fourth. Based on the 
variations in the sequence between the first two NH2-terminus proximal cysteines, chemokines are 
divided in four sub-families (Figure 1) [12].  
 
Figure 1: Chemokines classification. Chemokines are divided in 4 subfamilies named C, CC, CXC and CX3C, based on the relative 
position of first two NH2-terminal cysteines, with CX3C chemokines that have a COOH-terminus that anchors CX3CL1 to the 
plasma membrane [13].  
 
CXC chemokines have one amino acid positioned between the first two cysteines, in CC 
chemokines there are no intervening amino acids and the two cysteines are adjacent, the only member 
of the CX3C chemokine subfamily (CX3CL1) has three amino acids between the two conserved cysteines, 
while the (X)C chemokines constitute an exception with two members (derived from one alternative 
spliced mRNA) that have only one amino terminal cysteine [14, 15]. This classification not only allows to 
define chemokines on the basis of structural properties but also to define families of chemokine 
receptors, since one single conventional chemokine receptor can bind different chemokines but all its 
cognate ligands belong to one distinct subclass of chemokines, defining CXC, CC, CX3C and XC receptors 
[14]. In humans inflammatory chemokine genes are mainly clustered on chromosomes 4 and 17, 
indicating that a rapid evolution has been made by gene duplication, while homeostatic chemokines are 
mainly located alone or in small clusters on different chromosomes. Other than being well conserved 
across species, in the case of homeostatic chemokines their function is more maintained compared to 
the inflammatory ones, indicating that their role is more important and strictly conserved due to 
developmental and physiological functions [5]. Disulfide bridges mediated by the conserved cysteine 
residues, together with hydrophobic interactions, determine a common three-dimensional structure 
shared by all the chemokines, consisting of a core of three planar antiparallel β-sheets connected by 
short loops, a C-terminal α-helix bent compared the β-sheets plan and an extended unstructured N-
1-Introduction 
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terminus preceding the first cysteine [16, 17]. The domains that determine receptor specificity are a 
region connecting the first cysteines and the first β-sheet called N-loop and the NH2-terminus, 
responsible for chemokine binding to receptor extracellular NH2-terminus and for receptor activation, 
respectively [15, 18]. The C-terminal α-helix, rich in basic amino acids, is the most important mediator of 
chemokine interaction with glycosaminoglycans (GAGs), together with other basic residues distributed 
all over the sequence [15, 19]. In the case of CXC chemokines a further classification can be made on the 
presence prior to the first cysteine of a three-residue motif of glutamic acid, leucine and arginine, called 
ELR motif. This motif is present in CXC chemokines recognized by and active on CXCR1 and CXCR2 
receptors and is associated to angiogenic properties of these chemokines, while ELR-negative CXC 
chemokines display an angiostatic activity [20]. Angiogenic activity anyway is not peculiar of ELR-positive 
CXC chemokines, since has also been associated to CCL2, CCL11 and CCL16, three CC chemokines [20]. 
Another classification of chemokines can be made on the basis of their function and expression, since it 
is possible to distinguish between homeostatic and inflammatory chemokines. Homeostatic chemokines 
are constitutively expressed and regulate physiological migration and homing of various cell types, 
including leukocytes. On the opposite, inflammatory chemokines are upregulated upon inflammatory 
events and mainly mediate leukocyte recruitment towards inflamed tissues [5, 21]. This classification is 
not stringent since there are chemokines with both homeostatic and inflammatory functions, and 
chemokines that are constitutively present and circulating in plasma or inside platelets in an inactive 
form but during inflammation are processed or released and sustain an inflammatory behavior [16, 21, 
22]. This function-based classification is mostly reflected also by chemokine receptors, since single 
receptors bind mainly chemokines with similar functions, even if the chemokine system is very 
redundant and promiscuous, given the fact that in most the cases one receptor can bind different 
ligands, one chemokine can activate multiple receptors and one leukocyte subset can express different 
chemokine receptors [3, 21].  
 
1.3-CHEMOKINE RECEPTORS 
Three distinct subfamilies of chemokine receptors have been defined based on the function they 
exert. It is possible to identify conventional chemokine receptors, that drive directional cell migration in 
response to chemokines, atypical chemokine receptor that do not sustain cell migration but regulate 
chemokine activity, and microbial chemokine receptors, developed mainly by pathogens as viruses or 
parasites to escape host immune response [3]. Atypical and microbial chemokine receptors will be 
reviewed in separated sections to allow a better clarity and understanding of their own molecular and 
functional features, therefore in this text the generic definition of “chemokine receptors” will refer to 
conventional chemokine receptors, a definition used only in sections where disambiguation is needed. 
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Up to date 18 chemokine receptors have been characterized, regardless of splice variants. As 
already said, chemokine receptors are grouped in 4 classes depending on the bound chemokines, and 
even if one single receptor recognizes more than one chemokine, all the chemokines recognized belong 
to the same family (Figure 2A). Due to this characteristic, chemokine receptors have been divided in 4 
groups: CXC, CC, CX3C and XC receptors (CXCR, CCR, CX3CR and XCR, respectively). CCRs are the most 
abundant and ten receptors have been described so far, then there are six CXCRs, and only one CX3CR 
and one XCR [3, 12]. Many chemokine receptors genes are clustered in chromosome 3, and compared to 
their agonists, receptors are more conserved across species [5].  
 
Figure 2: The chemokine system and chemokine receptors structure. A- Chemokines and their receptors are listed with the 
following color-code: CXC chemokines are in green, CC chemokines in red, XC chemokines in light blue and CX3CL1 is in purple. 
Cell types expressing each receptor are reported next to each receptor’s name. B- 7TM structure of a class A GPCR, with the 
indication of Extracellular (EC) and Intracellular (IC) sides of the plasma membrane, and the visible TM domains and loops. 
Adapted from [3, 13].  
 
Chemokine receptors are class A GPCR coupled with pertussis toxin-sensitive Gαi class 
heterotrimeric proteins. Their structure consists of seven transmembrane domains made of α-helices 
spanning the plasma membrane, connected by three intracellular and three extracellular loops (Figure 
2B) [23]. At the NH2-terminus, positioned on the extracellular side of the membrane, these receptor 
have a rather flexible unstructured domain, with no precise crystallographic order, while at the COOH-
terminus on cytosolic side there is an unstructured carboxy terminal tail (Figure 2B). On the extracellular 
side, two disulfide bridges constrain the structure of the 7 TM. In detail, one is made between a cysteine 
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in extracellular loop (ECL) 1 at the beginning of TM 3 and a cysteine positioned within ECL2, which is 
conserved in rhodopsin-like class A GPCRs, and the other link is made by one cysteine on the NH2-
terminus with the one at the tip of TM 7, conserved among chemokine receptors [23]. The TM domains 
define two major binding crevices, one accessible by chemokines from the extracellular side of the 
transmembrane bundle [19, 24-26], and another cavity on the intracellular side hosts α subunits of G 
proteins mediating direct signal transduction by ligand-induced structural rearrangement [27, 28]. 
Fundamental in regulating GPCRs structure and activity are a set of amino acids conserved among GPCRs 
that organize the structural scaffold around which every GPCR polypeptide assembles to generate 
receptors with different specificity of ligands and signaling properties [23, 29]. Transmembrane domain 
3, due to its central position in the transmembrane bundle, is the most important domain involved in 
connecting most the domains of the receptor, sensing ligand binding and at its end is placed the DRY 
motif, highly conserved and involved in G protein coupling and their activation [29, 30]. This motif, 
placed at the boundary between TM3 and Intracellular Loop (ICL) 2, contains one of the most conserved 
residues among GPCRs, the Arginine (R) 3.50 (following Ballesteros-Weinstein numbering), and has been 
shown to regulate receptor activation by interacting with the preceding Aspartic acid (D) in the inactive 
status, while upon agonist activation interacts with G proteins and another conserved residue on the 
receptor, at the beginning of ICL3, the Tyrosine (Y) 5.58 [23, 27], acting therefore as a switch for 
receptor activation. Of notice, among chemokine receptors, this motif is changed to HRY in XCL1 and to 
DRF in CXCR6, with an histidine replacing the aspartic acid and a phenylalanine replacing the conserved 
tyrosine, respectively. The substitution in CXCR6 does not result in a change of charge, while in XCL1 the 
substitution of the acid aspartate with the basic histidine can underlie a constitutive activation of XCR1, 
as it has been reported for other mutated GPCRs [31, 32]. Other important features of GPCRs are highly 
conserved residues across all the TM domains that interacting with other residues spatially close to 
them determine the relative orientation of TM helices, influencing receptor activity state [23, 28, 33]. 
These residues in fact act as the aforementioned DRY lock that maintain the receptor in an inactive state 
with strong electrostatic interactions and hydrogen bonds, but at the moment an agonist binds the 
receptor these switches follow TM rotation and stabilize receptor active conformation, controlling 
receptor signaling not only in time but also in quality, since these switches can also determine which 
signaling pathways the receptor activates, contributing to the generation of balanced or biased signaling 
activities [23, 24, 34, 35]. The motif TxP in TM 2 is highly conserved in chemokine receptors, and plays 
an important role in sensing chemokines binding, with the proline (P) creating a kink in the 
transmembrane helix that can be moved upon entering of chemokine N-terminus in the extracellular 
bundle of the receptor [36, 37]. In TM 6 is present one micro-switch highly conserved in GPCRs, the 
CWxP motif, in which the cysteine (C)  interacts with asparagine (N) 7.45 in TM 7 and the tryptophan 
(W) forms hydrogen bonds with TM 3 and 7 in inactive state, pushing another micro-switch, the 
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NPxxY(x)5,6F at the end of TM 7, away from  the aspartate 2.50 in TM 2. Upon receptor activation this 
pattern of interactions changes, with tryptophan interacting with phenylalanine 5.47 in TM 5 while 
cysteine loses its interactions leaving asparagine 7.49 which remains free to interact with aspartate 2.50, 
inducing a tilt outwards of TM 6 [23, 38, 39]. The already introduced NPxxY(x)5-6F located between the 
end of TM 7 and the putative helix 8 is also important in determining the activity of GPCRs, with tyrosine 
7.53 interacting with phenylalanine 7.60 in inactive state and stabilizing receptor’s active conformation 
and TM 6 outwards tilting by its interaction with hydrophobic residues between TM 6 and 7 [23, 40]. 
However, while the TxP and NPxxY(x)5-6F are highly conserved in chemokine receptors, the CWxP motif 
is not completely conserved across chemokine receptors that may present alternative residues, that can 
confer differences in terms of constitutive or biased signaling [23, 24, 34]. In GPCRs a putative 8th helix 
occurs soon after the end of TM 7, usually anchored to the plasma membrane by palmitoylation, that 
regulates receptor activation, stability, internalization and signaling [41], but among chemokine 
receptors this motif is present in some molecules, such as CCR5 in which regulates receptor trafficking 
and signaling [42, 43], while it is absent in receptors like CXCR4 [25]. All these residues mainly conserved 
across conventional chemokine receptors generate a network of interactions that dictate receptor 
activity controlling its structural conformation. 
 
1.4-CHEMOKINE RECEPTORS EXPRESSION 
Chemokine receptors are expressed by stem cells during development to mediate cell 
positioning during developing organisms, but in adults are mostly expressed by immune cells [3]. 
Chemokine receptors have also been described to be expressed by several cancer cells, mediating 
different functions that can be even opposite one to another. In fact, other than tumor-expressed 
chemokines that can have angiogenic or angiostatic properties, chemokine receptor expression in 
tumors influences the aggressiveness of cancer cells, not only by promotion of survival and growth 
signals but mainly by guiding invasion and metastasis. In particular the major players in this regard are 
chemokine receptors CXCR4, CCR7 and CCR10 that respond to homeostatic chemokines, constitutively 
expressed in tissues such as bone marrow, lymph nodes and skin, respectively, that attract cancer cells 
within the tissue where they can generate metastasis [44, 45]. In physiological conditions leukocytes are 
the cells mainly expressing chemokine receptors with homeostatic functions as retention of 
hematopoietic precursors in the bone marrow or guiding leukocyte trafficking and homing in secondary 
lymphoid tissues [7]. In example, CXCR4 is expressed in hematopoietic stem cells and drives their 
retention in the bone marrow, where reticular cells produce high levels of CXCL12. During maturation 
CXCR4 is downregulated to weaken the retention signal, allowing mature immune cells to leave the 
bone marrow and enter peripheral blood [46]. This receptor can also be upregulated during neutrophil 
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senescence to drive their reentry and apoptosis in the bone marrow [47]. Another immune cell whose 
functions are regulated by controlled expression of chemokine receptors for constitutively expressed 
ligands are Dendritic Cells (DC). DC are present in periphery as immature resident cells, whose 
positioning can be driven in example by CCR2 in skin-resident DC or by CCR6 in Peyer’s patches DC. 
Upon maturation or inflammation DC increase expression of CCR7, the receptor responding to CCL21 
and CCL19, expressed by lymphatic endothelium and lymph nodes respectively, that guide DC in their 
egression from peripheral tissue towards lymph nodes where they can encounter and activate naïve T 
cells and exposing antigen-loaded major histocompatibility complex class II (MHCII) [7, 48]. As well, 
regulation of leukocyte migration towards gradients of inflammatory chemokines relies on the 
expression of specific receptors on different immune cell populations. Upon inflammatory or infectious 
stimuli resident innate immune cells such as mast cells, macrophages and DC either release vesicles with 
preformed chemokines or rapidly start expressing them [49, 50]. Not only particular but a wide range of 
chemokines is produced, together with inflammatory cytokines that boost inflammatory chemokine 
production by immune cells and also induce chemokine expression by epithelial cells [51]. As in the case 
of homeostatic chemokines, specific receptor expression influences the recruitment of determined 
peripheral blood or tissue resident leukocyte populations rather than others. Receptors for 
inflammatory chemokines are promiscuously expressed in different leukocytes, even if their abundance 
dictates cellular responsiveness to determined ligands. In example neutrophils are the first leukocyte 
population recruited to inflamed tissues thanks to their expression of CXCR1 and CXCR2, whose agonist 
are highly present in mast cells granules as CXCL1 and CXCL2 or can be found on activated endothelium 
as CXCL8, and also by formyl peptides and leukotriene B4, released by damaged mitochondria and 
produced by leukocytes after inflammatory stimulation, respectively [7]. Monocytes as well express 
formyl peptides receptors and CXCR2, but their arrival within inflamed tissues is mainly dependent on 
CCR2-ligand CCL2 [52, 53]. Monocytes can also be distinguished between patrolling and inflammatory 
monocytes on the basis of CX3CR1 or CCR2 expression, respectively. CX3CR1 ligand, named CX3CL1, is in 
fact expressed as a membrane bound chemokine, and remains mainly localized contributing to act more 
as an adhesion molecule [7, 52] in contrast to CCL2, which has been shown to form matrix-associated 
gradients that drive monocyte migration from blood vessels to peripheral inflamed tissues [7, 54]. CCR5 
is another chemokine receptor widely expressed on leukocytes, such as mast cells, DC, monocytes, and 
can be upregulated in activated neutrophils [7]. This wide expression of receptors sensitive to many 
different chemokines indicates that to support emergency recruitment of leukocytes towards inflamed 
tissues the chemokine system evolved maintaining a high grade of redundancy and complexity, to be 
able to robustly support in several ways the immune response [55]. 
 
1-Introduction 
9 
1.5-CHEMOKINE BINDING AND RECEPTOR ACTIVATION 
Interactions of chemokines with cognate receptors are considered to follow the model initially 
proposed for the binding of CXCL12 to CXCR4 [18] that resembles the one proposed for another class A 
GPCR that binds a peptide with chemotactic properties, the activated complement C5 receptor (C5aR1) 
[56]. This model based on experimental data proposes that chemokines present in soluble form, bound 
to GAGs or presented by other receptors such Atypical Chemokine receptors (ACKRs) initially interact 
with the receptor through their N-loop, binding the NH2-terminus of the receptor. After this initial 
contact, the NH2-terminus of the chemokine that initially is in a disordered structure in solution assumes 
an order that mediates the correct positioning of all the residues inside the extracellular bundle of the 
receptor, where these residues can interact with receptor TM helices activating the receptor (see Figure 
3) [18].  
 
Figure 3: Chemokines bind their cognate receptor in two subsequent steps. In the model proposed for CXCL12 (above, dark 
grey), after approaching it cognate receptor CXCR4 (below, light grey) (A), the chemokine initially binds the NH2-terminus of the 
receptor by its N-loop (B), that causes the receptor to assume a conformation more prone to host the NH2-terminus of the 
chemokine that becomes structured thanks to the interaction with the residues present in TM extracellular bundle (C) [18]. 
 
This explains the importance of chemokines NH2-terminus in dictating their activity, since 
modification of this region more than others affects dramatically their potency but not their binding 
affinity to the receptor [57-59]. The possibility to modulate chemokine activity by modification of their 
NH2-terminus, together with the binding relying on different structural motifs of the chemokines, also 
explains the ability of different chemokines to bind receptors to exert an antagonistic activity, either by 
carrying no active NH2-terminus or by binding chemokine receptors others than their own, occupying 
the binding site and preventing receptor activation by active chemokines [5, 18, 57]. Furthermore it has 
been observed that while CC chemokines activate their cognate receptors interacting mainly with 
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residues belonging to TM helices, deep in the binding crevice, CXC chemokines can also activate 
receptors acting on more exterior residues, and that different chemokines can bind their cognate 
receptor in different binding sites, indicating that even if the two step model can be applied to both the 
chemokine families, differences can be observed between different chemokines in terms of binding 
conformation that influence receptor occupancy and activation [60]. 
Chemokine binding to the receptor causes a movement of TM to interact with the chemokine, 
resulting in a reorientation of the micro-switches, unlocking receptor movement towards an active 
conformation. In particular, for GPCRs, it has been demonstrated that agonist activation induces, 
compared to other TM, a greater movement of TM 6 and TM 7, which while moving inward the 
extracellular segments shift outwards their intracellular half, moving on a fulcrum positioned around the 
middle of the plasma membrane, that together with other minor movements rearranges the interaction 
network of all the residues and contacts with signaling partners inducing the activation of signaling 
cascades [27, 61]. 
 
1.6-CHEMOKINE RECEPTOR SIGNALING 
1.6.1-HETEROTRIMERIC G PROTEIN-SIGNALING 
Responses evoked by binding of chemokines to their respective chemokine receptors rely on the 
activation of multiple signaling pathways sustained by a plethora of signaling molecules, which in an 
exemplified view can be attributed to two main signaling transduction modules, one controlled by 
heterotrimeric G proteins and one by β-arrestins [62, 63]. G proteins are heterotrimeric proteins mostly 
found just below the plasma membrane, associated to GPCRs, with the Gα subunit, the one with the 
GTP hydrolyzing activity, that on the one side interacts with the receptor and on the other binds the βγ 
dimer subunit [27, 62]. The general signaling mechanism adopted by GPCRs consists in an immediate 
activation of G proteins after agonist binding, which is possible thanks to the structural remodeling that 
the receptor undergoes. This receptor rearrangement induces in the inactive guanosine diphosphate 
(GDP)-bound Gα subunit of the G protein associated to the receptor the release of GDP [64]. The Gα 
subunit in its open conformation, free of guanosine nucleotide, has a high affinity for the GPCR, until it 
binds guanosine triphosphate (GTP), which activates the Gα subunit that dissociating from both the 
receptor and the βγ subunit becomes free, as the βγ subunit, to interact with other downstream 
signaling molecules (Figure 4) [62, 65]. Being constituted by three subunits acting together, G proteins 
can mediate the activation of different signaling pathways together, with an high grade of complexity 
and divergence due to the possible combination of different subunits, since up to date in humans have 
been characterized 21 Gα, 6 Gβ and 12 Gγ different subunits [62]. In particular, possibly due to their 
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ability to directly interact with GPCRs, Gα subunits differentiated to mediate diverse signaling pathways 
and can be grouped in four families on the basis of sequence similarities and signaling activity. They can 
be distinguished between Gαs subunits that stimulate adenylyl cyclase to convert ATP in cAMP, that as 
second messenger amplifies the signal modulating the activity of protein kinase A (PKA) and the small 
GTPase Rap1, in example [66]. On the opposite, Gαi subunits inhibit the activity of adenylyl cyclase, 
leading to a decrease in intracellular cAMP. To this family belong also Gαo proteins, which can, as Gαi 
do, regulate to the activation of the pathway of c-Src-STAT3 and the small GTPase Rap. Upon activation 
of Gαi/o subunits the βγ subunit becomes activated and signals as well, leading to the activation of 
phospholipase C-beta (PLC-β), which mediates the formation of inositol-1,4,5-trisphosphate (IP3) and 
transient Ca2+ fluxes [67]. The PLC-β pathway can also be activated by the Gαq family subunits, resulting 
in the formation of IP3 and diacilglycerol, that induce the release of Ca2+ from intracellular stores and 
mediate the activation of protein kinase C (PKC), respectively [66]. Gα12/13 subunits regulate different 
but cross-talking signaling pathway, operating mainly on the activity of small GTPases as Rho or on 
kinases [66, 68]. 
Chemokine receptors are mainly coupled to Gαi proteins, since their stimulation with agonists 
results in a decrease of intracellular cAMP, accumulation of IP3 and generation of transient intracellular 
Ca2+ currents. All these signaling pathways, as chemotaxis, are sensitive to pertussis toxin (PTX) 
inhibition [67, 69], which catalyzes the ADP-ribosylation of Gαi subunits causing their uncoupling from 
the receptor [70]. However, emerging evidences suggest that an additional, alternative Gαq-dependent 
pathway can be engaged by a subset of chemokines and is critically required for regulating chemokine 
receptor-mediated functions such as inositol trisphosphate (IP3) generation and calcium release and 
chemotaxis [71]. 
GPCR activation leads to G protein activation as the first signaling event due to their direct 
association, but soon after G protein dissociation the receptor remains free in an active conformation 
that permits the binding of several signal transducers, such as GPCR kinases (GRK) that phosphorylate 
residues mainly on receptor C-terminal tail, increasing the affinity of this domain for β-arrestins, which 
prevent further re-association of G proteins to the receptor by steric hindrance, mediate the assembly 
of the endocytotic machinery to internalize activated receptors desensitizing cells and within the last 15 
years have been demonstrated to scaffold a signalosome to sustain several different signaling pathways 
in a G protein-independent manner [63].  
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Figure 4: Chemokine receptor activation and signaling pathways. After chemokine binding, G-proteins bind receptor 
intracellular loops and become active, exchanging GDP into GTP. Activation results in α subunit dissociation from the receptor 
and from βγ subunits, that subsequently activate a variety of downstream effectors that lead to the physiological responses. 
The C-terminal tail of the receptor is phosphorylated by GRKs (G-protein receptor kinases), promoting binding of β-arrestins 
and receptor internalization. The receptor could recycled back to the cell surface (in a re-sensitization process) or is degraded 
(in a desensitization process). In addition, β-arrestins can function as signal transducers by activating different signaling 
pathways which lead to a variety of cellular responses (Figure derived from [72]). 
 
1.6.2-Β-ARRESTIN DEPENDENT SIGNALING PATHWAY 
Arrestins constitute a small family of 4 proteins that regulate similar functions interacting with 
GPCRs. Only two of them, named β-arrestin 1 and β-arrestin 2, are ubiquitously expressed while visual 
arrestin 1 and arrestin 4 are expressed only in retinal rods and cones, respectively [73]. These proteins 
have initially been described as able to block GPCR-induced G protein signaling and to desensitize 
receptors mediating their internalization, but by now it has been well established that they are also able 
to mediate the activation of several signaling pathways [74, 75]. β-arrestins structure is constituted by 
one N- and one C-domain consisting mainly of antiparallel β-sheets, with a polar core between the two 
domains that binds to the GPCR in close proximity of the intracellular bundle, with the N-domain that 
interacts with receptor C-terminus and the C-domain that can be used as scaffold for the signaling 
complexes [76]. Upon receptor activation, β-arrestins are recruited to the receptor by increased affinity, 
that depends on both receptor structural rearrangement that exposes high affinity residues or by 
phosphorylation of several residues, mainly clustered on receptor C-terminal tail, by different GRK, PKA, 
PKC or Casein Kinase 2 (Figure 4) [63, 74, 77-79]. β-arrestins not only sterically block any further 
interaction between G proteins and the receptor, but also act as scaffold to mediate receptor 
endocytosis via clathrin coated pits, clustering to the receptor different components of the endocytotic 
machinery [80], and concomitantly contributing to the assembly of a signalosome that mediates many 
intracellular signaling activities [74, 81]. The first signaling activity described as being regulated by β-
arrestins is the one generated by the β2-Adrenergic receptor (β2AR) leading to the phosphorylation of 
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the MAP kinases ERK 1/2, mediated by β-arrestins scaffolding of tyrosine kinase c-Src to the activated 
receptor [82]. This evidence lead to the characterization of many other different signaling pathways 
mediated by β-arrestins, pointing towards the attribution of the role as second alternative signaling 
pathway mediators, compared to G proteins [78, 83]. Furthermore these evidences disclosed β-arrestins 
as capable of associating receptors and activating signaling pathways independently from G proteins, 
raising the idea that a GPCR can possibly activate selected signaling pathways, rather than generating 
always a balanced signal that equally activates all the available pathways [83, 84]. This initial concept of 
proof has been demonstrated with experimental evidences showing that GPCRs that conventionally 
activate both G proteins and subsequently β-arrestins recruitment and signaling can be forced to signal 
preferentially through only one of these two mediators, inducing different functional outcomes, 
depending on the agonist bound and therefore this concept has been named functional selectivity, or 
biased signaling, which will be reviewed in a separate section [84].  
Chemokine receptors as well associate β-arrestins after ligand engagement, and this 
phenomenon has been well studied due to the fact that this interaction has been found to be essential 
to sustain chemotaxis, with impacts on immune regulation and diseases, and since β-arrestins are 
involved in internalization of chemokine receptors, that in the case of CXCR4 and CCR5 act as co-
receptors for HIV viral particles, sustaining virus internalization during infection [85-87]. The importance 
of β-arrestins to regulate leukocyte chemokine receptor-dependent activation, adhesion and 
chemotaxis is sustained by several evidences that not only linked β-arrestins functions to chemokine 
receptor mediated signaling and chemotaxis [88-91], but also elucidating their role in chemokine 
receptor activity amenable for leukocyte migration in various immune diseases [92-94]. In particular, β-
arrestins have been demonstrated to be able of coupling signaling machineries to chemokine receptors, 
such as CXCR4, whose activation is fundamental to support cell migration. In fact in the case of CXCR4 it 
has been shown that β-arrestin 2 mediates CXCL12-induced chemotaxis sustaining receptor 
internalization [87] and the activation of, among the other proteins involved, p38 MAPK, and that this 
activation is necessary to induce cell movement towards CXCL12 gradient [95], and when this 
interaction is affected by receptor structural modification as in CXCR4-mutated WHIM patients, receptor 
activation leads to defective C-terminal tail phosphorylation and impaired recruitment of β-arrestin to 
the receptor, resulting in a hyper activation and enhanced chemotaxis, with an increased leukocytes 
bone marrow retention and defective interaction formation of immunological synapse [92, 93, 96, 97]. 
β-arrestins are also involved in the desensitization and signaling of CC chemokine receptors, such as 
CCR2 [98, 99], CCR5 [99, 100] and CCR7 [101], which can activate selective signaling pathways and 
responses after stimulation with different endogenous ligands, claiming that signaling bias occurs also 
among chemokine receptors [34, 99, 102]. In the case of CXCL8 receptors CXCR1 and CXCR2, it has been 
observed that the same chemokine can induce different signaling activities on the two receptors, 
1-Introduction 
14 
correlated to different rates of receptor internalization and recycling, mediated by β-arrestin-recruited 
adaptor protein 2 (AP-2) to endocytic vesicles [103], and this resulted to be dependent on the activation 
of different GRKs [104], underlining the importance of biased signaling normally occurring among 
chemokine receptors [34, 84]. 
Another important feature that has been observed on GPCR and has been demonstrated on 
chemokine receptors is the ability to be constitutively active [105, 106]. GPCRs in fact can display ligand-
independent activity, which is considered to be dependent on exciting factor present in the 
environment, that reduce the energy needed to activate the receptor, that could be thermal exchange, 
receptor density on the plasma membrane, oligomerization or instability of the ionic lock, the 
interactions between micro-switches that stabilize GPCR conformation, that in fact can be mutated to 
generate GPCRs blocked in stable conformations allowing for the generation of  more precise structural 
definition and drugs impacting selected conformational status [35, 107, 108]. In the case of CCR1, it has 
been reported that the receptor can activate cellular migration independently of agonist stimulation, 
and this mechanism is driven by CCR1 that constitutively forms homo-oligomers, in which receptor 
molecules can activate PTX-sensitive Gαi proteins, leading to cAMP reduction, is phosphorylated on its 
C-terminus and undergoes constitutive internalization in a β-arrestin-dependent and G protein-
independent manner [106]. 
 
1.7-MICROBIAL CHEMOKINE RECEPTORS 
Constitutive signaling activity is a characteristic widely diffused among another class of GPCRs 
that are viral-encoded chemokine receptors [3, 109]. These receptors are able to bind different 
chemokines in a promiscuous manner, even binding chemokines belonging to different subfamilies, and 
display a non conventional cellular distribution, since are frequently found to be mainly expressed in 
intracellular compartments and undergo constitutive internalization and recycling [109-111]. Among 
these receptors US28 encoded by human cytomegalovirus (CMV) and ORF74 by human herpesvirus 8 
(HHV-8) are the best characterized, and have been described as able to activate several signaling 
pathways not only in response to host chemokine ligands but also in a constitutive, ligand-independent 
manner [112, 113]. These receptors, other than scavenging host chemokines to suppress immune 
response, have been found able to directly support infected cells by constitutive activation of several 
signaling pathways dependent on both G proteins and β-arrestins, among which the phosphorylation of 
MAPK, activation of NF-kB and STAT3-dependent transcription that sustain cell proliferation, tumoral 
transformation, angiogenesis and cell migration, that have been accounted for the association to these 
viruses of carcinogenic properties [109].  
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1.8-BIASED SIGNALING 
Biased signaling, also known as functional selectivity, is a relatively new emerging phenomenon 
in GPCR biology whereby distinct ligands of the same receptor can selectively activate different signaling 
pathways [84, 114]. Biased signaling does not simply comprise distinct signaling via either G proteins or 
β-arrestins, but also includes more subtle differences in the activation of other downstream signaling 
effectors, as different ligands can preferentially activate different subtypes of G proteins and β-arrestins 
isoforms, or differently affect signaling events such as ERK activation or Ca2+ mobilization [114]. 
Signaling bias can occur in three different scenarios, the first of which depends on the observation of the 
same receptor activity in two distinct tissues, where different cell types can express different signaling 
machineries to which the receptor, in the absence of its conventional signaling partner, can couple and 
transduce signals different from its conventional ones, that is the so-called system bias, that can be 
overcome comparing receptor activities assessed in the same cell type. The observational bias occurs 
when differences observed are dependent on the assay system exploited to assess agonist activity, since 
not all the readouts obtained have the same efficacy span, and can be avoided normalizing all the 
responses towards a single agonist that is reputed to have balanced signaling activity [84]. Given this 
points, agonist bias can be defined when given agonists, assayed for different signaling activities in the 
same cell type and compared to a reference agonist assayed in parallel, display different signaling 
activities on a given receptor, preferentially activating one or more signals compared to the reference 
ligand (Figure 5) [84]. Accumulating evidence suggest that biased agonists can induce biased signaling 
mediating GPCRs adoption of a specific ligand-induced conformation, that in row induces distinct 
conformation of signaling partners resulting in different signalosome scaffolding and signaling activities 
[115]. In particular, even if a direct comparison has not been made yet, recent data obtained by 
crystallography models and mutational studies indicate that biased agonists induce structural 
rearrangements with different positions of several receptor amino acids, among which micro-switches, 
with newly formed hydrogen bonds and salt bridges between receptor residues, that influence receptor 
association to downstream signaling modules [24, 63]. This explains also the ability of a given receptor, 
stimulated with a normally balanced agonist, to elicit only determined signals, due to sequence 
modifications in its residues important for receptor structure (Figure 5) [118]. 
Activation of only distinct signaling pathways opened the possibility of fine tuning receptor 
activation by mediating selective activation with biased ligands or modulating receptor activation by 
allosteric modulators, compounds that do not activate receptors on their own but bias receptor 
signaling only upon agonist activation [116]. These possibilities aim at generating drugs with biased 
signaling activity, selective only for activating receptor-desired beneficial functions avoiding adverse 
effects than can be generated by the multiplicity of activated pathways [116, 117].  
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Figure 5: Biased Signaling on GPCR. The same receptor can activate different cellular responses when triggered by different 
agonists, but can also mediate different responses when mutations occur in its sequence influencing it structural conformation 
[118]. 
 
1.8.1-BIASED AGONISM IN DRUG DISCOVERY 
The concept of agonists that activating only selected signaling pathways, producing not only 
GPCR blockade as antagonists but finely tuning receptor response lead to a re-evaluation of compounds 
screening, to search among molecule libraries not only compounds able to block a single receptor 
response assayed in one high throughput screening (HTS) assay, but pushed drug discovery to evaluate 
compound efficacy  assaying receptor activities through different read-outs, searching not only for 
antagonists but also for selective agonists [119]. An example of the potential benefits of having biased 
ligands has been given by two well studied receptors, the β-adrenergic receptors and the μ-opioid 
receptor [120, 121]. Sympathetic nervous system activation is mediated by the release of epinephrine 
that acts on α- and β-adrenergic receptors, acting mainly on cardiac tissues, kidney and blood vessels. 
On kidneys and blood vessels the action of α1-adrenergic receptor leads to sodium retention and 
vasoconstriction, that affect cardiac load since the cardiac muscle needs to work more to face the 
increase the systolic pressure, meaning it has to increase it work to generate higher pressures to allow 
blood to reach peripheral vessels. On cardiac tissue α- and β-adrenergic receptors activation cause 
myocyte hypertrophy and blood vessel dilatation that reduce heart efficiency, resulting in an increase of 
the heartbeat rate to maintain constant blood diffusion to peripheral tissues [122]. Therefore the ability 
of adrenergic receptors antagonists to reduce abnormal vascular smooth muscle tissue growth and the 
induction of electric potentials that induce muscle contraction made of this antagonists the most used 
drugs to prevent restenosis and controlling atrial fibrillation and tachycardia [122, 123]. In particular, 
antagonists specific for β-adrenergic receptors (β-blockers) revealed better efficacy compared to α-
blockers, and, among β-blockers, Carvedilol became one of the most used drugs thanks to its ability to 
block vascular smooth muscle cell growth and migration [123] and on cardiomyocytes exhibited 
antiarrhythmic and anti-ischemic properties [122], resulting in a better clinical outcome compared to 
patients treated with other β-blockers [124]. Molecular analysis of signaling pathways elicited by β2-
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adrenergic receptor revealed that, compared to other β-blockers, carvedilol acts as a biased agonist, 
acting as an inverse agonist for Gαs stimulation like other β-blockers that antagonize the β2-adrenergic 
receptor blocking its constitutive signaling activity, while maintains receptor the ability to induce ERK 
1/2 phosphorylation in a β-arrestin-dependent manner [120]. Thus, selectively blocking only the β2-
adrenergic G protein signaling while maintaining β-arrestin signaling activity results in improved 
therapeutic effects by carvedilol, compared to other β-blockers that completely abolish receptor activity 
[120].  
Another interesting pharmaceutical application of biased agonism to improve drug efficacy and 
reduce side effects is the one provided by biased agonists acting on the μ-opioid receptor [125, 126]. 
The μ-opioid receptor is a GPCR highly expressed in the central nervous system well know for mediating 
the analgesic effects of opioids such as morphine and its derivatives [126]. The analgesic activity induced 
by morphine and analogs on the receptor is accompanied by several adverse effects ranging from 
nausea and constipation to severe respiratory depression, sedation, abuse and tolerance [125, 127] and 
it has been shown that these adverse effects are directly mediated by the receptor itself, together with 
analgesy [127]. The only possibility to split these two functions of the receptor has been demonstrated 
to be possible in the absence of  β-arrestin 2, since in mice models knock out for β-arrestin 2 morphine 
induced a greater analgesic effect compared to wild type animals [128]. The analgesic effects of opioid 
receptor activation have been shown to rely on the other side of β-arrestin 2 signaling, since Gαi protein 
activation of potassium channels induces K+ ions exit and the Gβγ blockade of calcium channels support 
Ca2+ entrance, resulting together in neuron hyperpolarization and impossibility to transmit pain signals, 
leaving to β-arrestin 2 the task to block these analgesic signals and desensitize opioid receptors [129, 
130]. These evidences pushed drug development towards the investigation of G protein biased agonists 
for the μ-opioid receptor, to selectively elicit signaling activities aimed at blocking nociception without 
incurring in β-arrestin-dependent desensitization and signaling responsible for typical morphine severe 
side-effects, and brought to the development of different compounds. In particular, one compound 
named TRV130 showed in comparison to morphine higher potency in activating G protein signaling 
while poorly induced β-arrestin 2 recruitment to the μ-opioid receptor, that undergoes reduced 
phosphorylation and is no longer internalized [126, 131]. These biased agonist activity, together with the 
evidences that TRV130 induces sustained analgesia with reduced central nervous system depression and 
gastrointestinal diseases in mice models lead to TRV130 application in clinical trials to evaluate its better 
efficacy compared to morphine, and is now being tested in different phase 2 clinical trials [125, 131-
133]. 
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1.8.2-BIASED AGONISM IN CHEMOKINE SYSTEM 
Evidence of biased signaling in the chemokine system is rapidly accumulating, possibly due to 
the fact that the high degree of promiscuity makes the chemokine system particularly prone to include 
endogenous ligands that can act on the same or different receptors with different affinities and eliciting 
different responses [24, 34, 99, 134]. CCR7 in example is activated by CCL19 and CCL21, which elicit 
equivalent agonism for G protein signaling but differ in their ability to activate GRK and β-arrestins [101, 
135], that has been attributed to differences in the recruitment of GRKs to CCR7 by the two agonists 
[136]. CCR2 activates G protein/β-arrestin balanced signaling when engaged by all ligands except CCL8, 
which was found biased for signaling to β-arrestin2 versus β-arrestin1 [137], and as well CXCR3 is also 
subjected to biased signaling when engaged by CXCL11 compared to CXCL9 or CXCL10, but the extend 
and the nature of the bias reported may have been determined by the amount of receptor expressed in 
the cell and the cellular assay used [102, 138]. Evidence for biased signaling appears to be even more 
relevant for chemokine receptors with a large number of ligands. As an example, CCR1 has partial 
agonists (CCL14, CCL15, CCL23) becoming fully active after processing of their extended N-terminal 
domain [139], β-arrestin biased ligands (CCL3 and CCL15) and G protein biased agonists (CCL5 and 
CCL23) [102]. A second type of bias occurring in the chemokine system refers to cases where the same 
chemokine activates different signaling pathways from a given receptor in a tissue/cell-specific manner 
or in a species-specific manner [34, 102]. As an example, CCL19 has different roles in inducing 
chemotaxis depending on the cell type where CCR7 is expressed on [140, 141]. Besides these evidences 
of ligand bias observed for conventional chemokine receptors, atypical chemokine receptors (ACKRs) 
represent an example of signaling bias operating at the receptor level, that mediates these receptors 
activities of chemokine system regulation rather than operating as chemotactic receptors [142, 143], 
and will be discussed in the following sections.  
 
1.9-PHARMACOLOGICAL TARGETING OF THE CHEMOKINE SYSTEM 
Physiological and pathological leukocyte migration to lymphoid organs and inflamed tissues are 
regulated by chemokines and their receptors during both extravasation and directed migration inside 
tissues [10]. Dysregulation of the chemokine system can result on the one hand in immune deficiency in 
the case of poor leukocyte recruitment, but on the other hand, in the case of an exaggerated leukocyte 
recruitment, the inflammatory response can go from tissue damage after acute injury to inflammatory 
and auto-immune diseases [1, 10]. In the latter case, since chemokine system characterization, 
chemokine receptors have been considered an ideal therapeutic target not only because they are 
expressed with cell specific patterns and drive leukocyte recruitment within tissues, but also because of 
their GPCR structure. In fact GPCRs are the target of about the 30% of marketed prescription drugs, and 
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both the ability to target them by orally deliverable small molecules and the possibility to exploit not 
only their orthosteric binding site but also minor pockets contribute to maintain high interest on their 
therapeutic potential [144, 145]. Furthermore chemokine receptors activity has been proven to mediate 
leukocyte recruitment involved in the generation of several clinically relevant diseases, spanning from 
acute injury and allergy to autoimmune diseases, transplanted organs rejection, HIV and cancer [10]. 
Many compounds have been described to be able in blocking in vitro chemokine receptor activity and 
eventually displayed efficacy in mouse models, but only two compounds succeeded to arrive on the 
market, since most of them failed to progress over all the clinical trials [10, 11]. Common features and 
recurring problems have been characterized among all these failures, that can be attributed to the 
complexity and redundancy of the chemokine system, to its pleiotropy and to the lack of a precise 
correspondence between humans and animal models. In the chemokine system is pretty rare that one 
given chemokine acts only on one single receptor, and viceversa that one single receptor recognizes one 
single ligand [1, 5]. This characteristic decreases the chances of success when therapy aims to block one 
single chemokine or one single receptor, since leukocytes express different chemokine receptors at 
once. In addition, not only different chemokine receptors can respond to the same ligand but also can 
be able to be activated by other chemokines expressed together with the therapy target ligand in the 
inflamed tissue. Redundancy furthermore impedes the attempts to antagonize one single receptor, 
since agonist accumulation within the tissue can results on the improvement of its cross-reactivity on 
other receptors, even those that normally respond weakly to that ligand [10]. One chemokine does not 
only mediate cell migration on one specific cell types but also supports other biological functions on 
different cellular targets, making of pleiotropy a characteristic of the chemokine system, that increases 
the difficulty to block one single specific effect of a chemokine [10]. Furthermore speciation constitutes 
an issue of studying the chemokine system, since there is not complete correlation between human 
chemokine system and the ones of other animal models, such as murine models [5]. The absence of 
direct correspondence between human and murine genes and function impedes the translation of 
experimental evidences observed in mice to humans, and the design of drugs based on the human 
chemokine system can be not immediately applied to mice [5, 10]. It has also to be kept in mind that 
leukocyte positioning and recruitment to inflamed tissues are a fundamental component of immune 
system, and to this point completely blocking even single components of the chemokine system can 
result in a condition of induced immune deficiency that allows the development of opportunistic 
infections [10, 146]. To this point classical drug development aimed at targeting chemokine system 
encountered many more failures than in other fields, therefore with the intriguing opportunities offered 
by emerging concepts in pharmacology such as biased agonism and targeting of allosteric binding sites, 
different small molecules have been more or less successfully developed in the last few years, resulting 
1-Introduction 
20 
in the approval for market distribution of three chemokine-receptors targeting drugs, and more 
successfully translated from research to clinical trial phases [11, 145, 147]. 
 
1.9.1-MARAVIROC 
Human immunodeficiency virus (HIV) infects cells exploiting its ability to bind with its envelope 
protein Env cell-expressed CD4 antigen, that can be expressed on different leukocytes as T helper 
lymphocytes and monocytes. CD4 expression is not the only requirement for HIV fusion to plasma 
membrane and entry, but for cell infection co-expression of the chemokine receptors CXCR4 and CCR5 
are required as well [148, 149]. The discovery that individuals carrying mutations in CCR5 receptor or 
duplications in CCR5 agonist gene CCL3L1 are more resistant to viral infection and disease progression 
[150-152], due to the lack of CCR5 expression on cell surface and activity [153] or to increased agonist-
induced receptor down regulation [151]. Maraviroc is a small molecule CCR5 antagonist discovered from 
a HTS of a compound library designed to affect CCR5 functions. This molecule is a competitive CCR5 
antagonist, since displaces receptor agonists and impedes agonist induced receptor signaling and 
internalization [154, 155]. This receptor blockade is worth not only for endogenous receptor agonists 
but also for glycoprotein (gp) 120 subunit of HIV Env [154]. The inability of the virus to bind to its co-
receptor, and the blockade of CCR5 internalization,  both necessary for envelope fusion to cell 
membrane, resulting in reduced infectivity and proliferation of CCR5-tropic virus strains (R5-tropic) [154, 
155]. Maraviroc is now available on the market as a drug approved for the treatment of HIV-infected 
patients, in combination with other anti-retroviral drugs, since it showed in clinical trials to be well 
tolerated and most importantly to reduce HIV-RNA levels and maintain higher CD4+ cells levels 
compared to therapies consisting only of background therapies. Furthermore, long term treatment did 
not produce an increase in incidence of diseases associated to impared CCR5 activity, such as Western 
Nile virus infection or development of malignancies as lymphomas [155]. 
 
1.9.2-PLERIXAFOR – AMD3100 
Plerixafor, also known as AMD3100, is a selective CXCR4 antagonist initially developed for the 
inhibition of CXCR4-mediated HIV infection, on the basis of previous evidences indicating the role of 
bicyclams in HIV infection inhibition [156, 157]. Plerixafor became highly considered and tested for its 
efficacy in antagonizing CXCL12 binding to CXCR4, its signaling and internalization, and also for directly 
preventing gp-120 binding and therefore inhibits HIV T-tropic viruses infection [156]. Proven its ability in 
reducing HIV infection, plerixafor entered different clinical trials where validated its efficacy as virus 
entry inhibitor, but as well showed the ability to highly increase the number of circulating leukocytes in 
peripheral blood [157, 158]. This effect has been shown to depend on the inactivation of CXCR4 
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interaction with bone marrow CXCL12, that retains immature leukocytes and stem cells in bone marrow 
niches, resulting in hematopoietic CD34+ stem cell mobilization from bone marrow to peripheral blood 
[157, 159]. This lead to the application of plerixafor to clinical trials and the approval for its application 
as an inducer of CD34+ stem cell mobilization to peripheral blood for their collection aimed at their 
autologous transplantation in patients suffering of non-Hodgkin’s lymphoma or multiple myeloma [160]. 
In addition, plerixafor has been recently used to treat immune deficiency by increasing leukocyte 
circulation in peripheral blood in patients affected by the WHIM (warts, hypogammaglobulinemia, 
infections, and myelokathexis) syndrome [161, 162]. This patients suffer of a rare disease caused by 
different mutations in CXCR4 gene that result in the expression of a receptor truncated in its C-terminal 
tail, exhibiting an hyperactivated phenotype constraining leukocytes inside the bone marrow, impeding 
their egress to peripheral blood resulting in immune deficiency, that can be reverted antagonizing 
CXCR4 effect with long-term low doses of plerixafor [161, 162]. 
 
1.9.3-MONOCLONAL ANTIBODY MOGAMULIZUMAB 
The only other chemokine receptor-targeted drug already approved for therapy is a modified 
monoclonal antibody directed against CCR4, named Mogamulizumab, aimed at the treatment of T-cell 
lymphoma. This antibody binds CCR4 that is mostly expressed by T helper 2 (Th2) and T regulatory (T-
regs) cells, mediating antibody dependent cell citotoxicity [163]. Many other molecules are currently 
under evaluation in clinical trials to demonstrate their ability to improve patients outcome in a series of 
immune-related pathologies, in example asthma, allergy, psoriasis and transplant rejection or diseases 
where inflammation has a central role such as multiple sclerosis and cancer [11]. 
 
1.10-CXCR1 AND CXCR2, THE TWO CXCL8 RECEPTORS 
CXCR1 and CXCR2 are the first described prototypic chemokine receptors mediating 
inflammatory response, due to their ability to drive neutrophils recruitment to inflamed tissues in 
response to CXCL8 [164, 165]. These two receptors also mediate chemotaxis in response to other ELR+ 
CXC chemokines, with CXCR1 able to be activated by CXCL6 in addition to CXCL8, while CXCR2 can bind 
and actively recognize all the ELR+ chemokines[166, 167], and both the receptors can bind the 
cytomegalovirus (CMV) viral chemokine vCXCL1 [168]. In humans genes encoding these two receptors 
are clustered on chromosome 2q35, and they are mainly expressed by neutrophils, but also both CXCR1 
and CXCR2 are expressed by monocytes, natural killer (NK) cells, mast cells and other leukocytes [169]. 
Their expression can be down-regulated upon inflammatory stimuli, since metalloproteinases released 
by cells upon stimulation with lipopolysaccharide (LPS) or tumor necrosis factor α (TNF-α) can cleave 
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receptor extracellular domains resulting in a loss of cell responsiveness and chemotaxis [170]. CXCR1 
structure in the absence of any ligand or associated protein has been solved by nuclear magnetic 
resonance (NMR) applied to the receptor purified in phospholipid bilayer [171], indicating small 
differences compared to the crystallized CXCR4 and showing that an 8th helix occurs in CXCR1 C-terminal 
tail. In primary cells as neutrophils it has been demonstrated that CXCR1 and CXCR2 upon stimulation 
activate Gαi proteins relying on the interactions with residues at the end of TM3 and the beginning of 
TM6 [172, 173], and Gβγ subunits that are required for migration [174]. Receptor activation leads to the 
induction of Ca2+ fluxes, PLC activation, MAPK activation and receptor phosphorylation [167, 175] and 
internalization mediated by β-arrestin recruitment [176, 177]. This signaling results in the activation of 
several signaling pathways, such as the activation of small GTPases, MAP kinases, focal adhesion kinases 
and others [178] that together mediate cell movement and sustain cell rolling and adhesion to vascular 
endothelium, allowing leukocytes to egress bloodstream and reach inflamed tissues [179]. Even though 
their expression and binding abilities and  are overlapping, these two receptors have been proven to 
mediate the same activities eliciting partially different signaling pathways. In fact the two receptors are 
phosphorylated upon activation by two different kinases, with CXCR1 that is preferentially 
phosphorylated by GRK2 while CXCR2 by GRK6, resulting in different kinetics of desensitization and 
internalization [104], that is reflected too by their ability to induce cytoskeleton rearrangement and 
focal adhesion kinase activation in different manners [180]. This signaling selectivity is worth not only 
among the two receptors but also for chemokines, since only CXCL8 can induce phospholipase D 
activation, even if all CXCR1 agonists CXCL1, CXCL7 and CXCL8 activate Ca2+ fluxes [181]. 
Biological functions of CXCR1 and CXCR2 showed that other than mediating neutrophil response 
to acute inflammatory events such as bacterial infections and wounds [182, 183], these receptors have a 
role in mediating leukocyte recruitment and support to different diseases, such as arthritis, septic injury 
and several pulmonary diseases dependent as asthma and chronic obstructive pulmonary disease 
(COPD) [184-186]. In addition it has also been described a role for CXCR2 in different neural pathologies, 
as ischemic injury and multiple sclerosis [187]. CXCR1, CXCR2 and their ligands are also involved in 
tumor with different shades of complexity, since in certain tumors leukocyte recruitment is beneficial 
for host since they display an inflammatory phenotype and suppress tumor cells, while in other tumoral 
contexts they can have pro-tumorigenic phenotype [188]. In addition chemokines can be expressed by 
both infiltrating leukocytes, endothelial and tumor cells, and as well receptors can [189]. In this context 
anyhow the role of these ELR+ and chemokine receptors appears as dangerous to the host, since they 
seem to induce survival and proliferative signals, and display their angiogenic activity that is necessary 
to sustain tumor growth [188]. 
Given the relevance of these two receptors in disease development and support many drugs 
attempted to modify their response aimed at improving clinical outcomes. CXCL8 neutralization with 
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antibodies has been attempted but did not reach the market due to lack of efficacy in clinical trials, 
possibly because of the complexity and the marginal role exerted by neutrophils in psoriasis [3], and an 
inactive CXCL8 variant has been developed to inhibit the GAG-regulated activation of CXCR1 and CXCR2 
in COPD. Different compounds from different companies targeting CXCR1 and CXCR2 instead are now 
being evaluated in clinical trials to improve patient outcomes in a number of pulmonary diseases with 
promising results [11]. Among those, the CXCR2 competitive antagonist GSK-1325756B by 
GlaxoSmithKline is undergoing clinical trials, and also Schering-Plough SCH-527123 [3].  
 
1.10.1-REPARIXIN, A NONCOMPETITIVE ALLOSTERIC INHIBITOR OF CXCR1 AND CXCR2 
Reparixin is a small molecule non competitive inhibitor of CXCL8-mediated leukocyte migration 
developed and patented by Dompé with a higher affinity on CXCR1 than on CXCR2 [190, 191]. This 
molecule has been an under investigation from the evidence that ketoprofen, a non-steroidal 
antiinflammatory drug, inhibited inflammation not only by inhibiting cyclooxygenase (COX) pathway but 
also by blocking CXCL8-mediated leukocyte migration [192]. This lead to the analysis of the chemical 
properties and engineering of this molecule to generate a molecule aimed at specifically blocking CXCL8 
receptors, that initially brought to the development of DF1681Y, named Reparixin [190], which showed 
a preferential affinity for CXCR1 versus CXCR2, and also of other similar molecules with improved affinity 
for CXCR2 [191, 193]. These molecules are non-competitive inhibitors, they do not affect CXCL8 binding 
to the receptors, or receptor desensitization after ligand exposure, but are able to block GTPγS binding 
to neutrophil membrane preparations, they block transient Ca2+ fluxes, and suppress Pyk2 focal 
adhesion kinase phosphorylation [194]. Reparixin has been found to bind to an allosteric hydrophobic 
binding pocket of CXCR1 and CXCR2, where the inhibitor can interact with residues positioned of TM 1, 3 
and 6, allowing chemokine binding to the orthosteric site but impeding receptor structural 
rearrangement necessary to sustain signaling and chemotaxis [194]. This allosteric inhibitor has proven 
its efficacy in reducing neutrophil accumulation in inflamed tissues and consequent diseases in different 
preclinical models, as acute and chronic inflammation models [195, 196], preventing ischemia 
reperfusion injury [194, 197, 198] and reducing the development of arthritis [199, 200]. Application of 
Reparixin in the prevention of kidney and lung transplant failed to succeed in clinical trials [3], but is 
reaching advanced phases for the prevention of pancreatic islets transplantation rejection due to its 
inhibition of host immune system aggression against intra-hepatic engrafted islets [11, 201, 202]. 
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1.11-CCR5 
CCR5 gene is located in humans on chromosome, adjacent to CCR2 with which shares 70% 
amino acid sequence and several ligands [5]. CCR5 is able to respond to many inflammatory 
chemokines, all inflammatory and belonging to the CC family, among which CCL2, CCL3, CCL4, CCL5, 
CCL8 and CCL14 [21]. Among the chemokines CCR5 binds there is also CCL7, which has been reported to 
act as an antagonist [203], as well as viral-encoded MIP-2 (vMIP-II) from HHV-8 [204]. CCR5 binding 
properties rely on the interaction of ligands with receptor ECL2 and disulphyde bonds [205-207]. CCR5 is 
also able to bind nonchemokine ligands, such as gp120 protein from HIV, from which interaction derives 
its role as co-receptor with CD4 in viral infection [149], and raised interest around this receptor as a 
potential target for anti HIV therapy, that lead to the first approved chemokine receptor targeting drug, 
Maraviroc ([154] and previous section) and the definition of CCR5 structure in complex with this drug 
solved by crystallography [26]. Post-translational modification affect CCR5 biology, since it NH2-terminal 
residues can be sulfated and glycosilated, while its C-terminal tail is palmitoylated and this modification 
impacts its expression on the plasma membrane [208].  
Expression of CCR5 has been described on almost all leukocytes, in particular on antigen-
presenting cells (APC, that include macrophages and DCs), NK cells, T lymphocytes and CD34+ 
hematopoietic progenitors [209-211]. The discovery of the human CCR5Δ32 allele in caucasian 
population occurring in homozygosis, in which a mutation causes the production of a CCR5 receptor 
constituted of the first 4 TM only and resulting in the lack of functional receptor expression, helped the 
understanding of CCR5 biology, indicating that it is not fundamental to life since compensatory 
mechanisms can occur [212]. CCR5 mediates residency and homing into peripheral tissues of APCs, that 
upon activation and exposure to antigens downregulate CCR5 together with CCR1 to upregulate CCR7 
that drives their migration towards lymphatic vessels and lymph nodes [213]. In the lymph nodes APCs 
encounter CD4+ T helper cells, and this contact induces their production of CCR5 ligands CCL3 and CCL4 
inducing the recruitment of CD8+ T cytotoxic lymphocytes to APC for antigen presentation [209]. CCR5 
knockout mice models do not display obvious phenotypic alteration in physiological conditions but 
reveal deficient immune responses in several pathologies, showing reduced infiltrating leukocytes and 
deficient innate and adaptive immune responses to bacterial and viral infections [214, 215]. The 
supporting role of CCR5 to immune response also occurs in mediating CCL5 stimulation of anti-apoptotic 
signal on macrophages in viral infections [216]. On the opposite, CCR5 deficiency has been associated to 
the prevention of exaggerated immune response, during M. tuberculosis infection or ulcerative 
intestinal inflammation [217, 218]. CCR5 can have a beneficial role in myocardial wound healing in 
ischemia reperfusion injury models [219], but as well can have detrimental effects in the support of 
atherosclerotic plaque formation [220]. 
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CCR5 signaling is characterized by the activation of Gαi proteins, which transduce agonist 
binding that results in the activation of different signaling pathways [99, 208, 221]. CCR5 activation leads 
to the reduction of intracellular cAMP, the generation of transient Ca2+ fluxes, activation of different 
Rho-family small GTPases as RhoA and Rac1, that sustain actin polymerization and cytoskeletal 
rearrangement, focal adhesion kinases (FAK and Pyk2) activation and induces CCR5 C-terminus by GRK 
and PKC that supports β-arrestin recruitment that drives receptor internalization [24, 99, 208]. 
Interestingly CCR5 agonist stimulation can sustain MAPK phosphorylation both in a G protein- and β-
arrestin-dependent manner, since mutant CCR5 lacking phosphorylable sites on the C-terminus do not 
recruit anymore β-arrestins after ligand engagement [222], even if it has to be mentioned that it has 
also been shown that β-arrestins to CCR5 can occur in absence of phosphorylation, not only on receptor 
C-terminus but also on the second ICL, in the DRY region [85, 100]. Receptor activation leads to β-
arrestins recruitment and its internalization mainly through chaltrin-coated vesicles, and also through 
caveolae and lipid rafts in general in which CCR5 can localize thanks to its palmitoylated C-terminus 
[208]. After internalization, the receptor is recycled back on the plasma membrane without associating 
to late endosomes or lysosomes, oppositely to CXCR4 [208, 223]. Biased signaling has been described 
among CCR5 ligands, that have been evaluated in their ability to induce CCR5 dissociation from different 
G protein subunits, β-arrestin recruitment, adenylyl cyclase inhibition and Ca2+ fluxes generation [99, 
102]. In particular, in the paper from Corbisier et al. ligands activity have been compared to CCL3, that 
was chosen as reference ligand, and results indicated that CCL8 acts as a biased agonist, inducing 
stronger Gα subunits dissociation rather than adenylyl cyclase inhibition, and also a more pronounced 
Ca2+ fluxes generation compared to cAMP reduction or to β-arrestins recruitment, indicating a 
preferential activation of Gβγ subunits of CCL8 compared to CCL3 [99]. 
 
1.12-CHEMOKINE SYSTEM REGULATION 
As already mentioned, the chemokine system is regulated at several levels, beginning with the 
regulation of chemokines and chemokine receptors expression and limiting it to specific tissue and cell 
populations or also to specific induction as in the case of inflammatory stimuli as LPS, TNF-α and IL-1β 
[1, 5]. To this point a distinction between homeostatic and inflammatory chemokines can be made, but 
evidence indicate that certain chemokines can exhibit a dual behavior acting on different populations or 
on different receptors, or can be expressed and released in peripheral blood circulation in inactive form 
to be activated upon inflammation [5, 224]. Fundamental to chemotaxis is the formation of a chemical 
gradient, that indicates migrating cells the direction to be maintained. Gradient can be influenced by 
two major factors, one is the passive activity of glycosaminoglycans (GAGs)[54] and the other is 
mediated by atypical chemokine receptors (ACKRs)[225]. Important as well is the role of peptide-
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modifying enzymes that modify chemokines and chemokine receptors, influencing their availability and 
activity [226]. 
 
1.12.1-GAG ROLE IN CHEMOKINE ACTIVITY 
Glycosaminoglycans are constituted by long chains of repeated disaccharide units, that can be 
composed by different saccharides connected by different linkers and different chemical modifications 
[227]. GAGs are present on almost every cell as soluble or surface bound and the most abundant GAG is 
heparan sulfate, whose function as for other GAGs is to bind many different proteins, among which 
proteases and chemokines [227]. The interaction with chemokines is essential to induce correct 
leukocyte recruitment to inflamed tissues, since chemokines produced in inflamed sites are dispersed in 
the local area, until they reach endothelial cells of blood and lymphatic vessel where they remain bound 
to luminal GAGs, which prevent chemokine wash out in the circulation. This immobilization and 
presentation allows leukocytes rolling on the luminal endothelium to encounter chemokines, activate 
integrins that mediate firm adhesion to the endothelium and climb up the chemokine gradient in the 
tissue towards inflamed site [1, 227-229]. Interactions between chemokines and GAGs have been 
reported to depend on several factors, as electrostatic charges interactions, several residues across the 
chemokine sequence, their tertiary structure and their oligomerization [19, 54, 227]. All these properties 
con be modified by enzymes that by post-translational modifications alter chemokine amino acid 
sequence, structure, affecting GAG interactions [226]. 
 
1.12.2-NATURALLY OCCURRING POST-TRANSLATIONAL MODIFICATIONS 
Chemokine system can be regulated at the protein level by different enzymes that acting on 
chemokines can activate, inactivate or modulate chemokine activity with a number of modifications that 
can be found also in vivo [226, 230]. The most important modification occurring is protein truncation, 
mediated by several proteases, expressed by several leukocyte populations and stromal cells and also in 
response to inflammation, indicative of their role in inflammation, and  that preferentially cleave N- or 
C-terminus of chemokines. An example is given by chemokines CXCL16 and CX3CL1, which after 
synthesis remain bound to cell membranes, where in the case of CX3CL1 acts as adhesion molecule, and 
after cleavage by a disentegrin and a metalloproteinase of their transmembrane domain are released in 
their soluble chemotactic form [231, 232]. Another example of such regulation is given by CCL14 and 
CCL15, that are abundant in human plasma in an inactive form, that can be rapidly activated by 
urokinase-type plasminogen activator (uPA), plasmin and cathepsin G with NH2-terminal truncation, 
that activates their inflammatory potential [233, 234]. Matrix metalloproteinases (MMP) are expressed 
by stromal cells and leukocytes and can be upregulated in inflammation and cancer, and can regulate 
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activity of different CC and CXC chemokines [235, 236] as cathepsin G and elastase do [230]. NH2-
truncation of chemokines differently affects chemokine activity depending on the chemokine, since in 
the case of CXCL10 removal of the first three amino acids by CD26 reduces it chemotactic potential 
[237], while removal of NH2-terminus of CXCL7 are necessary to its activation [238]. Post-translation 
modifications can also induce chemokine selectivity for receptors, as it has been observed for CCL5, that 
in its intact form can activate CCR1, CCR3 and CCR5, but after NH2-truncation of its first two amino acids 
increases its potency on CCR5 but becomes an antagonist for CCR1 and CCR3, which is no longer able to 
activate [239], indicating that post-translational modification can possibly generate biased agonism. 
 
1.12.3-POST-TRANSLATIONALLY MODIFIED VARIANTS OF CXCL8 AND CXCL5 
CXCL8 is produced in cells as a precursor protein that after different cleavages of the signal 
peptide becomes a mature protein consisting of 77 amino acids (1-77) that can be released, that is the 
most abundant variant, even if a variant derived from alternative removal of the signal peptide has been 
described, with two residual NH2-terminal amino acids (-2-77) in addition compared to CXCL8 1-77 
(Figure 6) [240, 241]. CXCL8 is an ELR+ CXC chemokine, in which the ELR motif is positioned after 8 NH2-
terminal aminoacids, and is necessary to sustain CXCL8 chemotactic activity. Different proteases can 
cleave CXCL8 NH2-terminus generating different variants. CD13 can remove 1 or 2 amino acids to 
produce 2-77 and 3-77 CXCL8 (Figure 6), while plasmin, thrombin and MMPs can remove up to 8 
residues until the ELR motif, producing 6-77, 7-77, 8-77 and 9-77 CXCL8 (Figure 6) [16, 240]. CXCL8 
variants activity increases with NH2-terminal truncation, since -2-77, 1-77, 2-77, 3-77 variants display 
similar potency that is increased in 6-77 or further truncated variants [16, 240]. CXCL8 NH2-terminus can 
also be modified by peptidylarginine deiminases that removes from arginine NH2
+ groups, replacing 
them with oxygen changing a positively charged arginine in a neutral citrullne (Figure 6), therefore this 
process is also known as citrullination [242]. Citrullination of NH2-terminal  arginine in position 5 (Arg
5) 
results in similar induction of Ca2+ fluxes and desensitization on CXCR1 and in stronger activity on CXCR2, 
compared to the intact 1-77 non citrullinated variant, in similar chemotactic ability in vitro but shows an 
impared chemotactic activity in vivo, due to a reduced affinity to GAGs [242]. 
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Figure 6: NH2-terminal sequence of CXCL8 and truncated variants. A-The sequences of CXCL8 precursor, intact, truncated and 
citrullinated variants are reported, with the indication of the enzyme that can generate that variant [240]. B- Chemical 
modification exerted by peptidyl arginine deiminase that from arginine produces citrulline (B) [228].  
 
CXCL5, agonist of CXCR2 but not of CXCR1, has also been described to undergo different NH2-
terminal processing, leading to generation of variants occurring naturally in extracts from biological 
samples [243]. Intact CXCL5 (1-78) has been shown to mediate neutrophil chemotaxis in vitro, but in 
vivo lacks this ability, which instead occurs upon NH2-terminal cleavage by MMP-8 and -9 and cathepsin 
G that generate 8-78 and 9-78 CXCL5, increasing its potency both in vitro and in vivo [243-245]. CXCL5 as 
well can be citrullinated on its NH2-terminus, on Arg
9, but while for CXCL8 an activity reduction could be 
observed only in in vivo models, citrullinated 1-78 CXCL5 displayed reduced signaling and chemotactic 
activity compared to intact CXCL5 already in in vitro assays and evidences were confirmed in vivo [245]. 
These enzymes are present in inflammatory microenvironments, where many enzymes can act 
simultaneously, therefore this modifications have also been tested for the ability to prevent excessive 
truncation that results in chemokine degradation. Intact citrullinated CXCL5 is cleaved by cathepsin G as 
efficiently as intact CXCL5, while limited truncation of CXCL5 to 2-78 CXCL5 was able to prevent further 
cleavage [245], while in the case of CXCL8, citrullination prevents its cleavage to thrombin or plasmin 
processing [242]. 
 
1.13-ATYPICAL CHEMOKINE RECEPTORS (ACKRS) 
In addition to the above mentioned mechanisms, host chemokine system regulation relies on 
the activity of atypical chemokine receptors (ACKRs) that constitute a smaller group of chemokine 
receptors, including at present 4 members named ACKR1 (DARC), ACKR2 (D6), ACKR3 (CXCR7) and 
ACKR4 (CCX-CKR) and with two other members pending this classification at the moment, CCRL2 and 
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PITPNM3, waiting for better characterization and functional confirmation [3, 246, 247]. Previously called 
decoys, interceptors, scavengers, or chemokine-binding proteins, the acknowledged term is now 
“atypical” as a consequence of their inability to mediate cell migration as conventional chemokine 
receptors. Evidence indicates that ACKRs exert a non-redundant role in shaping chemokine gradients 
and dampening inflammation by sequestering chemokines from the microenvironment, thus emerging 
as crucial regulatory components of chemokine networks in a wide range of developmental, 
physiological and pathological contexts [225, 246]. Recent increasing evidence have shown that to 
mediate their function ACKRs use alternative signaling pathways as compared to those observed for 
conventional chemokine receptors, acting as biased signaling receptors, compared to their conventional 
counterparts [143, 225, 246]. Consistent with their regulatory activity on a highly promiscuous system, 
all ACKRs have more than one ligand [225, 248], and in particular ACKR1 and ACKR2 have a large 
spectrum of ligands, while ACKR3, ACKR4 and CCRL2 are specific for a narrow spectrum of ligands [225]. 
Interestingly, even if some ACKRs recognize only a limited number of chemokines, this is a very 
promiscuous receptor family, since while only ACKR2 is specific for inflammatory CC chemokines [249], 
while the others can bind both CXC and CC chemokines, as ACKR1 and ACKR4 [250, 251]. Evidence on 
CCRL2 are not clear, but at the moment it is considered able to bind two CC chemokines, inflammatory 
CCL5 and homeostatic CCL19, other than Chemerin, a non-chemokine migratory protein [252], and 
ACKR3 is able to bind not only CXCL12 and CXCL11 [253, 254] but also regulates the activity of different 
peptides, the Macrophage Migration-Inhibitory Factor, a pleiotropic cytokine with chemokine-like 
functions involved in numerous inflammatory conditions [255], the intermediate opioid peptide BAM22, 
and adrenomedullin, involved in circadian glucocorticoid oscillation and in cardiac and vascular 
development, respectively [256, 257].  
 
1.13.1-ACKRS EXPRESSION 
According to their intrinsic inability to promote cell migration and their role in shaping the 
chemokine gradient, ACKRs are mainly expressed on endothelial and epithelial cells at barrier sites (i.e. 
skin, lung, gut, brain, placenta) rather than on migratory cells as their conventional counterparts [225]. 
All ACKRs except ACKR4 are expressed at the blood-brain barrier, and all are expressed on endothelial 
cells. In particular, ACKR1 and CCRL2 are specifically expressed on vascular endothelium [258, 259] 
whereas ACKR2 and ACKR4 on the lymphatic one [260, 261]. ACKR3 expression on vascular endothelium 
is well established, while data on its expression on lymphatic endothelium are controversial [256, 262]. 
Differently from conventional counterparts, ACKRs are usually poorly expressed on cells of 
hematopoietic origin. ACKR1, ACKR2 and CCRL2 have been reported in some leukocytes subsets, B 
lymphocytes in particular, whereas data on ACKR3 and ACKR4 are currently controversial due to 
different techniques and protocol used and to the absence of specific tools [3, 225, 246]. ACKR1 is the 
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only ACKR expressed on erythrocytes [263], whereas platelets express constitutively ACKR3 [264, 265] 
and ACKR2 upon systemic sclerosis [266]. Under specific conditions, ACKRs are co-expressed with 
conventional counterparts on leukocytes and fine tune the chemokine system also interfering with the 
activation of conventional chemokine receptors through direct competition for cognate ligands. Best 
example is the CXCL12/CXCR4/ACKR3 “eccentric trio” [267], with ACKR3 co-expressed with its 
conventional counterpart CXCR4 in several leukocytes, including B and T lymphocytes [268, 269]. Co-
expression of ACKR1 and CCR5 has been observed on primary endothelial cells [270], whereas CCRL2 is 
co-expressed with its conventional counterpart CCR7 on B cells in a maturation stage-dependent 
manner and on DCs upon stimulation with pro-inflammatory stimuli [271, 272]. ACKRs have also been 
reported to interfere with the signaling pathways of co-expressed conventional chemokine receptors, 
indicating their regulatory activity may not be restricted to receptors with shared ligands but also apply 
to receptors co-expressed on the same cell. Examples are provided by ACKR2 interfering with CXCR5 
signaling on B lymphocytes [273] and ACKR4 interfering with CXCR3 signaling on T lymphocytes [274]. 
Finally, it has to be noted that ACKRs expression on different cell contexts may correspond to different 
functional properties, as exemplified by ACKR1 which acts as a sink on erythrocytes and as a transporter 
on endothelial cells [258]. Gene-targeted animal models have been generated for all ACKRs, and while 
ACKR1-/- and ACKR2-/- animals exhibit normal development and show defects only upon challenge with 
inflammatory stimuli [275, 276], ACKR3-/- and ACKR4-/- animals exhibit severe phenotypes correlated to 
their regulation of homeostatic chemokines. ACKR4 deficiency alters thymic homeostasis resulting in the 
spontaneous development of autoimmune reactions [277], while ACKR3-/- animals suffer early lethality 
caused by severe cardiovascular defects [278] due to its regulation of adrenomedullin signaling [256]. 
CCRL2-/- mice develop normally to term, have normal lifespan and do not show an overt phenotype 
under steady-state conditions, but exert defects in DCs migration to peripheral lymph nodes and mast 
cells responsible for reduced Th2 responses and cell-mediated contact hypersensitivity, respectively 
[271]. 
 
1.13.2-MECHANISMS OF ACTION OF ACKRS 
Though as mentioned the ability to shape the chemokine gradient is a common property, 
different ACKRs use different mechanisms to fulfill this function, allowing ACKRs to be further classified 
into three “professional” categories: scavengers, transporters, and presenter [3]. ACKR2, ACKR3, ACKR4 
and CCRL2 share the ability to scavenge chemokines [274, 279-283], mediating their clearance to reduce 
leukocyte migration. ACKR1 and ACKR5 share the ability to transport and present their ligands to other 
receptors [252, 258, 284, 285], and when expressed on erythrocytes ACKR1 also acts as a sink/reservoir 
for chemokines, thus working as a chemokine “buffering” receptor [275, 286].  
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The ability to interfere with conventional chemokine receptors activation represents an 
additional common theme among ACKRs, though the underlying molecular mechanisms are still largely 
undefined. All ACKRs but not ACKR4 have been demonstrated to be able to interfere with signaling 
properties of conventional receptors through direct binding of cognate ligands, and ACKR1, ACKR3 and 
ACKR4 have also been shown to homo- and heterodimerize with conventional chemokine receptors 
[270, 274, 281, 287], impacting on the activity of other receptors [271, 272], mainly inhibiting 
chemokine activity. In the case of ACKR3 though co-expression with CXCR4 improves CXCR4 chemotactic 
ability [278, 287, 288]. Intracellular trafficking properties of ACKRs are of major relevance for their 
chemokine gradient shaping functions. Constitutive trafficking has been interpreted as a mechanism 
allowing to rapidly cope with changes in cellular requirements and is a common feature to most 
scavenger ACKRs, though information on ACKR1 is not available and currently debated for ACKR5 [225, 
248, 289]. Of note however, constitutive trafficking is not a unique feature of scavenger ACKRs, as 
increasing emerging evidence indicates that several conventional chemokine receptors also undergo 
constitutive internalization and recycling as CXCR4, CCR7 and CCR1 [106, 290, 291]. Interestingly, 
constitutive trafficking correlates with ACKR subcellular localization, as scavenger ACKRs are mainly 
located in recycling endosomes, whereas transporter and presenter ACKRs are preferentially expressed 
on the cell membrane [225, 248, 289].  
 
1.13.3-ACKRS SIGNALING ACTIVITIES 
A distinguishing feature of ACKRs, which initially allowed their classification as “silent” receptors, 
is their inability to sustain cellular migration [8], which is caused by absent or negligible ability to 
activate G protein signaling [143, 246, 247, 282, 292]. The only exception is ACKR3, which is 
constitutively associated to Gαi protein [287] and activates Gαi signaling upon CXCL12, but not CXCL11, 
stimulation in rodent astrocytes and human glioma cell lines [293]. Noteworthy, although ACKR4 is 
unable to activate Gαi, Gαs or Gαq subunits, uncoupling of constitutively associated Gαi by pertussis 
toxin allows the receptor to slightly increase cAMP levels upon ligand engagement [294]. This lack of G 
protein activity can rely in some alterations ACKRs share in sequence motifs responsible for Gα 
activation and in some micro-switches [33, 143]. Changes are particularly evident for the DRYLAIV motif 
located in the second intracellular loop, which is mutated very differently among ACKRs, with ACKR3 
retaining the sequence most similar to the canonical one. However, with some exceptions in specific 
conditions and cell types, ACKRs are usually unable to activate the Gα protein-dependent signaling 
pathway, which is in any case dispensable for their chemokine regulatory functions [282, 292]. Though 
chemokines acting on conventional chemokine receptors in most the cases signal in a balanced fashion 
through the G protein and β-arrestin modules [61, 295], specific ligand or specific conditions can 
influence receptor signaling, inducing biased signaling [78] and this occurs also in the chemokine system 
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[34, 99, 134]. In line with this emerging view ACKRs have been proposed as structurally β-arrestin-biased 
receptors [143], since they are able to associate β-arrestins  and this interactions regulate ACKRs 
intracellular distribution, trafficking, signaling and functions [281, 282, 292, 294, 296, 297]. Exceptions 
are represented by CCRL2, which has not been investigated in this respect, and ACKR1, which has been 
shown to induce ERK1/2 phosphorylation in human airway smooth muscle cells whose expression of β-
arrestins is debated [270, 298, 299]. In conclusion, β-arrestins recruitment is emerging as a unifying 
theme among ACKRs, that therefore can be considered as structurally β-arrestin-biased receptors, that 
could contribute to the fine characterization of GPCR signaling activities [143, 225].  
 
1.14-ACKR2 
ACKR2 is the best-characterized atypical chemokine receptor, which shapes the chemokine 
gradient by acting as scavenger for CC inflammatory chemokines. The predominant expression sites are 
“barrier tissues” such as the skin, gut, and lung. Within these tissues, lymphatic endothelial cells (LECs) 
of afferent lymphatic vessels are the major site of expression [300]. In addition, ACKR2 is strongly 
expressed in the placenta where it is present on invading trophoblast cells, on the apical side of 
syncytiotrophoblast cells and on decidual macrophages [301]. This specific ACKR2 expression confirms 
its important role in modulating the inflammation and immunosuppressive function status on lymphatic 
vessel and at materno-fetal barrier, respectively. Moreover, ACKR2 has been reported also to be 
expressed on vascular tumors [300] and at low levels in a range of circulating leukocytes [302, 303], 
including mast cells, macrophages, neutrophils [304], with most marked expression being evident on 
subsets of B cells as well as on both plasmacytoid, myeloid DCs and human alveolar macrophages of 
chronic obstructive pulmonary disease (COPD) patients [305]. Its expression has been also observed on 
astrocytes, at central nervous system [306]. Most recently, strong expression of ACKR2 on murine 
innate-like B cells has been shown suggesting that these cells are the major vehicles for in vivo ACKR2 
function [273, 307]. 
ACKR2 7TM structure is well conserved compared to conventional CCR2 and CCR5 chemokine 
receptors, with an overall sequence identity that is in the 30–35% range of similarity with these 
conventional receptors, as same as the N-terminal domain that presents several charged residues, 
mainly involved in ligand recognition such as acidic amino acids, sulphated moieties and N-linked 
glycosylation sites, but whether receptor sulphation or glycosylatation are important for ligand binding 
remains still to be demonstrated [308]. The main structural differences are observed within the 
transmembrane and C-terminal domains. First, the aspartic acid and the DRYLAIV motif are mutated into 
an asparagine and DKYLEIV respectively. Interestingly, the DKYLEIV motif is highly conserved across the 
species [273]. The correction of this motif confers weak G proteins-mediated signaling [297], showing 
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how the alteration of DRY motif is at least in part responsible for the lack of conventional signaling 
activities of ACKR2. Conversely, the TxP motif is highly conserved, suggesting that receptor could be 
activated upon ligand engagement as same as the conventional counterparts. Second, ACKR2 C-tail, 
starting at amino acid 312 till 384, is longer than conventional receptor, and contains a serine/threonine 
cluster and a putative 8th helix. The C-tail is involved in ACKR2 internalization both in basal and upon 
ligand stimulation, allowing receptor recycling to and from the plasma membrane and progressive 
chemokine depletion [72, 292]. Moreover, this domain prevents ACKR2 degradation protecting the 
receptor from entrance into late endosomes. In fact, truncation of ACKR2 C-tail or 8th helix, or 
substitution of serine cluster with alanine, strongly impairs receptor stability on cell surface, by targeting 
to lysosomal compartment through ubiquitination of 142 and 324 lysine residues, that are highly 
conserved in all mammalian ACKR2 sequences [309]. 
Although ACKR2 recognizes a wide spectrum of chemokines, the receptor expresses some 
selectivity in ligand recognition. Neither homeostatic CC-chemokines, mainly agonists of CCR6–CCR10 
receptors, nor chemokines belonging to other chemokine subfamilies (i.e. CXC, XC, CX3C) [249, 300] are 
recognized. Conversely, ACKR2 is able to interact with most agonists at inflammatory CC chemokine 
receptors from CCR1 to CCR5 (Figure 7) [249, 300]. Even among inflammatory CC chemokines, ACKR2 
recognition is restricted to the biologically active form. For example, the intact biologically active 
molecule form of CCL22 is efficiently recognized by ACKR2, while N-terminal CD26-processed CCL22 
variants, which lose their ability to trigger leukocyte recruitment once bound to CCR4, are not 
recognized by the receptor [300]. The chemokine binding does not necessary induce ligand degradation, 
as demonstrated by Savino et al. In fact, ACKR2 is not able to degrade the three cleaved form of CCL14, 
but only the active one. CCL14(1-74) is a homeostatic chemokine, prevalently presents in inactive form 
in blood flow, having a reduced agonist activity on CCR1. The protease CD26 cleave CCL14 into its active 
form CCL14(9-74), which is recognize and degraded by ACKR2 [310]. This truncated form can be further 
cleaved into CCL14(11-74), biologically inactive and not degraded by ACKR2. ACKR2 binds with high 
affinity all the three cleaved form of CCL14, but only the active one is degraded. The degradation seems 
to be induced by the presence of a proline in position 2 at the N-terminus (Figure 7), as has been 
observed in other active chemokine, such as CCL3 and CCL8, which exist also in the truncated form 
lacking proline in position 2 and consequently inactive [310]. For this reasons, chemokine are classified 
in active and neutral ligand, as reported in Figure 7. 
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Figure 7: ACKR2 ligand classification. The first class also known as active ligands, having a proline residue in position 2 
at the N-terminus, bind ACKR2 with high affinity and are degraded with high efficiency. Neutral ligands, of the second and the 
third classes, bind ACKR2 with high affinity, but are degraded with low efficiency or are not degraded, respectively (Figure 
derived from [310]). 
 
ACKR2 scavenger activity relies on its peculiar trafficking properties. In fact, ACKR2 is not 
regulated or inducible at transcriptional level, but its membrane expression is highly regulated by its 
intracellular traffic (Borroni E.M., unpublished observation). In resting condition, the receptor is 
predominantly located in intracellular compartments at perinuclear levels and only 10% is detectable on 
the cell surface. ACKR2 is constitutively associated to both early (Rab4/5) and recycling endosomes 
(Rab11) [311], but not with lysosomes (Rab7) [308, 312], which finely control its constitutive 
internalization and recycling. Differently from canonical chemokine receptors, after chemokine 
engagement, ACKR2 does not decrease its membrane expression, thus optimize its degradatory activity 
by increasing its membrane abundance through a slow Rab11-dependent recycling pathway [313]. Once 
internalized, ligand dissociate from the receptor, and is targeted into lysosomal vescicles (Rab7) for 
degradation, while the receptor is recycled back to the plasma membrane through both rapid (Rab4) 
and slow (Rab11) recycling endosomes [313] (Figure 8). Thus, constitutive internalization and recycling, 
and ligand-dependent receptor mobilization to cell surface are mechanisms adopted by ACKR2 to allow 
rapid modulation of ligand uptake and degradation [314].  
 
 
 
1-Introduction 
35 
Figure 8: ACKR2 intracellular traffic. In basal condition, ACKR2 is internalized in a Rab5/Dynamin-dependent 
mechanism and it recycles back to the plasma membrane through a Rab4/Rab11-dependent way. ACKR2 mobilization from 
intracellular compartments is induced by stimulation only with active ligands, having a proline residue in position 2 at the N-
terminus. These ligands are degraded in a Rab7-dependent mechanism. On the other hand, neutral ligands do not induce 
receptor up-regulation and its distribution, and they are not degraded (Figure modified from [311]).  
 
To date, chemokine-dependent mobilization is the only mechanism known to regulate ACKR2 
membrane expression and degradative activity [248]. It is important to note that only active ligands can 
induce rapid mobilization of the receptor to the plasma membrane [310, 313], suggesting that some 
signal events activated upon ligand engagement can occur in order to promote receptor cycling. 
According to that, a G protein-independent β-arrestin1-Rac1-PAK1-LIMK1-cofilin signaling dependent 
signaling events downstream ACKR2 controlling the actin cytoskeletal dynamics, have been recently 
demonstrated that to be required for regulating receptor trafficking properties and scavenger 
performance [292]. 
ACKR2 scavenger activity and its role in dampening inflammation have been confirmed in 
several murine models of inflammatory-based pathologies using ACKR2 KO mice. These mice have been 
generated by D.N. Cook and S.A. Lira [276] and present a highly inflammatory responses and high levels 
of pro-inflammatory CC chemokines, in particular at skin and lymph nodes level, developing a prolonged 
inflammatory response [301]. Interestingly, in homeostatic condition, ACKR2 KO mice present an 
increased number of Ly6Chigh circulating and spleen monocytes, while this population is highly decreased 
in the bone marrow [228]. In addition, circulating monocytes present an immature phenotype, possibly 
due to the absence of ACKR2 expression on the non-hematopoietic compartment and lymphatic vessels, 
which normally express ACKR2 at high levels [315].
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Chemokines and chemokine receptors drive leukocytes migration in homeostatic and 
inflammatory conditions, therefore are considered key regulators of immune response [1]. Chemokines 
and chemokine receptors are divided into four families (out of which CXC an CC families are the best 
characterized) depending on chemokine structure which determines their recognition by different 
receptors, since receptors can bind different ligands but only from the same family, with receptors that 
can be activated by different ligands and as well chemokines that can activate different receptors [5]. 
Chemokine system regulates cell migration in different and fundamental activities in controlling cell 
positioning during development [4], and in adult organism directing immune system activity in both 
physiological and pathological conditions [3, 55, 316]. Given the complexity and the many functions 
regulated by this system, its regulation is crucial to increase system potency at defined moments to fight 
against infections or adverse events, but is also important to turn off the system when the danger has 
been removed to allow tissue repair prior returning to homeostasis and prevent off-target activity of 
immune cells. Dysregulation of chemokine system in fact has been associated to immune-deficiency, 
infections, allergy, auto-immune diseases and cancer, where tumor cells-secreted chemokines recruit 
leukocytes within the tumor to support tissue remodeling and vascularization and chemokine receptors 
expressed by tumor cells can promote cells survival [8-11, 225]. Chemokine activity regulation occurs 
through different mechanisms, among which the most important are chemokine post-translational 
modifications, mediated by several enzymes that affect chemokines activity and binding specificity, and 
atypical chemokine receptors (ACKRs) that despite binding chemokines with high affinity do not induce 
cell migration on the cells they are expressed but rather regulate chemokines activity by their 
transportation, degradation, or presentation [3, 224-226]. Chemokine receptors belong to the 
superfamily of G protein coupled receptors (GPCRs), constituted by 7 transmembrane spanning 
molecules that upon agonist recognition activate several downstream signaling pathways, mainly 
mediated by G protein, arrestins and kinases, that in recent years have been challenging classical 
pharmacology with the concept that receptor does not simply switch from an inactive to an active 
status, but different agonists can produce only selected outcomes on receptor signaling, generating 
what is now called biased signaling or functional selectivity [84, 115, 317]. In the chemokine system this 
ability has already been characterized to occur, with different chemokines activating on the same 
receptor different signaling pathways with different intensities [34, 102, 114, 134], giving biased 
agoinsm, or with receptors activating different signals depending on the cell they are expressed in [293] 
resulting in system bias. Another possible bias can depend on the inability of the receptor itself to 
activate all the signaling pathways conventionally activated by the same ligand on conventional 
receptors, due to sequence modifications in key signaling motifs that result in structural bias, as in the 
case of atypical chemokine receptors [282, 292, 294]. To this point the aim of this thesis is to investigate 
the existence of biased signaling occurring in the chemokine regulation system to provide a better 
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understanding of mechanism involved in the fine tuning of chemokine activity. Therefore the first aim of 
this thesis is to assess whether post-translational modification naturally occurring in inflamed tissues on 
CXCL5 and CXCL8, that regulate activity of this two chemokines by both increasing and decreasing their 
potency, could underlie the generation of a bias on the signaling properties of CXCR1 and CXCR2 
receptors. This has been made in collaboration with professor Paul Proost from KU Leuven in Belgium, 
who provided us different post-translational chemokine variants. We also evaluated the signaling ability 
of ACKR2, one of the best characterized atypical receptors, that is a structurally biased receptor unable 
to activate G proteins but able to signal through a β-arrestin dependent mechanism, to support its 
activity of inflammation suppressor. 
Despite their involvement in many immune diseases and inflammatory-related pathologies and 
the investments made so far by different companies, only three drugs are currently available on the 
market targeting the chemokine system, due to the complexity and the redundancy of the chemokine 
system [10, 11, 125]. Therefore the second aim of this thesis is to translate to a clinical relevance 
acquired skills and knowledge to provide a possible understanding on the molecular reasons why drug 
development for chemokine receptors often results in adverse side effects or in therapeutic inefficacy. 
In particular, we investigated if allosteric non-competitive inhibitors for chemokine receptors could 
represent a novel mechanism to prevent leukocyte chemotaxis, by blocking only selected signaling 
pathways and modulating receptor signaling towards a biased signaling. To this point we performed in 
vitro assays aimed at determining whether signaling bias on CXCR1 can be induced by Reparixin, a small 
molecule designed by the Italian pharmaceutical company Dompé to target the allosteric binding pocket 
of CXCR1. This molecule, able to block leukocyte migration and not CXCL8 binding to the receptor, has 
already demonstrated to be a promising drug to inhibit inflammation in several preclinical models and in 
advanced clinical trials to be an efficient therapy for preventing rejection of pancreatic islets after 
transplantation. 
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3.1-CHEMICALS AND ANTIBODIES 
Recombinant human CCL3, CCL3L1, CXCL8 and CXCL5 chemokines were from R&D Systems (Minneapolis, 
Minnesota, US). Modified variants of CXCL5 and CXCL8 have been synthesized by FMOC technology and kindly 
provided by professor Paul Proost from KU University of Leuven.  
For Western blot analysis, antibodies for phosphorylated cofilin (P-Cofilin, Ser-3) and mouse anti α-tubulin 
antibody were from Cell Signaling Technologies and Sigma-Aldrich, respectively. Anti-rabbit and anti-mouse IgG-
horseradish peroxidase conjugated secondary antibodies were provided by GE Healthcare GmbH (Freiburg, 
Germany).  
For cytofluorimetric analysis, unconjugated anti-HA monoclonal antibody and mouse IgG1 isotype control 
were from Covance. Goat anti-mouse IgG Alexa® Fluor 647-conjugated secondary antibody was purchased from 
Molecular Probes. Antibody staining is performed in FACS buffer: PBS 1X with Ca
2+
/Mg
2+
 + 1% BSA + 0.01% Sodium 
Azide. 
 
3.2-CELL CULTURES AND TRANSFECTIONS 
Human embryonic kidney (HEK293) wild type cells or stably expressing human CXCR1 and CXCR2 were 
cultured in DMEM (Lonza) supplemented with 10% fetal bovine serum (FBS) (Euroclone, Milan, Italy), 2mM 
UltraGlutamine (Lonza), 100 U/ml of penicillin/streptomycin (P/S) (Lonza), 25 mM HEPES (Gibco, Life Technologies 
Ltd). Stable transfectants were generated by lipofection with Lipofectamine2000 (Life Technologies) following 
manufacturer's instructions, with the HA-CXCR1 pcDNA6 or HA-CXCR2-pcDNA6 plasmids, and selected with 50 
µg/ml of Blasticidin (Invitrogen, Life Technologies Ltd) and maintained as bulk populations. HEK293 cells were co-
transfected with various combinations of donor and acceptor plasmids with acceptor plasmid used 3 times the 
amount of donor plasmid used for the BRET using Polyethylenimine (PEI), as described in BRET1 and BRET2 
sections. 
 
3.3-PLASMIDS 
Plasmids encoding HA-CXCR1, HA-CXCR2, HA-ACKR2 and HA-CCR5 fused to RLuc were generated by 
amplification with Q5 high fidelity polymerase (New England Biolabs, NEB) cDNA sequences of plasmids already 
available in the laboratory, with degenerate primers inserting restriction enzyme sites at the extremities, to clone 
by restriction enzyme digestion and ligation the sequences in pRLuc-N3 (Perkin Elmer). Restriction sites used are 
HindIII at 5’ of all the sequences, while at the 3’ we used BamHI for ACKR2 and CCR5 and SmaI for CXCR1 and 
CXCR2, and these plasmids were used to generate by sub-cloning all the plasmids encoding receptors sequences 
fused to VENUS, in empty vectors kindly provided by dr. Julie Perroy. Bovine β-arrestins fused to EYFP were kindly 
gifted by dr. Bice Chini and dr. Marta Busnelli from the Italian National Research Council, Department of 
Neurosciences, Milan, Italy, and have been used to sub-clone β-arrestins sequences in pGFP
2
-N3 (Perkin Elmer) to 
generate β-arrestins-GFP
2
 and in RLuc8 empty vector provided by dr. Julie Perroy. Human β-arrestins sequences 
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have been cloned by human cDNA collection to empty pRLuc-N3 (Clontech) and subsequently sub-cloned with 
ACKR2 and CCR5 in pEYFP-N1 and pEYFP-C3 (Clontech), and pRLuc-C1 (Perkin Elmer) to generate all the 
combinations to explore how reporter orientation affected BRET. HA-ACKR2 and HA-CCR5 were sub-cloned in 
empty pcDNA4/To exploiting HindIII and XhoI restriction sites present in plasmids available in the lab. All the 
constructs were Sanger-sequenced on both strands to verify correct insertion of the sequence in the vector, 
absence of mutations and that undesired stop codons or frame-shifts were  not intercurring between proteins of 
interest and reporters. 
 
3.4-CHEMOKINE RECEPTORS EXPRESSION AND CXCR1 INTERNALIZATION  
Chemokine receptors membrane expression was evaluated as followed. Cells (5x10
5
) were labelled with ice-
cold FACS buffer containing 5 μg/ml of anti-HA antibody for 1 hour. Cells were then stained with an APC-
conjugated goat anti-mouse IgG as secondary antibody for 30 minutes in FACS buffer and fixed in PBS with 1% 
formalin for 15 minutes. 10
4
 events of viable cells identified by FSC-H and SSC-A parameters were acquired by BD 
FACSCanto flow cytometer and analyzed by BD FACSDiva software (BD Biosciences). Data were calculated as 
percentage of mean fluorescence intensity (MFI) of stimulated over unstimulated cells or treated over untreated 
cells. 
To evaluate CXCR1 cell surface abundance after chemokine stimulation, 2x10
5
 cells were resuspended in 90 
μl of DMEM + 1% BSA and incubated 20 minutes at 37°C before stimulation with with or without CXCL8 (100 nM) 
for indicated time points, then transferred on ice, washed with PBS and stained and analyzed by flow cytometry as 
previously described.  
 
3.5-COFILIN PHOSPHORYLATION ASSAY 
HEK293 T-Rex ACKR2 and CCR5 cells (3 x 10
5
) were seeded onto 12 wells plate, previously coated with 100 
µl/well of poly-L-lysine for 30-40 minutes at 37°C and grown in complete culture media without antibiotics at 37°C 
for 18 hours. Cells were serum-starved by replacing FBS with 0.1% BSA for 18 hours before chemokine stimulation. 
Cells were subsequently stimulated in pre-warmed DMEM + 1% BSA with 100 nM of CCL3L1 added at the indicated 
time points. After chemokine stimulation, cells were washed with PBS, lysed and processed as described in 
western blot paragraph. 
 
3.6-WESTERN BLOT 
Cells were lysed for 5 minutes with ice-cold lysis buffer (50 mM Tris HCl pH 8 + 150 mM NaCl + 5 mM 
EDTA + 1.5 mM MgCl2 + 1% Triton X-100 + 10% glycerol) freshly prepared and supplemented with protease 
inhibitors EDTA-free (Roche, Basel, Switzerland), 100 µg/ml PMSF and phosphatase inhibitors: 0.01 M sodium 
3-Materials and Methods 
42 
pyrophosphate, 50 mM sodium fluoride (NaF) and 0.01 M sodium orthovanadate (Na3VO4). After centrifugation at 
13000 rpm at 4°C for 20 minutes, cell supernatants were quantified by DC Protein Assay (Bio-Rad, Hercules, 
California, US) following manufacturer’s instruction. Equal protein amounts of total cell lysates (20-50 µg) were 
diluted in Laemmli Sample Buffer (Bio-Rad), containing 0.71 M β-mercaptoethanol, loaded in 12% or 4-20% 
polyacrylamide pre-casted minigels (Bio-Rad) and then transferred polyvinylidene fluoride (PVDF) membrane (Bio-
Rad). Membranes were blocked in 5% non-fat dry milk (Nestlé, Vevey, Switzerland) in TBS-T (TBS + 0.1% Tween 20. 
TBS: 25mM Tris HCl pH 7.5 + 150 mM NaCl) for 1-2 hours at RT, rinsed with TBS-T for 5 minutes and then incubated 
overnight at 4°C with 1:1000 dilution in TBS-T + 5% BSA of the primary antibody against phospho-Ser3 Cofilin (CST). 
Membranes were washed 5 times for 5 minutes with TBS-T and incubated for 1 hour at RT with 1:2000 dilution in 
TBS-T + 5% BSA of anti-rabbit IgG-horseradish peroxidase conjugated secondary antibody. Membranes were 
washed 5 times for 5 minutes with TBS-T and incubated with chemiluminescent HRP substrate (Immobilon 
Western- Millipore, Billerica, Massachusetts, US). Blots were acquired by ChemiDoc XRS Imaging System (Bio-Rad). 
Densitometric analysis was performed by Quantity One software (Bio-Rad) and protein band intensity was 
calculated by normalization over α-tubulin band intensity. α-tubulin staining was performed by using 1:4000 
dilution, in TBS-T + 5% BSA of mouse anti-α-tubulin primary antibody for 2 hours at RT, followed by incubation at 
RT for 1 hour with 1:2000 dilution in TBS-T + 5% BSA of anti-mouse IgG-horseradish peroxidase conjugated 
secondary antibody. Bands were detected as approximately 50 kDa (α-tubulin) and 19 kDa (cofilin). 
 
3.7-BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET). 
BRET1. In this assay the receptor is fused at its C-terminal tail with the donor RLuc and coexpressed with a 
fusion protein between EYFP and β-arrestins (β-arrestin1 or β-arrestin2). Variations in the BRET1 signal were 
monitored kinetically or in a concentration-dependent manner after ligand addition. To co-express the two fusion 
proteins, 3x10
6
 HEK293 cells were seeded in 10 ml of complete DMEM into 100 mm tissue culture dish and after 
18 h at 37°C, cells were transiently co-transfected with 1,5 μg of RLuc fusion-donor plasmid and 5 μg of EYFP 
fusion-donor plasmid or empty pcDNA3 vector, mixed in 1,5 ml of Optimem (Life Technologies), to which 19.5 μg 
of PEI (from a 1 mg/ml stock solution) were added, gently vortexed for 15 seconds and incubated 20 minutes at 
room temperature before being transferred onto cells. 48 hours later, cells were washed twice with PBS, detached 
with Versene, and resuspended in BRET assay buffer (PBS, pH 7.4 + 0.5 mM MgCl2 + 0.1% (w/v) glucose). Cells were 
quantified as protein content by DC Protein Assay and 80 µg of proteins/well were distributed in a 96-wells 
microplate (polystyrene Black Frame & White Well; PerkinElmer). Kinetic measurements were done assaying at 
most 4 wells at once to measure luminescence emission values of each sample every 13 seconds. Measurements 
were made by incubating cells with 5 µM of Coelenterazine h (Life Technologies) for 8 min before stimulation with 
100 nM of chemokines or PBS as vehicle and then luminometer readings were started. All reagents were 
previously diluted in BRET assay buffer. Alternatively, dose-response curves were generated by incubating 80 μg 
cells with various concentrations of chemokines and after 20 minutes Coelenterazine h was added for 8 additional 
minutes. BRET1 signal between RLuc and YFP was measured using a Synergy H4 reader (BioTek) that allows the 
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sequential integration of signals detected with RLuc filter (440/40 nm) and YFP filter (540/35 nm). BRET ratio was 
calculated as follows:  
 
𝑩𝑹𝑬𝑻 𝒓𝒂𝒕𝒊𝒐 =
𝑬𝒎 𝒀𝑭𝑷
𝑬𝒎 𝑹𝒍𝒖𝒄
 
 
The changes in BRET induced by the ligands reflect the amount of β-arrestins recruitment to the receptor. 
These were monitored in real-time up to 20 minutes and expressed on graphs as Δ BRET or BRET ligand effect 
using the formula:  
 
𝑩𝑹𝑬𝑻 𝑳𝒊𝒈𝒂𝒏𝒅 𝒆𝒇𝒇𝒆𝒄𝒕 =
𝑩𝑹𝑬𝑻 𝒓𝒂𝒕𝒊𝒐 (𝒍𝒊𝒈𝒂𝒏𝒅 − 𝒕𝒓𝒆𝒂𝒕𝒆𝒅 𝒄𝒆𝒍𝒍𝒔)
𝑩𝑹𝑬𝑻 𝒓𝒂𝒕𝒊𝒐 (𝑷𝑩𝑺 − 𝒕𝒓𝒆𝒂𝒕𝒆𝒅 𝒄𝒆𝒍𝒍𝒔)
 
 
For dose-response curves, BRET values obtained by cells co-transfected with donor plasmids and empty 
pcDNA3, stimulated with different concentrations of chemokine as other samples, were subtracted from BRET 
values obtained by cells co-expressing donor and acceptor proteins and stimulated with the corresponding 
concentrations of chemokines, to obtain a BRET value devoid of background aspecific signal, called Net BRET. 
 
𝑵𝒆𝒕 𝑩𝑹𝑬𝑻 = 𝑩𝑹𝑬𝑻 𝒓𝒂𝒕𝒊𝒐 (𝑹𝑳𝒖𝒄 𝒂𝒏𝒅 𝑬𝒀𝑭𝑷 𝒄𝒆𝒍𝒍𝒔) − 𝑩𝑹𝑬𝑻 𝒓𝒂𝒕𝒊𝒐 (𝑹𝑳𝒖𝒄 𝒐𝒏𝒍𝒚 𝒄𝒆𝒍𝒍𝒔) 
 
Kinetic curves can be generated fitting data with one phase exponential association function, dose response 
curves by non-linear fitting calculated with GraphPad Prism 5 software, to obtain BRETmax and LogEC50 
parameters. 
 
BRET2. Cells were seeded in 1 ml of complete DMEM at a density of 4x10
5
 into P12 multiwell plate. After 18 
hours at 37°C, cells were transiently transfected with 200 ng of CCR5-RLuc and 10 serial 1 to 2 dilutions starting 
from 1 µg of empty pGFP
2
 vector, β-arrestin1-GFP
2
 or β-arrestin2-GFP
2
, comprising of a blank sample transfected 
with donor plasmid only. To each transfection was added sufficient amount of pcDNA3 or any empty vector to 
bring the final DNA amount to 1.2 µg, and to plasmids diluted in 150 μl of Optimem and 3.6 μg of PEI were added. 
48 hours after transfection, cells were washed twice with PBS, detached with Versene, and resuspended in BRET 
assay buffer. Cells were quantified as previously described and 80 µg of proteins/well were distributed in a 96-
wells microplate. Using a Tecan F500 reader, fluorescence was measured through filters with excitation peak at 
340/35 nm and excitation at 535/25 nm and refers to the amount of GFP
2
 (β-arrestins) transfected. Subsequently, 
Coelenterazine h was added to the final 5 μM concentration, incubated 8 minutes in the dark and luminescence 
detected to obtain luciferase quantification. Background fluorescence measured from the blank sample was 
subtracted from fluorescence derived from all the samples (1), and fluorescence of each transfectant was 
normalized over its own luminescence (2) to obtain a fluorescence/luminescence ratio (acceptor/donor): 
 
  
(1) 𝑭𝑳𝑼𝑶𝑹𝑬𝑺𝑪𝑬𝑵𝑪𝑬 𝒗𝒂𝒍𝒖𝒆 =  𝑴𝒆𝒂𝒏 𝑭𝒍𝒖𝒐𝒓𝒆𝒔𝒄𝒆𝒏𝒄𝒆 –  𝑩𝒂𝒄𝒌𝒈𝒓𝒐𝒖𝒏𝒅 𝑭𝒍𝒖𝒐𝒓𝒆𝒔𝒄𝒆𝒏𝒄𝒆 
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 (2) 𝑭𝑳𝑼𝑶𝑹𝑬𝑺𝑪𝑬𝑵𝑪𝑬 𝑳𝑼𝑴𝑰𝑵𝑬𝑺𝑪𝑬𝑵𝑪𝑬⁄ =
𝑭𝒍𝒖𝒐𝒓𝒆𝒔𝒄𝒆𝒏𝒄𝒆 𝒗𝒂𝒍𝒖𝒆 𝒂𝒕 𝟓𝟏𝟎 𝒏𝒎
𝑳𝒖𝒎𝒊𝒏𝒆𝒔𝒄𝒆𝒏𝒄𝒆 𝒗𝒂𝒍𝒖𝒆 𝒂𝒕 𝟒𝟕𝟓 𝒏𝒎
 
 
 
 80 µg of cells were plated in each well, Coelenterazine 400a/Deep Blue C (5 μM, Gentaur) was added and 
immediately BRET2 readings were collected using the same reader. BRET2 ratio was calculated as previously 
described for BRET1. The measured BRET was plotted as a function of the Fluorescence/Luminescence ratio for 
each donor-acceptor couple, resulting in a linear trend in the case of non-specific interactions and in a hyperbolic 
curve indicating specific association of the donor molecule with the acceptor. 
 
3.8-BRET IMAGING  
BRET imaging experiments have been performed in the laboratory of dr. Julie Perroy at the Institut de Genomique 
Fonctionnelle, in Montpellier (France), following already published protocols [318, 319]. Briefly, HEK293 cells 
transfections were carried out by calcium phosphate technique, seeding 3x10
6
 cells onto each 100mm diameter 
cell culture dish 24 hours before transfection, performed diluting 4 µg of donor plasmid (β-arrestin 1 or 2-RLuc8) 
and 4 µg of acceptor plasmid (ACKR2 or CCR5-Venus) or empty pDsRedMono in sterile water with 250 mM CaCl2, 
mixed with 2x Hepes Buffered Saline (2x HBS, 280 mM NaCl, 50 mM Hepes pH 7 and 1,5 mM Na2HPO4) and 
immediately transferred on cells. After 16 hours cells were harvested, seeded on glass-bottom culture dishes and 
cultured for an additional 24 hours. All images were obtained using a bioluminescence-dedicated Axiovert 200 M 
inverted fluorescence microscope with a Plan-Apochromat 63×/1.40 Oil M27 objective and images were collected 
with an EMCCD camera at room temperature. We identified transfected cells with a monochromatic light and 
appropriate filters to image VENUS or DsRed (Excitation 480/40 nm- Emission 525/50 nm or Ex 540/40 nm- Em 
600/50 nm, respectively). We then applied to cells Coelenterazine H (CoelH) to the final concentration of 20 µM 
and we performed sequential acquisitions with emission filters  for Luciferase emission at 480/60 nm and VENUS 
emission at 535/50 nm of 20 seconds each, using the Metamorph software (Molecular Devices). After collecting 3 
to 6 images of unstimulated cells we added 100 nM ligands (recombinant human CCL3L1 or CCL3) and resumed 
image collection up to 20 minutes. For each timepoint we calculated the pixel-by-pixel 535 nm/480 nm ratios 
(BRET Ratio) by dividing the absolute light intensities per pixel of images obtained at 535 nm over 480 nm. The 
ratios obtained (comprised between 0,3 and 1,2) were converted to a continuous 256 pseudo-color look-up table 
and visualized as displayed in the figures. After defining areas of interest on plasma membrane and cytoplasm, we 
calculated the mean intensity and standard deviation of pixels to determine the average intensity and distribution 
of the 535 nm/480 nm ratio within the cell of interest using Image J software (NIH). Constitutive association was 
calculated by subtracting from the BRET ratio obtained from cells with β-arrestins-RLuc8 and ACKR2/CCR5-Venus 
the BRET ratio obtained by cells expressing the β-arrestins-RLuc8 only, positive for DsRed expression. Ligand-
induced association of β-arrestins to receptors at different timepoints was measured as percentage of ligand-
induced BRET ratio over the mean of BRET ratio measurements in unstimulated cells. Statistical analysis of the data 
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obtained from at least 7 replicates for each condition ±SEM were performed with two-ways ANOVA with 
Bonferroni post-hoc test. 
 
3.9-CAMP MEASUREMENT ASSAY BY ALPHASCREEN TECHNOLOGY 
Quantification of intracellular cAMP in HEK293 cells stably expressing CXCR1 or CXCR2 was performed with 
the AlphaScreen cAMP assay kit (Perkin Elmer) as follows: 70% confluent cells were washed twice with PBS, 
detached with Versene (PBS + 0.5mM EDTA, Gibco/LifeTechnologies) and resuspended at 10
7
 cells/ml in 
stimulation buffer (StimB: Hanks Balanced Salt Solution (HBSS; Lonza) containing 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX; Sigma-Aldrich), 0.1% w/v Bovine Serum Albumin (BSA; Sigma-Aldrich) and 5 mM HEPES 
(Lonza), pH 7.4. 5 µL of cells/anti-cAMP AB mix solution containing StimB (30%) + 10
7
 cells/mL (20%, corresponding 
to 104 cells final) + anti-cAMP AB working solution (50%, prior 1 to 25 dilution of AB stock solution in StimB) were 
plated in triplicate on a white opaque 384 well microplate (PerkinElmer). Chemokine serial dilutions were prepared 
2X concentrated in StimB containing 2X concentrated forskolin (20 µM) and finally 5 µL of each dilution was added 
in triplicate to the wells. In addition, vehicle was performed in triplicate by adding to the cells 5 µL of StimB mixed 
1 to 2 with 20 µM forskolin. Control points were performed in triplicate as follows: 5 µL cells/anti cAMP AB mix 
with 5 µL StimB without forskolin and chemokine to measure the maximal recordable AlphaScreen signal in resting 
cells, 5 µL of a 1 to 2 dilution of anti-cAMP AB working solution in StimB with either 5 µL of StimB or 5 µL of cAMP 
(5 µM, prior 1 to 10 dilution of 50 µM cAMP stock solution in StimB), to detect the maximal and the minimal 
AlphaScreen signal, respectively. Plate was incubated 30 minutes at room temperature (RT) in the dark. 
Streptavidin DB/biotinylated cAMP detection mix was prepared in lysis/detection buffer (prior 1 to 10 dilution of 
10X stock solution in MilliQ H2O) by 1 to 150 dilution of the Streptavidin DB stock and 1 to 24 dilution of the 
biotinylated cAMP solution (1 µM, prior 1 to 10 dilution of 10 µM biotinylated cAMP stock solution in PBS). This 
solution has to be prepared 30 minutes before use and incubated at RT in the dark to allow biotinylated cAMP 
binding to streptavidin DB. Chemokine stimulation was blocked by adding to each well 15 µL of Streptavidin 
DB/biotinylated cAMP detection mix to each well. Plate was incubated for at least 1 hour at RT in the dark. The 
measurement of AlphaScreen signal was performed by a Synergy H4 Microplate Reader (BioTek) equipped with 
the following filter setting: excitation was provided by a tungsten lamp through a 680/30 nm filter placed on the 
excitation wheel and plug on emission wheel, whereas emission arising from the sample was subsequently 
acquired after filter switching through a 570/100 nm filter placed on the emission wheel with a plug on excitation 
wheel. Dose-response curves can be generated plotting the AlphaScreen signal measured against agonist 
concentration expressed as logarithm of molarity and analyzed with nonlinear curve fitting equations (GraphPad 
Prism 5 software). Statistics can be obtained by ANOVA and Bonferroni post-hoc test. 
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3.10-BIAS CALCULATION 
To determine bias between the ability of the receptors to inhibit adenylyl cyclase and to induce β-arrestin 
recruitment to the receptors, we stepwise-approached the method described by van der Westhuizen E.T. et al. on 
Molecular Pharmacology in 2014 [117]. Briefly, we used the formula they provide to calculate with Graphpad 
Prism 6 the Transduction Coefficient (TC) = log(τ/KA), where the term τ incorporates ligand efficacy, receptor 
density and coupling within the system, and the dissociation constant KA is the reciprocal of the conditional 
affinity of the ligand in the functional system. TC value is calculated for each ligand in each assay by fitting dose-
response curves obtained for pathway A and B with the Black-Leff operational model [320]. For each assay, TC 
values of tested ligands undergo the subtraction of the one generated by the reference ligand chosen arbitrarily 
(intact chemokine variants or vehicle treated cells) to obtain a relative effectiveness of the ligand for each signaling 
pathway [Δlog(τ/Ka) = log(τ/Ka)ligand - log(τ/Ka)reference), that can be subsequently compared across the signaling 
pathways A and B analyzed [ΔΔlog(τ/Ka) = Δlog(τ/Ka)A - Δlog(τ/Ka)B]. Statistical analysis was performed using a 
one-way Anova on the Δlog(τ/Ka) to make pairwise comparisons between two pathways activated by a 
given ligand, where P < 0.05 was considered statistically significant.  
 
3.11-SILAC  
HEK293 T-Rex cells are HEK293 stably expressing the tetracycline repressor, generated and sold by Life 
Technologies. HEK293 T-Rex cells were maintained in complete DMEM with 25 µg/ml Blasticidin, were transfected 
with Lipofectamine2000 and HA-ACKR2 or HA-CCR5 pcDNA4/To plasmids and maintained in the presence of 500 
μg/ml Zeocin (Life Technologies) to generate bulk populations of HEK293 T-Rex ACKR2 or CCR5. For SILAC 
experiments, SILAC-DMEM medium lacking glutamine (Glu), arginine (Arg) and lysine (Lys) (Life Technologies) was 
supplemented with 2mM UltraGlutamine (Lonza), and with [
12
C6,
14
N4]arginine and [
12
C6,
14
N2]lysine or 
[
13
C6,
15
N2]lysine and [
13
C6,
15
N4]arginine (Cambridge Isotope Laboratories, Tewksbury, MA, USA) we prepared light 
or heavy medium, respectively, with final concentrations of 21 mg/l for Arg and 48 mg/l for Lys. To colture cells, 
complete medium was obtained adding to light and heavy media 10% dyalized FBS (Life Technologies) and 100 
U/ml PenStrep (Lonza) (complete SILAC-DMEM). During the adaptation phase, HEK T-Rex ACKR2 or CCR5 were 
grown in light or heavy SILAC medium for five passages to achieve complete amino acid incorporation, prior to 
further manipulation of the cells. Cells in complete SILAC-DMEM were seeded in plates for 24 h in presence or 
absence of 1 μg/ml tetracycline (Life Technologies). After 24 h, complete SILAC-DMEM was replaced with heavy or 
light SILAC-DMEM with 0.1% BSA, with or without tetracycline for 18 hours. The day of the experiment and 10
7
 of 
all cell types were resuspended in 1 ml of heavy or light SILAC DMEM with 0.1% BSA and incubated at 37°C with 
gentle shaking for 30 minutes, at the end of which non-induced cells were transferred to ice, while induced cells 
were stimulated with 100nM of CCL3L1 for the indicated time points at the end of which a small amount of cells 
was kept to analyze cofilin phosphorylation, while the rest of cells were washed with ice-cold PBS and stored at -80 
for further mass spectrometry analysis performed by Prof. Gabriella Tedeschi at Filarete Institute (Milan, Italy).  
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Data analysis was performed mainly with excel-formatted databases, Gene Ontology (GO) analysis was 
performed with the Panther GO Enrichment analysis tool available on the Gene Ontology Consortium website 
(http://geneontology.org/). Venn diagrams and pie charts were realized with Excel software (Microsoft Office 
suite) and Histograms with Graphpad Prism 5 software. 
 
3.12-STATISTICAL ANALYSIS 
All statistical analysis were performed with GraphPad Prism 5 software, assaying statistical significance 
with Student’s t-test for comparing one single parameter between two distinct samples, One-way analysis of 
variance with Dunnett’s multiple comparison for analysis of one single parameter between different samples, and 
Two-ways Anova with Bonferroni post-hoc test to compare different parameters between multiple samples. The 
test used in each assay with p values considered statistically significant and reported in figure legends. 
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4.1-EFFECTS OF POST-TRANSLATIONAL MODIFICATIONS ON CXCL5 AND CXCL8 SIGNALING 
Chemokines are small soluble mediators that once released from cells diffuse within tissues 
forming a chemical gradient that drives migrating cells towards the highest concentration of chemokine 
[1], directing immune cells recruitment to inflamed tissues and their activation and interaction [1, 4, 7]. 
Chemokine activity is finely regulated in several ways, among which one consists of chemokine post-
translational modification, mediated by a number of peptide-modifying enzymes. In fact in serum not 
only active chemokines or their degradation products can be found, but also many naturally modified 
variants [16, 226, 228, 230]. These modified chemokine variants exhibit truncated N- or C-terminus, an 
altered glycosylation pattern or arginine residues modified to citrulline compared to their intact or 
natural or predominant variant [226, 228]. All these modifications are made by different enzymes, which 
have been found to be expressed by leukocytes and different cell types inside inflamed tissues, in 
tumors, by bacteria or are induced during viral infection [16]. Once modified, chemokines exhibit 
differences in potency, stability and GAG binding affinity compared to their unmodified variants and 
these properties are reflected by alteration in leukocyte recruitment, modulating inflammatory 
responses [16, 226, 230]. Among chemokines, modified variants of the CXC chemokines are the best 
characterized, with CXCL5, CXCL8, CXCL10 and CXCL11 that can also undergo specific citrullination on 
their arginine residues close to the N-terminus, the chemokine region mostly involved in receptor 
signaling activation [228].  
Chemokine receptors, as other GPCRs, upon binding of their cognate chemokines activate 
multiple signaling pathways elicited by both G proteins and β-arrestins, which respectively on the one 
hand immediately activate calcium release from intracellular stores and inhibit adenylyl cyclase, and on 
the other hand uncouple G proteins from the receptor, sustain delayed signaling and mediate receptor 
internalization [114]. Conventionally chemokines equally activate all the signaling pathways, but in some 
cases, defined by the cellular context or by ligand specificity, chemokines can preferentially activate one 
signaling pathway rather than the other [34, 99, 134]. This can be the case of CCR5, which, upon binding 
of CCL8 preferentially signals inducing Ca2+ release rather than inhibiting adenylyl cyclase or mediating 
β-arrestin recruitment to the receptor, compared to CCL3 [99]. Another example is the activity of 
CXCL11 on CXCR3, which induces receptor internalization better than G protein or β-arrestin 
recruitment [102]. This phenomenon, known as functional selectivity or biased signaling, dictates ligand 
activity and can influence the chemotactic potential of one agonist compared to another one. 
Post-translational modification of two chemokines specific for CXCR1 and CXCR2 receptors, 
CXCL5 and CXCL8, have already been described to modify chemokine activity both in vitro and in vivo 
[228]. In particular, N-terminal truncation of both chemokines increases their signaling and chemotactic 
activity, while citrullination of their most N-terminal arginine reduces or increases signaling activity of 
CXCL5 and CXCL8, respectively [240, 242, 245]. Given the role of these two chemokines in neutrophils 
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and monocytes recruitment, the role of these cells in inflammation and that these modifying enzymes 
are released in inflamed tissues regulating chemokine activity, we decided to investigate in vitro how 
post-translational modifications affect G protein activation and β-arrestin recruitment of chemokines 
CXCL5 and CXCL8 signaling elicited through their receptors CXCR1 and CXCR2, and whether possible 
differences observed between differently modified chemokines could underlie a signal bias. 
 
4.1.1-POST-TRANSLATIONAL MODIFICATIONS OF CXCL8 ALTER CXCR1 SIGNALING ABILITY 
Modifications of NH2-terminus of CXCL8 have been demonstrated to modify chemokine binding 
and activity on its receptors CXCR1 and CXCR2 [240]. In particular evidences reported that while 
citrullination of arginine in position 5 does not produce major changes in in vitro chemokine activity, 
truncation of the most NH2 residues up to the 9
th, which leave an intact ELR motif, improve chemokine 
binding and in vitro ability to signal and mediate chemotaxis on CXCR1 and CXCR2. To understand 
whether these differences observed among CXCL8 variants in terms of activity underlie a biased 
activation of CXCL8 receptors, we evaluated the ability of several CXCL8 variants (intact CXCL8 1-77, 
truncated CXCL8 2-77, 3-77, 6-77 and the citrullinated CXCL8 on arginine 5 in intact 1-77 –cit5 CXCL8 1-
77) to activate G proteins reducing intracellular cAMP and to induce β-arrestins recruitment to both 
CXCR1 and CXCR2, by Alphascreen technology and BRET, respectively.  
Measurement of CXCL8 variants ability to activate G proteins by Alphascreen assay in presence 
of forskolin results in an increase in Alphascreen signal, indicating that increasing chemokine 
concentration results in a stronger energy transfer between donor and acceptor beads. This assay is in 
fact based on the formation of a complex consisting of donor beads coated with streptavidin, 
biotinylated cAMP and acceptor beads coated with an antibody against cAMP and the necessity for the 
energy transfer to occur between donor and acceptor beads in close proximity. This assay is based on 
the production upon excitation with light at 680 nm by donor beads of oxygen singlets that diffuse 
within 200 nm at most before decaying, and if acceptor beads are in close proximity can be excited by 
oxygen singlets and emit light between 520 and 620 nm. The close proximity and the energy transfer 
between donor and acceptor beads is achieved only when a biotinylated cAMP is bound on one side by 
the streptavidin coated donor bead, and on the other side by the antibody against cAMP on the 
acceptor bead, therefore the maximal luminescent signal can be recorded when all the beads are 
complexed together by biotinylated cAMP, and any interference by non-biotinylated cAMP that is bound 
by acceptor beads cannot bring donor beads in close proximity to the acceptor and results in a loss of 
energy transfer and signal. The assay is designed to provide a robust signal in response to endogenous 
cAMP, which can be generated by stimulated adenylyl cyclases (as in the case of stimulatory Gαs 
proteins), resulting in a great displacement of biotinylated cAMP from donor-acceptor beads complexes 
and signal reduction, while in the case of adenylyl cyclases inhibition (as by Gαi proteins activation) the 
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resolution of the assay is reduced because it would have to measure minimal difference of cAMP 
concentrations. To overcome this problem we tested the ability of forskolin to induce adenylyl cyclase 
activation and cAMP accumulation in HEK293 cells in a dose-dependent manner, to measure forskolin 
concentration necessary to induce cAMP increase in at least 90% of the cells (EC90), and we found out 
that 10 μM of forskolin was sufficient. To this point we performed the assay adding to cells not only 
different concentrations of chemokines but also simultaneously constant 10 μM forskolin to increase 
our sensitivity range. When we measured the ability of the different CXCL8 variants to reduce forskolin 
activity, we normalized the values recorded to the ones assayed for intact CXCL8 1-77, to compare all 
the differences observed to the same reference chemokine. Results obtained indicate that citrullination 
on Arg5 of CXCL8 increase chemokine potency measured as G protein activation of more than 10 fold, 
compared to CXCL8 1-77 (Figure 9, A and H), and truncation of NH2-terminus of CXCL8 as well 
progressively increases chemokine potency, with only a trend measurable for CXCL8 3-77 but a 
statistically significant increase for CXCL8 2-77 and even more important increase for CXCL8 6-77, that 
displays a potency comparable to the citrullinated variant (Figure 9, B and H). Notably, the variant 
derived from the alternative CXCL8 precursor -2-77, appeared to be slightly more potent than the 1-77 
variant (Figure 9, B and H). 
G protein activation by GPCR is conventionally followed by receptor desensitization, that 
prevents excessive cellular responses and regulates agonist activity. Desensitization is initiated both by 
G protein-activated kinases that phosphorylate GPCR and by structural rearrangement of the GPCR 
itself, that exposes its carboxy-terminal intracellular tail to kinases and also to β-arrestins, that binding 
the GPCR on the one side sterically occupy GPCR intracellular site preventing inactive G proteins 
association to the receptor, and on the other side scaffold the assembly of different proteins and 
mediate their interaction with the receptor. These proteins are mainly components of the endocytotic 
machinery that induces receptor internalization to dampen cellular responsiveness to agonist, but also 
are components of different signaling machineries that can be activated by the receptor. Both CXCL8 
receptors have been demonstrated to undergo agonist-induced desensitization and internalization in a 
β-arrestin-dependent manner [176, 177], therefore we decided to assess if post-translational 
modifications of CXCL8 can affect its ability to induce β-arrestins translocation and association to CXCR1 
and CXCR2.  
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Figure 9: Effects of CXCL8 modifications on CXCR1 signaling. CXCL8 variants are reported as CXCL8 1-77 (, black circle), CXCL8 
cit
5
 1-77 (, petrol square), CXCL8 2-77 (, green rhombus), CXCL8 3-77 (◧, half clear, blue square), CXCL8 6-77 (, red 
triangle) and CXCL8 -2-77 (, orange square). A-B) Alphascreen measurement of intracellular cAMP in HEK293 CXCR1 cells 
stimulated with 10 μM forskolin and different concentrations of CXCL8 variants, with the result reported as percentage of 
inhibition of forskolin-induced cAMP increase normalized over intact CXCL8 1-77 ±SEM; N=3. C-D) Measurement of CXCL8 
variants-induced β-arrestin 2 recruitment to CXCR1 in living HEK293 cells by BRET. Results are expressed as Net BRET calculated 
subtracting the BRET ratio obtained by cells expressing CXCR1-RLuc only stimulated for 30 minutes with different 
concentrations of commercial CXCL8 from the BRET ratio obtained from cells co-transfected with CXCR1-RLuc and β-arrestin 2-
EYFP and stimulated for 30 minutes with corresponding concentrations of CXCL8 variants ±SEM; N=3. A and C are the 
comparison of citrullinated CXCL8 versus intact CXCL8, and B and D report the effects of NH2-terminus truncation on CXCL8. E-
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F) Effect of citrullination and truncation on CXCL8-induced β-arrestin 1 (panel E) and β-arrestin 2 (panel F) recruitment to 
CXCR1. HEK293 cells co-transfected with CXCR1 and β-arrestin 1 or 2 were first incubated with 5 μM Coelenterazine H for 8 
minutes at room temperature and subsequently CXCL8 variants were added at the final concentration of 100 nM before 
beginning recording luminometer readings up to 15 minutes. One representative experiment out of 4 performed is shown for 
each condition. G) Bias plot indicates the ΔΔlog(τ/KA) ±SE for cAMP signaling over β-arrestin 2 recruitment. H) Table reports the 
mean LogEC50 ±SEM obtained by nonlinear regression curve fitting in the cAMP and β-arrestin 2 recruitment assays. Values 
statistically different from CXCL8 1-77 are reported in bold, with *=p<0.05, **=p<0.01 calculated by one-way Anova with 
Dunnett’s multiple comparison.  
 
To investigate interactions between chemokine receptors and β-arrestins we used BRET, a 
technique based on the energy transfer occurring between Renilla Luciferase (RLuc), that catalyzes its 
substrate Coelenterazine H emitting light peaking at 480 nm and EYFP, a modified GFP variant that is 
excited by the light produced by RLuc and emits light peaking at 530 nm, only if it is found in close 
proximity (100 nm) to the donor. BRET exploits this properties of RLuc and EYFP to measure interactions 
between two proteins in live cells by the co-expression of the protein of interest fused to the donor or 
to the acceptor by co-transfecting plasmids encoding the two fusion proteins in cells and measuring the 
energy transfer by assessing luminescence at 480 and 530 nm generated by samples [321]. 
To measure β-arrestins recruitment to CXCR1 after stimulation with the different CXCL8 variants 
we initially performed kinetic BRET measurements assessing interactions between CXCR1-RLuc and β-
arrestins-EYFP overexpressed in HEK293 cells by co-transfection of the two plasmids. Therefore we 
recorded luminescence generated by coelenterazine H and transferred to CXCR1-RLuc and β-arrestins-
EYFP arising from samples stimulated with PBS or 100 nM of each CXCL8 variant over 15 minutes time, 
collecting luminescence from each sample every 13 seconds. Results obtained indicate that energy 
transfer expressed as BRET ratio (Emission 530 nm/ Emission 480 nm) increases over time in cells 
stimulated with CXCL8 variants compared to cells stimulated with PBS, assessed subtracting BRET ratio 
obtained in cells stimulated with PBS from BRET ratio obtained in cells stimulated with chemokines, in 
curves with a trend towards positive values (Figure 9 E, F). Apparently the same chemokines induce a 
stronger increase in association between CXCR1 and β-arrestin 2 than β-arrestin 1, but anyway both β-
arrestins increase their association to CXCR1 after chemokine stimulation, and similarly between the 
two β-arrestins CXCL8 6-77 and citrullinated CXCL8 induce a stronger increase compared to CXCL8 1-77 
(Figure 9 E, F), while the other truncated variants induce comparable β-arrestins recruitment to CXCR1 
to CXCL8 1-77 (Figure 9 E, F). Since all the variants generate a similar efficacy ranking in the recruitment 
between β-arrestin 1 and 2 to CXCR1, but apparently β-arrestin 2 is recruited better than β-arrestin 1, 
we decided to characterize how CXCL8 variants affect only β-arrestin 2 recruitment to CXCR1 in a dose-
dependent manner, to avoid generating experimental bias dependent on poor signal output. Dose-
response curves generated stimulating HEK293 cells co-expressing CXCR1-RLuc and β-arrestin 2-EYFP 
show how citrullination (Figure 9 C) and truncation of the first 5 amino acids in CXCL8 6-77 (Figure 9 D) 
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increase CXCL8 potency in terms of CXCR1 association to β-arrestin 2 almost ten times (Figure 9 H). 
More modest truncation on NH2-terminal residues of CXCL8 and the elongated -2-77 variants 
demonstrate to be able to minimally increase the β-arrestin 2 recruitment ability of CXCR1, compared to 
CXCL8 1-77 (Figure 9 C and H). 
To determine whether post-translational modifications of CXCL8 could induce a preferential 
signaling of CXCR1 between cAMP or β-arrestin 2-recruitment, we calculated the bias occurring between 
these two signaling pathways comparing for the two assays the activity of each CXCL8 variant, compared 
to the activity of intact CXCL8 1-77. To quantify bias we recurred to the operational model of bias, that 
allows to compare the activity of different ligands in different pathways normalizing all the signals 
recorded from all the ligands regardless their agonistic activity is full or partial, obtaining a single 
parameter that is called transduction coefficient (TC, =log(τ/KA)) [117, 322, 323]. In this valure are 
included several parameters of the system assayed, since τ incorporates ligand efficacy, receptor density 
and coupling with the system used for the assay, while KA is the reciprocal of the conditional affinity of 
the ligand in the assay system [322], and this value can be calculated by fitting the Black-Leff operational 
model to dose-response curves in all the pathways assayed. This system allows to calculate bias in a way 
preventing the interference of system or observational bias that could occur due to experimental 
settings [84]. Transduction coefficients measured have been for each assay have been compared for all 
the CXCL8 variants, resulting in no statistically significant variation in bias factors measured on CXCR1.  
  
4.1.2-POST-TRANSLATIONAL MODIFICATIONS OF CXCL8 MODIFY CXCR2 SIGNALING 
We next sought to address the effects of post-translational modifications of CXCL8 on the 
signaling activities of its second receptor, CXCR2. To evaluate the impact of CXCL8 modifications on 
CXCR2 signaling we used HEK293 cells stably expressing CXCR2 to measure cAMP modulation and 
transiently transfected HEK293 cells to monitor β-arrestins recruitment to CXCR2 by BRET. 
Dose response curves generated by Alphascreen cAMP assay indicate that both citrullination of CXCL8 
and removal of its NH2-terminal residues induce an increase in CXCL8 potency (Figure 10 A, B and H), 
with curves shifted to the left and EC50 concentrations decreasing, but only for CXCL8 6-77 this increase 
in potency is statistically relevant, even if for citrullinated CXCL8 has been calculated a potency 10 times 
higher than CXCL8 1-77 (Figure 10 H).  
Measurement of the ability of the different variants to induce β-arrestins association to CXCR2 over time 
showed that after agonist activation both β-arrestin 1-EYFP and β-arrestin 2-EYFP are recruited to 
CXCR2-RLuc (Figure 10 E and F), with a higher trend for β-arrestin 2 than β-arrestin 1. Dose response 
curves indicate that CXCL8 6-77 can induce a strong increase of more than 10 times in β-arrestin 2 
recruitment to CXCR2 compared to CXCL8 1-77 (Figure 10 D and H), while all the other variants only tend 
to increase CXCL8 activation of this signaling pathway (Figure 10 C, D and H). 
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Figure 10: Effects of CXCL8 modifications on CXCR2 signaling. CXCL8 variants are reported as CXCL8 1-77 (, black circle), 
CXCL8 cit
5
 1-77 (, petrol square), CXCL8 2-77 (, green rhombus), CXCL8 3-77 (◧, half clear, blue square), CXCL8 6-77 (, red 
triangle) and CXCL8 -2-77 (, orange square). A-B) Alphascreen measurement of intracellular cAMP in HEK293 CXCR2 cells 
stimulated with 10 μM forskolin and different concentrations of CXCL8 variants, with the result reported as percentage of 
inhibition of forskolin-induced cAMP increase normalized over intact CXCL8 1-77 ±SEM; N=3. C-D) Measurement of CXCL8 
variants-induced β-arrestin 2 recruitment to CXCR2 in living HEK293 cells by BRET. Results are expressed as Net BRET calculated 
subtracting the BRET ratio obtained by cells expressing CXCR2-RLuc only stimulated for 30 minutes with different 
concentrations of commercial CXCL8 from the BRET ratio obtained from cells co-transfected with CXCR2-RLuc and β-arrestin 2-
EYFP and stimulated for 30 minutes with corresponding concentrations of CXCL8 variants ±SEM; N=3. A and C are the 
comparison of citrullinated CXCL8 versus intact CXCL8, and B and D report the effects of NH2-terminus truncation on CXCL8. E-
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F) Effect of citrullination and truncation on CXCL8-induced β-arrestin 1 (panel E) and β-arrestin 2 (panel F) recruitment to CXCR2 
monitored over 15 minutes time in presence of PBS or 100 nM of CXCL8 variants. One representative experiment out of 4 
performed is shown for each condition. G) Bias plot indicates the ΔΔlog(τ/KA) ±SE for cAMP signaling over β-arrestin 2 
recruitment. H) Table reports the mean LogEC50 ±SEM obtained by nonlinear regression curve fitting in the cAMP and β-
arrestin 2 recruitment assays. Values statistically different from CXCL8 1-77 are reported in bold, with *=p<0.05 calculated by 
one-way Anova with Dunnett’s multiple comparison.  
 
Bias analysis has been performed to assess the existence of a bias in signaling activities elicited 
by CXCL8 on CXCR2 after post-translational modifications. The results obtained indicate that neither 
citrullination of arginine 5 on cit5CXCL8 nor truncation of the NH2-terminus of CXCL8 1-77 induce a 
preferential activation of β-arrestin 2 recruitment to CXCR2 over adenylyl cyclase inhibition (Figure 10 
G). 
Taken together, these results indicate that post-translational modifications of CXCL8 NH2-
terminus affect chemokine signaling properties on both CXCR1 and CXCR2, with more evident effects on 
CXCR1, increasing agonist potency in the cases of citrullination of arginine 5, cleavage of the first amino 
acids by different proteases. Notably, the elongated variant CXCL8 -2-77 also displays an increased 
activity on CXCR1 and a trend towards increase on CXCR2. 
 
4.1.3-POST-TRANSLATIONAL MODIFICATIONS ALTER CXCL5 SIGNALING ACTIVITY ON CXCR2 
We also investigated the ability of post-translational modifications to unbalance CXCR2 signaling 
properties modifying CXCL5. As CXCL8, CXCL5 can be truncated on its NH2-terminus and can also 
undergo the action of peptidyl deiminases, that citrullinate arginine in position 9, resulting in 
modifications of CXCL5 signaling properties in vitro and chemotactic ability in vivo. To investigate the 
effects of these modifications on CXCR2 signaling we assayed the ability to activate G proteins and β-
arrestins recruitment to CXCR2 of CXCL5 citrullinated on arginine 9 in both intact CXCL5 1-78 (cit9CXCL5 
1-78) and truncated 9-78 CXCL5 (cit9CXCL5 9-78) and of truncated CXCL5 4-78, 8-78 and 9-78 variants.  
Results indicate that citrullination of CXCL5 decreases chemokine potency to activate Gα inhibitory 
proteins of about 4 times (Figure 11 A and H) both in the case of cit9CXCL5 1-78 compared to intact 
CXCL5 1-78 and also in the case of cit9CXCL5 9-78 compared to the non citrullinated truncated CXCL5 9-
78. Interestingly, cit9CXCL5 9-78 displays an increased potency compared to CXCL5 1-78 of more than 10 
fold (Figure 11 A and H). CXCL5 truncation of NH2 residues increases chemokine potency, ranging from 
more than 10 times in the case of CXCL5 4-78 and CXCL5 8-78 to about 50 times for CXCL5 9-78 (Figure 
11 B and H). 
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Figure 11: Effects of CXCL5 modifications on CXCR2 signaling. CXCL5 variants are reported as CXCL5 1-78 (, black circle), 
CXCL5 cit
9
 1-78 (, petrol square), CXCL5 4-78 (, green rhombus), CXCL5 8-78 (◧, half clear, purple square), CXCL5 9-78 (, 
red triangle) and cit
9
 CXCL5 9-78 (, orange down-facing triangle). A-B) Alphascreen measurement of intracellular cAMP in 
HEK293 CXCR2 cells stimulated with 10 μM forskolin and different concentrations of CXCL5 variants, with the result reported as 
percentage of inhibition of forskolin-induced cAMP increase normalized over intact CXCL5 1-78 ±SEM; N=3. C-D) Measurement 
of CXCL5 variants-induced β-arrestin 2 recruitment to CXCR2 in living HEK293 cells by BRET. Results are expressed as Net BRET 
calculated subtracting the BRET ratio obtained by stimulated for 30 minutes with different concentrations of commercial CXCL5 
from the BRET ratio obtained from cells co-transfected with CXCR2-RLuc and β-arrestin 2-EYFP and stimulated for 30 minutes 
with corresponding concentrations of CXCL5 variants ±SEM; N=2. A and C are the comparison of citrullinated CXCL5 versus non 
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citrullinated variants, and B and D report the effects of NH2-terminus truncation on CXCL5. E-F) Effect of citrullination and 
truncation on CXCL5-induced β-arrestin 1 (panel E) and β-arrestin 2 (panel F) recruitment to CXCR2 monitored over 15 minutes 
time in presence of PBS or 100 nM of CXCL5 variants. One representative experiment out of 4 performed is shown for each 
condition. G) Bias plot indicates the ΔΔlog(τ/KA) ±SE for cAMP signaling over β-arrestin 2 recruitment. H) Table reports the 
mean LogEC50 ±SEM obtained by nonlinear regression curve fitting in the cAMP and β-arrestin 2 recruitment assays. I) Table 
reporting the mean BRETmax ±SEM obtained by one phase exponential association curve fitting in the kinetics of β-arrestins 
recruitment assays.  N.D.=not determined. Values statistically different calculated by one-way Anova with Dunnett’s multiple 
comparison are reported in bold, with *,#=p<0.05, **,##=p<0.01 and ***,###=p<0.001 indicating statistically relevant 
differences compared to CXCL5 1-78 (*) or CXCL5 9-78 (#).  
 
We next assessed the activity of the different CXCL5 to induce β-arrestins recruitment to CXCR2 
by BRET, and we observed that CXCL5 1-78 and its citrullinated variant did not induce over time an 
increase compared to PBS treated cells and CXCL5 4-78 shows only a tendency to increase over time 
with BRET ligand effect values oscillating above zero (Figure 11 E, F and I). Only variants truncated of 
more than 7 amino acids induce a significant increase in energy transfer between β-arrestin 1 and 2-
EYFP and CXCR2-RLuc compared to PBS stimulated cells (Figure 11 E, F), with progressive truncation that 
progressively increases CXCL5 activity (Figure 11 panel I). In addition, citrullination of CXCL5 9-78 results 
in a significant decrease in BRETmax between CXCR2 and both β-arrestin 1 and 2, compared to CXCL5 9-
78 (Figure 11 E, F and I). 
We also monitored BRET between CXCR2 and β-arrestin 2 in cells stimulated with different 
concentrations of CXCL5 variants, but all these chemokines, at the concentrations assayed, induced an 
increase in BRET signal only at high concentration, far from reaching a point of signal saturation in all the 
cases (Figure 11 C and D). This lead to ambiguous fitting of nonlinear regression curves to all the curves, 
except for cit9CXCL5 1-78, for which it has been impossible to calculate the fitting and for CXCL5 9-78 
that generated a precise fitting but anyway it has to be taken into account that the result is influenced 
by the poor output recorded. This also affects bias calculation, since even if the operational model of 
bias generated a fitting for each condition, it resulted in values with high standard errors and that would 
anyway be influenced by the inability of CXCL5 to induce a strong β-arrestin 2 recruitment to CXCR2 at 
the concentrations tested. 
These results indicate that citrullination of CXCL5 affects chemokine ability to activate CXCR2-
dependent G protein signaling while on the opposite truncation improves chemokine potency. In terms 
of β-arrestin recruitment we cannot do precise quantitative conclusions of the ability of CXCL5 variants 
to induce a dose-dependent increase in  β-arrestin 2 recruitment, but from kinetics measures we can say 
qualitatively that, as we observed for G protein signaling, β-arrestins recruitment to CXCR2 is induced by 
CXCL5 only after NH2-terminus truncation, and that this effect can be reduced by CXCL5 citrullination of 
arginine 9. 
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4.2-ATYPICAL CHEMOKINE RECEPTOR 2 (ACKR2) INTERACTIONS WITH Β-ARRESTINS 
Atypical chemokine receptors are fundamental regulators of chemokine activity that instead of 
directly promoting cellular migration, support system activity by transporting, presenting or scavenging 
their ligands, actively regulating chemokine activity or preventing excessive ligand accumulation [248]. 
Since their discovery and deorphanization, ACKRs have long been considered as decoy molecules unable 
to activate intracellular signaling, because high affinity binding of chemokines did not elicit Ca2+ fluxes 
generation or chemotaxis as the same ligands did on cognate conventional receptors. Recent evidences 
indicate indeed that chemokine binding on these receptors activates cellular responses, but these 
signaling events are more prone to occur in a biased fashion, since these receptor elicit only selected 
signals, compared to the activities of the same chemokines on conventional chemokine receptors [3, 
143, 225]. This differences are believed to depend on mutation of key residues in motifs involved in 
GPCR signaling, generating seven transmembrane receptors that on the one hand lost G protein-
dependent signaling and on the other retained the ability to signal towards different pathways, many of 
which mediated by β-arrestins, making of ACKRs structurally biased receptors that evolved from 
conventional chemokine receptors to play an important regulatory role in chemokine biology [33, 143, 
225]. Among ACKRs, ACKR2 is one of the best characterized in terms of signaling, trafficking activity and 
biological function. ACKR2 is expressed more prominently in cells of barrier tissues such as trophoblasts 
in placenta and endothelial cells in afferent lymphatic vessels, where it binds with high affinity a broad 
range of inflammatory CC chemokines and mediates their degradation [142, 297]. Efficient chemokine 
degradation is possible thanks to ACKR2 peculiar trafficking properties and is supported by its biased 
signaling activity. In fact, upon active ligand stimulation, ACKR2 activates a G protein-independent and 
β-arrestin 1-dependent signaling pathway that improves receptor scavenging ability [292, 310]. This 
biased signaling activity allows the receptor to actively modify its trafficking properties increasing its 
recycling rate to upregulate its expression on plasma membrane and offer more binding sites to 
chemokines, that once bound to the receptor are continuosly internalized with ACKR2 that targets them 
to degradation [292, 313]. Given ACKR2 characteristics of structurally biased signaling receptor and its 
role in the regulation of the chemokine system, with an impact on inflammation and tumor biology, we 
decided to better investigate ACKR2 signaling activities focusing on the characterization of molecular 
mechanisms underlying the differences between ACKR2 and CCR5 activity that allow this atypical 
receptor to control chemokine activity dampening inflammation rather than mediating cell migration. 
To this points we wanted to better define ACKR2 interactions with β-arrestins, since the signaling 
machineries controlled by these proteins are fundamental to regulate ACKR2 trafficking and activity 
[292, 309, 324]. 
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4.2.1-ACKR2 IS ASSOCIATED TO Β-ARRESTINS IN BASAL CONDITIONS 
ACKR2 colocalization to β-arrestin has already been described to occur constitutively in cells 
transfectants analyzed by confocal microscopy [309, 324]. Published evidences show that ACKR2 
overexpression is able to induce relocalization of β-arrestin in basal conditions in HEK293 cells [309] and 
that in β-arrestin knock out mouse embryonic fibroblasts overexpressed ACKR2 loses its subcellular 
localization and trafficking properties [324]. To confirm this evidence we decided to assess ACKR2 
constitutive interactions with β-arrestins by BRET2, a BRET variant that compared to BRET has a broader 
emission peaks resolution and therefore has a better quality of detection [321]. To this point we 
transfected HEK293 cells to express constant amount of ACKR2 or CCR5 fused to RLuc and increasing 
amounts β-arrestin 1 or β-arrestin 2 fused to GFP2 or free GFP2 to measure non-specific interactions. As 
it can be observed in panel A of Figure 12, energy transfer between ACKR2 and both β-arrestin 1 and β-
arrestin 2 rapidly increases from low ratios of fluorescence over luminescence, meaning that luciferase 
fused to ACKR2 can easily transfer exciting light to β-arrestins-GFP2 also in conditions of poor relative 
abundance of donor protein compared to acceptor. In contrast, in the case of co-transfection of ACKR2-
RLuc with free GFP2, BRET ratio increases linearly due to spontaneous collision between donor and 
acceptor (Figure 12 A), differently from energy transfer occurring between ACKR2-RLuc and β-arrestins-
GFP2, which increases as a hyperbolic function, reaching a plateau at saturating concentrations of 
acceptor. This is indicative of a strong specific constitutive association between ACKR2 and β-arrestins. 
Differently from ACKR2, when CCR5-RLuc association with β-arrestins-GFP2 is investigated, saturation 
curves generated by CCR5-RLuc with β-arrestins-GFP2 do display an hyperbolic behavior ending with a 
plateau, but are poorly separated by the curve generated by CCR5-RLuc and free GFP2 (Figure 12 B), 
meaning that only a minimal association between CCR5 and β-arrestins occurs in basal conditions.  
Figure 12: ACKR2 strongly associates β-arrestins in unstimulated conditions. Saturation binding curves obtained plotting Net 
BRET
2
 values, measured after addition of 5 μM DeepBlueC, as functions of the amount of donor and acceptor molecules 
present in each transfectant, expressed as ratio between GFP
2
 quantification, measured after direct fluorescent excitation, and 
RLuc quantification obtained as measurement of luminescent signal after addition of 5 μM Coelenterazine H. Curves were 
obtained by coexpression of ACKR2-RLuc (A) or CCR5-RLuc (B) together with β-arrestin 1-GFP
2
 (blue circle, ), β-arrestin 2-GFP2 
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(red triangle, ), or free GFP2 (green square, ). Data reported are representative of 1 experiment out of three independent 
replicates. 
 
4.2.2-ACTIVE LIGANDS STIMULATION INCREASES PREFERENTIALLY Β-ARRESTIN 1 RECRUITMENT TO ACKR2 
Activation of CCR5 by agonists results in the modulation of several signaling pathways sustained 
by G proteins and β-arrestins, with the latter that also occupy receptor intracellular domains to block 
further G protein coupling and mediate its internalization through clathrin-dependent endocytosis [86]. 
Conversely, high affinity binding to ACKR2 of many CC inflammatory chemokines does not result in Ca2+ 
fluxes generation and cell migration but in the activation of a β-arrestin-dependent signaling pathway. 
This signaling pathway exploits  β-arrestin 1 to activate the small GTPase Rac1, that activating different 
downstream effectors as PAK1, LIMK1 and inducing Cofilin phosphorylayion controls actin cytoskeleton 
rearrangement, that sustains an increase in receptor expression on the cell surface and improves ACKR2 
scavenging activity [292, 310, 325]. To better elucidate the relationship existing between ACKR2 and β-
arrestins we decided to investigate their association in presence of ACKR2 ligands by BRET, 
overexpressing in HEK293 cells ACKR2-RLuc and  β-arrestins-EYFP by transient transfection. Experiments 
demonstrate that in presence of CCL3L1 the energy transfer between ACKR2-RLuc and β-arrestin 1-EYFP 
rapidly increases compared PBS-stimulated cells, while stimulation of cells expressing ACKR2-RLuc and 
β-arrestin 2-EYFP results in a weak increase of energy transfer (Figure 13 A and C). In contrast, 
stimulation of CCR5 with the same ligand CCL3L1 results in a strong increase in energy transfer between 
CCR5-RLuc with both β-arrestin 1- and β-arrestin 2-EYFP (Figure 13 B and C). These results indicate that 
ACKR2 stimulation with its active ligand CCL3L1 induces preferentially β-arrestin 1 recruitment to 
ACKR2, while in the case of CCR5, CCL3L1 induces comparable recruitment to both β-arrestin 1 and β-
arrestin 2. 
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Figure 13: ACKR2 stimulation with CCL3L1 strongly increases receptor association preferentially with β-arrestin 1. BRET ligand 
effect kinetic curves were generated measuring up to 20 minutes BRET occurring in cells coexpressing ACKR2-RLuc (A) or CCR5-
RLuc (B) together with β-arrestin 1-EYFP () or β-arrestin 2-EYFP (), stimulated with  5 µM coelenterazine H for 8 minutes 
and, prior to beginning luminescence recordings, with PBS or 100nM CCL3L1. Curves are obtained by fitting one phase 
exponential association function to BRET ligand effect plotted as function of time C) Table reports the BRETmax ±SEM values 
obtained by fitting one phase exponential association equation to BRET ligand effect plotted as function of time. Data reported 
are the results from at least 4 independent experiment, in bold are reported BRETmax values statistically different between β-
arrestin 1 and β-arrestin 2 recruitment for each receptor. **=p<0.01 and ***=p<0.001 calculated by two-tailed unpaired 
Student’s t-test comparing the results obtained for each receptor with the two β-arrestins. 
 
Based on the degradative efficiency of the receptor, ACKR2 ligands can be distinguished 
between active ligands (agonists), the ones efficiently degraded by the receptor and able to activate 
ACKR2 signaling activity increasing ACKR2 expression on the plasma membrane, and neutral ligands, 
chemokines that bind ACKR2 with high affinity but are poorly or not degraded, do not activate the 
signaling cascade that leads to cofilin phosphorylation and receptor upregulation [292, 310]. We 
decided  to evaluate the ability of some active and neutral ACKR2 ligands to induce β-arrestins 
recruitment, comparing their activity to CXCL8, a chemokine that does not bind to ACKR2. Stimulation of 
ACKR2 with its neutral ligand CCL3 and its NH2-terminally truncated variant CCL3(-4) or the chemokine 
CXCL8 that does not bind ACKR2 results in BRET ligand effect values oscillating around zero in both β-
arrestin 1 and β-arrestin 2 recruitment assay, where it has been possible to fit one phase exponential 
association curve only to CXCL8 and CCL3, respectively. (Figure 14 C,D and E). On the opposite active 
ligands such as CCL2, CCL4, CCL5 and CCL17 significantly induce energy transfer increase between 
ACKR2-RLuc and β-arrestin 1-EYFP compared to CXCL8 (Figure 14 A,E), while when tested on their ability 
to increase ACKR2 association to β-arrestin 2 all active ligands produce a trend towards the increase of 
BRET signal, but only CCL4 and CCL5 stimulation resulted in significantly different BRETmax, that we had 
to compare to CCL3 due to the inability of the equation to fit a curve to CXCL8 in this assay (Figure 14 
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B,E). These results indicate that active agonists induce an increase in ACKR2 association to β-arrestin 1, 
an effect that occurs better than with β-arrestin 2, and these increases occur only with ACKR2 active 
ligands and not with neutral or irrelevant ligands.  
 
Figure 14: Only active ligands induce an increase in ACKR2 association with β-arrestin 1. BRET ligand effect kinetic curves were 
generated measuring up to 20 minutes BRET occurring in cells co-expressing ACKR2-RLuc together with β-arrestin 1-EYFP (A, C) 
or β-arrestin 2-EYFP (B, D) stimulated with PBS or with 100nM of active ligands (A, B) CCL3L1 (), CCL2 (), CCL4 (), CCL5 
() and CCL17 (); or stimulated with neutral ligands or chemokines not bound by ACKR2 (C, D) as CCL3 (), CCL3(-4) (), 
CXCL8 (). Reported results are the mean of at least 3 independent replicates ±SEM, curves are obtained by fitting one phase 
exponential association equation to BRET ligand effect plotted as function of time. E) Table reports the BRETmax ±SEM values 
obtained and compared by one-way Anova with Dunnett’s multiple comparison test, in bold are reported values statistically 
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different compared to CXCL8 (*) in the case of β-arrestin 1 recruitment assay, and to CCL3 (#) in β-arrestin 2 recruitment assay. 
*,#=p<0.05, **,##=p<0.01 and ***,###=p<0.001. 
 
Even if CCR5 activation induces recruitment of both β-arrestins with only minimal differences in 
terms of magnitude in our assay, our results indicate that stimulation with active ligands increases 
ACKR2 association preferentially to β-arrestin 1. To exclude that observed differences in energy transfer 
magnitude are due to differences in terms of reporter proteins expression, we decided to assay by flow 
cytometry expression of β-arrestins and ACKR2 in parallel with each BRET experiment. We decided to 
quantify proteins expression by flow cytometry instead of assessing EYFP fluorescence and RLuc 
luminescence on plate-reader luminometer since ACKR2 is mainly expressed in intracellular 
compartments and interaction with β-arrestins regulate its subcellular distribution [292, 309, 324], so 
we wanted to avoid differences that can occur in receptor localization after β-arrestins overexpression 
since only receptor molecules present on plasma membrane are accessible to chemokine stimulation. 
Because of this, rather than assessing ACKR2 expression by measuring luminescence arising from RLuc 
that arises also from intracellular ACKR2 molecules, we quantified ACKR2 expression as the ability of an 
antibody directed against hemoagglutinin (HA) tag, expressed by our receptors, to bind to differently 
transfected cells. Therefore receptor expression has been determined on the flow cytometer as cell 
associated fluorescence recorded on the Allophycocyanin (APC) channel thanks to the recognition of 
cell-bound anti-HA antibody generated in mouse of a secondary antibody directed against mouse IgG1 
and conjugated to APC, while β-arrestins-EYFP have been quantified by EYFP fluorescence recorded on 
the FITC channel. Our results indicate that ACKR2 is similarly expressed between β-arrestin 1 and β-
arrestin 2 transfectants, when measuring APC mean fluorescence intensity (MFI) in these cells 
normalized to cells expressing ACKR2-RLuc alone (Figure 15 A), and also β-arrestin 1 and β-arrestin 2-
EYFP have the same relative abundance when normalized to ACKR2 (Figure 15 B), indicating that both 
ACKR2 and β-arrestins expression is similar in both co-transfectants, meaning that differences observed 
in ACKR2 / β-arrestins energy transfer are not dependent on differences in reporter protein expression. 
Different cell types have evolved to exert different functions, therefore can express different 
sets of molecules which regulate specific cellular responses in terms of intracellular signaling and 
phenotype. This differences can be also reflected by differences in the ability of one molecule to activate 
cell responses in different cell types, that depending on the ability of the signaling molecule to couple its 
downstream effectors in determined cell types, can result in a biased signaling defined as system bias 
[84]. Therefore to assess bias downstream a molecule, all the assays have to be performed in the same 
cell type, to avoid insurgency of system bias. HEK293 cells are considered as a model system to study 
intracellular signaling because of their high rate of proliferation, the easiness by which they can be 
transfected, and in the field of chemokine receptors because they endogenously express relevant 
amounts of CXCR4 receptor only, responding only to CXCL12. To be confident that differences observed 
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in HEK293 cells by BRET on ACKR2 recruitment to β-arrestins are not dependent on an intrinsic inability 
of ACKR2 to recruit β-arrestin 2 in HEK293 cellular system, we decided to repeat the experiments of β-
arrestins recruitment to ACKR2 induced by CCL3L1 in the cell line HTR8. This cell line is derived from a 
malignant choriocarcinoma originated from placental trophoblasts, endogenously expressing ACKR2, 
and therefore can represent a system where ACRK2 can find a set of signaling partner more similar to 
the ones it has when endogenously expressed in vivo, compared to HEK293 cells. As it can be observed 
in panel C of Figure 15, in presence of CCL3L1 ACKR2-RLuc preferentially interacts with β-arrestin 1, 
compared to β-arrestin 2, in both the independent replicates we performed, indicating that preferential 
recruitment of β-arrestin 1 to activated ACKR2 is not an artifact dependent on the HEK293 cellular 
system used to assess these interactions. 
Figure 15: Differences between β-arrestin 1 and β-arrestin 2 recruitment by activated ACKR2 are not dependent on reporter 
expression or on the cellular system used for the assay. A-B) Flow cytometric analysis of anti-HA and APC-anti-mouse 
antibodies staining and EYFP-associated fluorescence on HEK293 cells co-transfected with HA-tagged ACKR2-RLuc and empty 
pcDNA3, β-arrestin 1-EYFP or β-arrestin 2-EYFP. Mean results obtained in 4 independent experiments are expressed as fold 
increase in APC mean fluorescence intensity (MFI) over cells co-transfected with HA-ACKR2-RLuc and pcDNA3 (A), or as relative 
β-arrestins-EYFP-dependent FITC fluorescence normalized over anti-HA antibody fluorescence (B). Statistical analysis was 
performed with paired Student’s t-test and gave no significativity. C) Kinetic measure of 100 nM CCL3L1 effect on BRET in HTR8 
cells co-transfected with ACKR2-RLuc and β-arrestin 1-EYFP (, black circle and line) or β-arrestin 2-EYFP (, empty square and 
disconnected line), over 20 minutes. Curves were generated by one-phase exponential association fitting, N=2. 
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Energy transfer techniques as BRET rely on the close proximity between donor and acceptor 
molecules, therefore energy transfer signals are extremely sensitive to distance between reporter 
proteins which, in the quaternary complex of proteins of interest and reporters, is influenced by their 
spatial orientation [321, 326]. Thus we investigated how reporter protein orientation and species-
specificity affects BRET signal between ACKR2 and β-arrestins. To this point we cloned from human 
peripheral blood monocytes cDNA available in the laboratory β-arrestin 1 and β-arrestin 2 sequences in 
pEYFP-N1, pEYFP-C3, pRLuc-N3 and pRLuc-C1 vectors, to generate plasmids encoding for human β-
arrestins fused to EYFP or RLuc by their C- or N-termini that we named hsβ-arrestin (1 or 2)-EYFP, EYFP-
hsβ-arrestin, hsβ-arrestin-RLuc and EYFP-hsβ-arrestin, respectively, to distinguish them from plasmids 
encoding bovine β-arrestins previously used. We also generated plasmids to express ACKR2 and CCR5 
fused by their intracellular C-termini to EYFP by subcloning their sequences from ACKR2-RLuc and CCR5-
RLuc to pEYFP-N1. BRET measurements indicate that the combination of receptors fused to RLuc and 
hsβ-arrestins to EYFP allows to record best increases in BRET signal, compared to the combination of 
receptors fused to EYFP and hsβ-arrestins to RLuc, in cells stimulated with CCL3L1 (Figure 16 A-C versus 
B-D). In particular, for both ACKR2-RLuc and CCR5-RLuc the strongest energy transfer induced by CCL3L1 
can be recorded when RLuc-fused receptors are co-transfected with EYFP-hsβ-arrestins, indicating that, 
compared to EYFP fused to hsβ-arrestin C-terminus, N-terminus-fused EYFP is brought to closer 
proximity to receptor C-terminus-fused RLuc, when β-arrestins are recruited to the receptor (Figure 16 A 
and C). Data indicate that in the case of activated CCR5-RLuc energy transfer occurs with a hierarchy 
that reflects data obtained with bovine β-arrestins-EYFP, with EYFP-hsβ-arrestin 2 that is recruited 
better than EYFP-hsβ-arrestin 1, and following EYFP-hsβ-arrestin 1 is recruited better than hsβ-arrestin 
2-EYFP and hsβ-arrestin 1-EYFP (Figure 16 C). CCL3L1-stimulated ACKR2 instead recruits hsβ-arrestins 
with an energy transfer hierarchy that is EYFP-hsβ-arrestin 1 > hsβ-arrestin 1-EYFP > EYFP-hsβ-arrestin 2 
> hsβ-arrestin 2-EYFP, meaning that, differently from CCR5 and despite EYFP orientation in the ACKR2-β-
arrestin complex, ACKR2 preferentially increases its association to β-arrestin 1 rather than β-arrestin 2 
(Figure 16 A). 
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Figure 16: Energy transfer between ACKR2 and β-arrestin 1 occurs better than with β-arrestin 2 independently of reporter 
orientation. BRET ligand effect kinetic curves were generated measuring up to 20 minutes BRET occurring in cells stimulated 
with 100 nM CCL3L1 co-expressing ACKR2 fused to RLuc or EYFP (A, B) or CCR5-RLuc or EYFP (C, D) together with EYFP-human 
β-arrestin 1 (), human β-arrestin 1-EYFP (), EYFP- human β-arrestin 2 () or human β-arrestin 2-EYFP (). Results are 
expressed as mean ± SEM of three independent replicates with curves were generated by one-phase exponential association 
equation. 
 
4.2.3-ACKR2 IS DIFFERENTLY ASSOCIATED TO BOTH Β-ARRESTIN1 AND Β-ARRESTIN2 IN BASAL CONDITIONS 
To efficiently scavenge inflammatory CC chemokines, ACKR2 exploits its ability to be 
constitutively internalized in Rab5-positive vesicles formed by clathrin-coated pits to reach intracellular 
compartments [312] that occurs in a β-arrestin-dependent manner [309, 324]. From intracellular stores 
ACKR2 is continuosly recycled back on the plasma membrane with Rab4- and Rab11-positive vesicles, 
while chemokines that have been internalized by ACKR2 are driven to degradation [313]. This peculiar 
trafficking affects receptor cellular distribution, in fact ACKR2 is mainly localized in perinuclear 
compartments, with only a minor portion of total molecules distributed on plasma membrane [312]. 
This distribution can be actively altered by ACKR2 upon ligand binding, activating G protein-independent 
and β-arrestin1-dependent signaling that sustains mobilization of intracellular receptor reserve from 
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perinuclear compartments towards cell surface [292]. To better understand our results obtained by 
BRET on cell populations, we decided to deeper investigate whether the differential association of β-
arrestins to ACKR2 can be correlated to ACKR2 trafficking or localization. Therefore, to investigate 
whether this interactions occurred in defined cellular compartments, such as the cell surface or 
intracellular compartments, we decided to monitor interactions of both ACKR2 and CCR5 with β-
arrestins by Image BRET, a technique based on BRET that allows to visualize protein-protein interactions 
in single live cells by a CCD camera-equipped microscope [319].  
For this technique we generated plasmids encoding for bovine β-arrestins fused to RLuc8, a 
Renilla Luciferase engineered to produce a brighter signal compared to wild type RLuc, and we also 
fused ACKR2 and CCR5 sequences to VENUS, a brighter variant of EYFP with comparable spectral 
properties. In HEK293 cells we separately co-transfected plasmids encoding one β-arrestin fused to 
RLuc8 together with ACKR2-Venus, CCR5-Venus or an empty pDsRedMono vector, generating different 
cell lines transiently expressing either a combination of β-arrestin-RLuc8 and a receptor-Venus, or β-
arrestin-RLuc8 with DsRed, a fluorophore irrelevant for the coelenterazine H-based BRET assay. The day 
after transfection, cells were harvested and each combination of cells expressing β-arrestins with 
receptors was mixed 1 to 1 with β-arrestin and DsRed-transfected cells before being seeded onto glass-
bottomed culture dishes and 24 hours later images were acquired. Seeding together cells expressing β-
arrestins-RLuc8 and DsRed together with cells expressing both β-arrestins-RLuc8 and one receptor fused 
to VENUS allows to discriminate on microscope field cells in which is expressed the BRET donor and not 
the acceptor (β-arrestins-RLuc8/DsRed) from cells expressing both the donor and the acceptor (β-
arrestins-RLuc8/receptor-VENUS) by different fluorescence positivity. This allows to measure BRET ratio 
derived from donor emission overflow in the acceptor emission channel or from specific protein-protein 
interactions on the same visual field, at the same time. When we measure in HEK293 cells the 
interaction between ACKR2 and β-arrestins in absence of chemokine stimulation, ACKR2-VENUS strongly 
interacts with both β-arrestin 1- and β-arrestin 2-RLuc8 (Figure 17 A-K and U), as previously shown by 
BRET saturation assay. In particular, while there are only, even if statistically different, minimal 
differences in the localization of ACKR2-VENUS interaction with β-arrestin 2-RLuc8 (Fig. R9 and U), β-
arrestin1-RLuc8 association occurs more prominently with ACKR2-VENUS present at the level of plasma 
membrane (Fig. R9 and U). By Image BRET we can also reproduce data obtained on CCR5 by BRET on cell 
population, in fact we can record a weak energy transfer occurring between β-arrestins-RLuc8 and 
CCR5-VENUS (Fig. R9 I-T and U). 
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Figure 17: Constitutive association of ACKR2 and CCR5 to β-arrestins. Representative images of HEK293 cells co-transfected 
with either ACKR2-Venus and β-arrestin1-RLuc8 (A-E) or β-arrestin2-RLuc8 (F-K), or with CCR5-Venus and β-arrestin1-RLuc8 (I-
O) or β-arrestin2-RLuc8 (P-T). Images were generated acquiring from the same optical field fluorescence filtered for Venus (A, F, 
I, P) and DsRed (B, G, L, Q), or collecting luminescence filtered through the 480/60 nm filter for RLuc (C, H, M, R) and 535/50 
filter for Venus (D, J, N, S). Ratios obtained from Em480 and Em535 images are reported in figures (E, K, O, T), where pixel 
values between 0,3 and 1,2 are pictured as 256 pseudo colors reported on the scale bar. Net BRET obtained by subtraction of 
mean BRET ratios in intracellular or cell surface ROI of DsRed-positive cells from respective mean values measured on Venus-
positive cells are reported in graph (U), and were obtained from at least 10 replicates. **= P<0,01; ***= P<0,001 for values in 
intracellular versus plasma membrane ROI. ###= P<0,001 for values obtained for ACKR2 versus CCR5.  
 
4.2.4-CCL3L1 STIMULATION SELECTIVELY INCREASES ACKR2 ASSOCIATION TO Β-ARRESTIN 1 INDEPENDENTLY ON 
CELLULAR LOCALIZATION 
Since upon agonist stimulation ACKR2 preferentially increases β-arrestin 1 association and is 
rapidly mobilized from intracellular compartments to the plasma membrane [313], while on the 
opposite CCL3L1 stimulation of CCR5 induces its internalization [86], we assessed whether a distinct 
cellular distribution of interactions between ACKR2 or CCR5 and β-arrestins could correlate with these 
opposite behaviors, by monitoring image BRET after ligand stimulation. It can be observed a strong 
increase in ACKR2 interaction with β-arrestin 1 after cell stimulation with the active ligand CCL3L1, and 
in particular this interaction occurrs both inside the cell and on plasma membrane (Figure 18, A and F), 
whereas β-arrestin 2-RLuc8 interaction with ACKR2-VENUS statistically increases rapidly only on plasma 
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membrane, appearing weaker and transient compared to β-arrestin 1 (Figure 18 B and K). On the 
contrary, CCR5-VENUS stimulation with CCL3L1 results in a rapid and strong increase in BRET signals 
with both β-arrestins-RLuc8 (Figure 18 A, B, N and R), with a stronger interaction all over the cells with 
β-arrestin 2 (Figure 18 B and R), while in the case of β-arrestin 1 this increase is statistically relevant on 
the cell surface and shows only a trend in intracellular compartments (Figure 18 A and N). 
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Figure 18: CCL3L1 induces different β-arrestins recruitment to ACKR2 and CCR5. A, B: Graphs reporting the CCL3L1-induced β-
arrestin 1 (A) and β-arrestin 2 (B) recruitment to ACKR2 and CCR5 at different timepoints in intracellular (IC) or on plasma 
membrane (PM) ROI, expressed as increase over unstimulated conditions. C-R: Representative images of transfected HEK293 
cells obtained at different timepoints after stimulation with 100nM CCL3L1. Images of cells expressing ACKR2-VENUS and β-
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arrestin 1-RLuc8 (C-F) or β-arrestin 2-RLuc8 (G-K) or CCR5-VENUS in combination with β-arrestin 1-RLuc8 (I-N) or β-arrestin 2-
RLuc8 (O-R) are reported, with indications of the filter used to acquire luminescent images. Dotted lines define the ROI 
considered for analysis on each cell. *= P<0,05, **= P<0,01 and ***= P<0,001 indicate values statistically different from 
unstimulated conditions (0 min) by two-way Anova with Bonferroni post-hoc test. #= P<0,05, ##= P<0,01 and ###= P<0,001 
indicate differences between BRET signal recorded in IC or PM compartments. 
 
To verify that ACKR2 recruitment of β-arrestins occurrs only after active ligands stimulation as in 
BRET on cell populations, we stimulated cells also with CCL3. As expected, CCL3 does not induce any 
significant change in ACKR2 association to β-arrestins (Figure 19 A, B, F and K). In the case of CCR5, CCL3 
induces preferentially on the plasma membrane a β-arrestin 2 recruitment that is stronger than the one 
with β-arrestin 1 (Figure 19 A, B, N and R), similarly to CCL3L1 stimulation but with less intensity, as 
could be expected by published data indicating that CCL3L1 is a stronger CCR5 agonist compared to 
CCL3 [327]. 
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Figure 19: CCL3 induces β-arrestins recruitment to CCR5 and not to ACKR2. A, B: Graphs reporting the CCL3-induced β-arrestin 
1 (A) and β-arrestin 2 (B) recruitment to ACKR2 and CCR5 at different timepoints in IC or on PM ROI, expressed as increase over 
unstimulated conditions. C-R: Representative images of transfected HEK293 cells obtained at different timepoints after 
stimulation with 100nM CCL3. Images of cells expressing ACKR2-VENUS and β-arrestin 1-RLuc8 (C-F) or β-arrestin 2-RLuc (G-K) 
or CCR5 in combination with β-arrestin 1 (I-N) or β-arrestin 2 (O-R) are reported, with indications of the filter used to acquire 
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images. Dotted lines define the ROI considered for analysis on each cell. *= P<0,05, **= P<0,01 and ***= P<0,001 indicate 
values statistically different from unstimulated conditions (0 min) and ###= P<0,001 indicates differences between BRET signal 
recorded in IC or PM compartments, determined by two-way Anova with Bonferroni post-hoc test. 
 
4.3-ANALYSIS OF ACKR2 SIGNALING BY GLOBAL PHOSPHOPROTEOME ANALYSIS 
The idea that ACKRs are signaling GPCRs rather than decoy chemokine receptors that silently 
contribute to chemokine system activity became consistent only in the last few years. In fact, since their 
characterization, ACKRs have been shown to be unable to activate typical chemokine signaling events 
that are G proteins activation and Ca2+ fluxes generation to promote cell migration, and evidences 
demonstrated that chemokine binding induced certain activity, such as receptor trafficking modification, 
but the formal demonstration of receptor signaling arrived with the observation that ACKR3, the second 
receptor for CXCR4 ligand CXCL12, is able to activate several signaling pathways in a G protein-
independent and β-arrestin-dependent manner [282], and these signaling not only regulate chemokine 
degradation and gradient formation [4] or antagonize CXCR4 activity competing for β-arrestin binding 
[328], but are also involved in tumor cell survival and proliferation [329]. From our results and published 
observations, ACKR2 as well is able to be activated by its agonists, to recruit β-arrestin 1 that mediates 
its signaling for which up to date the only regulated functions are receptor trafficking and ligand 
degradation [292, 313], which explain ACKR2 involvement in different inflammation and tumor models 
only in part or by it chemokine degradative activity [142, 315, 330], and not by its ability to directly 
sustain signaling events. To explore the possibility that ACKR2 can regulate different signaling pathways 
we decided to investigate ACKR2 signaling activity measuring by mass spectrometry after Stable Isotope 
Labeling by Amino acids in Cell colture (SILAC) differences in the phosphoproteome of cells after ACKR2 
expression and stimulation with its agonist CCL3L1; aimed at characterizing not only ACKR2 signaling 
events impacting on different cell functions, but also with the goal to understand differences in signaling 
events underlying a structurally biased receptor. This approach is based on the differential labeling of 
proteins in different samples adding to colture media amino acids with natural carbon and nitrogen or 
with their heavier isotopes, that allow to discriminate protein peptides derived from different sample 
preparations in mass spectrometry, which allows to quantify the abundance of one peptide inside a 
mixture, making possible to compare the amount of one peptide in one sample to another, assessing 
simultaneously the whole cell proteome [331]. When this analysis is performed on peptide fractions 
enriched for phosphorylation the result is a comparison between the phosphorylation status of all the 
peptides (and by bioinformatics all the proteins they belong) present in one sample versus samples 
differently treated [332]. This approach has already been used also to assess the implications of biased 
agonists acting on a GPCR on the global phosphoproteome of cells and compare it to a balanced agonist 
[333] and has also been successfully applied to study CXCR4 signaling events in breast cancer stem cells 
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[334], therefore we decided to look at all the modifications in phosphorylation of the whole proteome 
that can be generated by ACKR2, comparing them to what happens in the case of CCR5 both in a 
constitutive and ligand-induced manner. 
 
4.3.1-ACKR2 AND CCR5 EXPRESSION AND ACTIVATION CAN BE INDUCED IN HEK293 T-REX SYSTEM 
To investigate proteome phosphorylation differences induced by CCL3L1 on ACKR2 and CCR5, 
we had to prepare 100 millions of cells for each experimental condition to generate enough material for 
lysate preparation, protein separation and phosphoprotein enrichment, tryptic digestion of proteins and 
mass spectrometry analysis; therefore we had to use cell lines transfected to express exogenous ACKR2 
and CCR5. To this point we used HEK293 T-Rex, a HEK293 cell line engineered to stably express the 
tetracycline repressor protein, which occupies tetracycline-responsive operons positioned between any 
promoter and its downstream gene, inhibiting gene expression. In presence of tetracycline the repressor 
protein binds tetracycline and releases DNA operon, allowing RNA polymerase to transcript the 
tetracycline regulated gene. To this purpose we subcloned from plasmids already present in the 
laboratory DNA sequences encoding HA-tagged ACKR2 and CCR5 in pcDNA4/To vector, in which 2 
repetitions of tetracycline operator sequence have been positioned immediately downstream the CMV 
promoter sequence and upstream the gene insertion site, to allow constitutive recruitment of 
polymerase on the CMV promoter but gene expression only in response to tetracycline stimulus, that 
induces the dissociation of tetracycline repression when it is present, as in HEK293 T-Rex cells. We 
generated HEK293 T-Rex stably expressing HA-tagged ACKR2 (HEK T-Rex ACKR2) and HA-tagged CCR5 
(HEK T-Rex CCR5) by plasmid transfection and antibiotic selection of cells that incorporated the plasmid 
adding to colture medium 100 μg/ml Zeocin, to whom resistance is conferred by a resistant transgene 
present in pcDNA4/To plasmid. Stable transfectants were maintained as bulk populations, and after 
testing different effective concentrations of tetracycline at different time points (data not shown), we 
decided that induction of receptor expression with 1 μg/ml of tetracycline for 24 hours resulted in 
efficient induction of receptors expression, and began preparing samples for SILAC.  
In detail, we generated 4 different samples for each receptor-transfected cell, to make by SILAC 
3 different paired comparisons, since this kind of analysis is based on the direct and paired comparison 
of differences in quantification of peptides labelled with different isotopes. Our first aim of this analysis 
is to investigate if these two receptor have constitutive signaling activities, therefore to assess which 
signaling events are activated upon receptor expression induction by tetracycline we generated cells 
coltured in light medium, maintained without tetracycline, and compared this condition to cells coltured 
with heavy medium, in which receptor expression was induced by 1 μg/ml tetracycline for 24 hours. We 
also wanted to investigate globar receptor signaling activities after their stimulation with 100 nM 
CCL3L1 at short and long time points, stimulating for 3 or 30 minutes cells coltured with light medium in 
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which receptor expression was induced, comparing their phosphorylation to unstimulated cells 
expressing receptors, labeled with heavy aminoacids. To this point the same populations of HEK T-Rex 
ACKR2 or CCR5 were split to be coltured with mediums additioned with light or heavy amino acids. 
Manipulation of 100 million of cells at once could have represented an issue in terms of homogeneity of 
receptors expression and cells stimulation, therefore we decided to prepare all the samples in 10 
different replicates of 10 million cells each, which have been assessed every time by flow cytometry for 
receptor expression induction and for effective responsiveness to chemokine evaluating by western blot 
the phosphorylation of Cofilin, a signaling pathway that we already described to be activated in ACKR2 
stimulation [292]. As it can be observed in panels D and G of Figure 20, only a minimal percentage of 
HEK293 T-Rex ACKR2 or CCR5 cells coltured in light medium and in absence of tetracycline are positive 
to anti-HA antibody staining, that can be reconduced to signal background or aspecific binding of the 
antibody on cell surface, as occurs on cells stained with an irrelevant mouse IgG1 used as isotype control 
(Figure 20 C). Induction of receptor expression by 24 hours stimulation with 1 μg/ml of tetracycline 
induces expression of HA-tagged ACKR2 or CCR5 in at least 90% of analyzed cells, with only minimal 
differences between cells coltured in light (Figure 20 E,H) and heavy medium (Figure 20 F,I), indicating 
that expression of ACKR2 and CCR5 in HEK293 T-Rex cells has been efficiently achieved prior to 
generating samples for SILAC analysis. To preserve sample quality and avoid loss of protein 
phosphorylation before performing SILAC analysis cells were collected after stimulation as intact cells, 
transferring them to ice, adding ice-cold TBS to block stimulation and centrifuging them to collect the 
cell pellet that has been stored at -80°C before analysis performed by an external service. To collect 
intact cells, we performed stimulation on cells in 1 ml suspension, at 10 million cells/ml concentration 
and incubated for 30 minutes before chemokine stimulation at 37° C, with constant gentle shaking to 
prevent cell precipitation. In detail, we used cells coltured with heavy amino acids and receptor 
expression induced to generate samples representative of basal conditions of stimulation. After sample 
cooling, before centrifugation, 5% of the samples were collected to be lysed and analyze cofilin 
phosphorylation on Ser3 to assess efficacy of CCL3L1 stimulation. Western blots show that on both 
ACKR2 and CCR5 induction minimally affect cofilin phosphorylation compared to cells unstimulated with 
tetracycline, and that stimulation over time with 100 nM CCL3L1 induces an increase in cofilin 
phosphorylation compared to the initial time point (Figure 20 J,K). These results indicate that in the 
samples we prepared, CCL3L1 response is elicited in a comparable manner with respect to what we 
already described in other cellular models [292], therefore their proteome phosphorylation can be 
assayed to generate, at the best of our knowledge, reliable databases to interrogate ACKR2 and CCR5 
biology. 
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Figure 20: ACKR2 and CCR5 are functionally expressed in HEK293 T-Rex cells upon induction with tetracycline. A-I: Flow 
cytometric analysis of receptors expression after anti-HA and APC-anti-mouse antibodies staining of HEK T-Rex ACKR2 and 
CCR5, one experiment is reported as representative of all the experiments performed. A-B: dot plots reporting forward scatter 
height (FSC-H) versus side scatter area (SSC-A) (A) or side scatter width (SSC-W) versus area (SSC-A) fluorescences (B), used to 
discriminate live cells from debris and macroscopic agglomerates and singlets of cells from doublets, respectively. Panels from C 
to I show histograms of APC fluorescence intensity distribution in different cell samples. Panel C reports fluorescence the 
mouse IgG1 antibody stained cells that allows to define P3 gate, which will include all events with higher fluorescence 
considered as positive for HA expression, whose parental percentage of events reported represents the percentage of positive 
cells included in P2, defined as cell singlets. D-F and G-I report APC FI of HEK T-Rex ACKR2 and CCR5 cells, respectively, gated on 
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P2 population, coltured with light (D, E, G, H) or heavy medium (F, I), after 24 incubation with (E, F, H, I) or without (D, G) 1 
μg/ml of tetracycline. In panels J and K are shown representative western blots for HEK T-Rex ACKR2 (J) and CCR5 (K) cells in 
absence and presence of 1 μg/ml tetracycline and after the addition of 100 nM CCL3L1 for the indicated time points, probed 
with anti-phospho-Cofilin (p-Ser3) or anti-Tubulin antibodies. 
 
4.3.2-PHOSPHOPROTEOME ANALYSIS OF ACKR2 AND CCR5 REVEALS CONSTITUTIVE RECEPTOR ACTIVITY 
Sample processing, protein separation and phosphorylated peptide enrichment have been 
performed by an external service cared by professor Gabriella Tedeschi in Fondazione Filarete (Milano, 
Italy), that returned to us databases containing protein fragments identified by mass spectrometry and 
their relative abundance in heavy medium-coltured cells expressing the receptor and unstimulated, 
expressed as fold increase compared to each condition of light medium coltured cells, that are cells 
without receptor expression induction (that will be referred to as basal condition) and cells expressing 
ACKR2 or CCR5 stimulated for 3 or 30 minutes with 100 nM CCL3L1 (referred to as T3 or T30, 
respectively). We here compare the categories of protein modulated differentially and similarly 
between ACKR2 and CCR5 to investigate the possible signaling implications underlying structural 
signaling bias of ACKR2. 
A first level of analysis can be performed evaluating the number and the functional classification 
by gene ontology of proteins whose expression is increased between cells in which receptors expression 
was not induced and cells where receptors where expressed, to evaluate whether expression of these 
molecules can impact on expression levels of other proteins. Among 9858 proteins identified, only 283 
proteins are quantitatively different between cells not induced and induced for receptors expression 
(Figure 21 A), and of proteins differentially expressed only the 1.83% percent is common between 
ACKR2 and CCR5 transfected cells, meaning that these two receptors can modulate expression of 
different proteins. It has to be mentioned that even if the number of different proteins whose 
expression is modulated by the expression of ACKR2 or CCR5 is similar (135 vs 133), and they are 
similarly divided between proteins that are up- and down-regulated (Figure 21 B and C), these proteins 
that change their levels of expression after receptor induction constitute more than 25% percent of total 
proteins identified and specific for ACKR2, while only less than 10% of total proteins identified 
specifically in HEK293 T-Rex CCR5 cells change their level of expression after CCR5 induction (Figure 21 B 
and C). This results indicate that induction of ACKR2 expression induces more important modifications in 
the proteome regulating expression levels of more proteins compared to CCR5.    
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Figure 21: Modifications on protein expression levels modulated by ACKR2 and CCR5 expression. A: Venn diagrams represent 
the amount of total proteins (on the left) and the amount of protein with different abundance (on the right) identified by mass 
spectrometry by ratiometric comparison of signals generated by peptides with heavy amino acids (HEK T-Rex cells treated with 
tetracycline) over peptides with light amino acids (cells untreated with tetracycline). The diagrams show the overlap between 
the two datasets of proteins derived by cells transfected with plasmids encoding tetracycline-inducible ACKR2 and CCR5. Pie 
charts in panel B show the amount of proteins (and their proportion over total identified proteins) not modified (in blue), up-
regulated (in red) and down-regulated (in green) by ACKR2 (on the left) and CCR5 (on the right) expression induction. 
 
We next analyzed if receptor expression can induce modifications of proteome phosphorylation, 
indicative of a consititutive signaling activity of receptors that has already been described to occur in 
chemokine receptors [106, 290, 291]. If prior to SILAC analysis is performed an enrichment of lysate for 
phosphoresidues, by mass spectrometry can be visualized the differences in phosphopeptide abundance 
between the two different conditions discriminated by incorporation of light or heavy amino acids [332]. 
Our analysis detected 3005 phosphopeptides in HEK T-Rex cells induced and not for receptor expression 
by tetracycline, representative of phosphosites belonging to 1238 different proteins (Figure 22 A). Only 
38.77% of proteins has been detected in samples derived from both cell transfectants, and with a minor 
absolute abundance of phosphoproteins in ACKR2-transfected cells (20.19% of all phosphoproteins 
detected) compared to CCR5 (41.03%). Among the proteome detected, only 280 phosphosites belonging 
to 178 different proteins (14.38% of total) are differentially phosphorylated after receptor expression 
induction, and more than 60% out of these phosphorylation events occur only in ACKR2 expressing cells, 
while CCR5 induction specifically activates 30% of these proteins (Figure 22 A). Specifically, tetracycline 
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induction of ACKR2 expression modifies phosphorylation of almost 17% (126 proteins) of the cell 
proteome (Figure 22 C), with most of the phosphosites of these proteins being de-phosporylated (Figure 
22 B), while CCR5 expression changes the phosphorylation status of less than 7% (69 proteins) of the 
proteome specific for each cell type (Figure 22 C). This indicates that ACKR2 can constitutively regulate 
phosphorylation levels of more proteins compared to CCR5. 
 
Figure 22: Changes in proteome phosphorylation levels modulated by ACKR2 and CCR5 expression. A: Venn diagrams 
represent the amount of phosphosites detected (on the left) and the protein to which phosphosytes belong (on the right) and 
their sharing between generated datasets by HEK T-Rex ACKR2 and CCR5 cells. The diagrams show the overlap between the 
two datasets of phosphopeptides and phosphoproteins derived by cells in which receptor expression was induced by 
tetracycline, above are reported all the phosphopeptides and proteins detected and below only peptides who revealed 
differences in phosphorylation after tetracycline stimulation. Pie charts in panel B show the amount of phosphopeptides (and 
their proportion over total identified phosphopeptides) not modified (in blue), up-regulated (in red) and down-regulated (in 
green) found specifically in ACKR2 (on the left) and CCR5 (on the right) datasets obtained after receptor expression induction, 
while panel C shows receptor-specific differences in protein phosphorylation levels. 
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4.3.3-PHOSPHOPROTEOME ANALYSIS OF ACKR2 AND CCR5 AFTER CCL3L1 STIMULATION REVEALS DIFFERENCES IN 
RECEPTOR SIGNALING ACTIVITIES 
To assess how agonist-induced signaling activity of ACKR2 and CCR5 affects proteome 
phosphorylation, indicative of the multiple activation of kinases and downstream effectors, we analyzed 
datasets obtained from cells stimulated for 3 or 30 minutes, representative of immediate and long-term 
responses of agonist stimulation. To this point we analyzed proteome phosphorylation of cells with 
receptor expression was induced and stimulated for 3 or 30 minutes with 100 nM CCL3L1, coltured with 
light amino acids additioned to the medium, comparing them to cells in which receptor expression was 
induced as well but coltured with heavy amino acids and stimulated with agonist-free medium. 
Dataset analysis reveals that only 45% of 932 phosphoproteins analyzed (to which belong 2072 
different peptides detected) can be found in both ACKR2 and CCR5 datasets, and among those proteins 
3 minutes of CCL3L1 stimulation can modify phosphorylation of almost 30% of these proteins, indicating 
that ACKR2 and CCR5 activation leads to a great number of signaling events soon after stimulation 
(Figure 23 A). Among these protein phosphorylation events only a minor proportion is common to the 
two receptors (13,04%), with CCR5 that specifically regulates phosphorylation of more than a half of the 
proteins (51.09%). In detail, the vast majority of these proteins become phosphorylated after CCL3L1 
stimulation, while only about 10% of the modified phosphoproteins are de-phosphorylated (Figure 23 
B), and together these phosphorylation-modified proteins constitute almost 30% of all phosphoproteins 
detected in CCR5 expressing cells (Figure 23 C). Regarding ACKR2 activation, at 3 minutes it is able to 
modulate phosphorylation of about 18% of the phosphoproteins detected in HEK T-Rex ACKR2 cells 
(Figure 23 C), and differently from CCR5 only 60% of modifications are increases in protein 
phosphorylation, while the remaining 40% are events of de-phosphorylation (Figure 23 B), indicating a 
massive activation of phosphatases downstream of ACKR2 rapidly after CCL3L1 stimulation. 
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Figure 23: Proteome phosphorylation changes induced after 3 minutes CCL3L1 stimulation of ACKR2 and CCR5. A: Venn 
diagrams represent the amount of phosphosites detected (on the left) and the protein to which phosphosytes belong (on the 
right) and their sharing between datasets derived from HEK T-Rex ACKR2 and CCR5 cells. The diagrams show the overlap of 
datasets obtained by cells expressing receptors and stimulated with 100 nM CCL3L1, compared to unstimulated cells. Above are 
reported all the phosphopeptides and proteins detected in both the conditions, and below only peptides and proteins who 
revealed differences in phosphorylation after chemokine stimulation. Pie charts in panel B show the amount of 
phosphopeptides (and their proportion over total identified phosphopeptides) not modified (in blue), up-regulated (in red) and 
down-regulated (in green) by CCL3L1 stimulation found only in ACKR2 (on the left) and CCR5 (on the right) datasets, while 
panel C shows receptor-specific differences in protein phosphorylation regulation. 
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Analysis of phosphorylation events induced by receptor at 30 minutes after stimulation, 
indicative of distal downstream effectors, show that at later time points receptor stimulation results in a 
bigger number of phosphorylated proteins detected, compared to 3 minutes stimulation. Among the 
513 phosphoproteins differentially phosphorylated between unstimulated cells and cells stimulated 
with CCL3L1, only 19.49% occur in both ACKR2 and CCR5 datasets (Figure 24 A), while opposite to 3 
minutes stimulation 51.07% of these modifications occur specifically downstream of ACKR2. This is 
reflected by the fact that in ACKR2 dataset 37.47% of proteins are modified compared to basal levels 
(Figure 24 C), among which 25% of phosphosites display higher levels of phosphorylation and 5% are 
less phosphorylated than in basal condition (Figure 24 B). CCR5 has instead approximately the same 
percentage of modulated phosphoproteins that it showed at 3 minutes, but in this case the unbalance 
between phosphosites up and down-regulated is less prominent (11% phosphosites with increased and 
6% with decreased phosphorylation over total phosphosites detected, compared to basal level) (Figure 
24 B). 
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Figure 24: Proteome phosphorylation changes induced after 30 minutes CCL3L1 stimulation of ACKR2 and CCR5. A: Venn 
diagrams represent the amount of phosphosites detected (on the left) and the protein to which phosphosytes belong (on the 
right) and their sharing between datasets derived from HEK T-Rex ACKR2 and CCR5 cells. The diagrams show the overlap of 
datasets obtained by cells expressing receptors and stimulated for 30 minutes with 100 nM CCL3L1, compared to unstimulated 
cells. Above are reported all the phosphopeptides and proteins detected in both the conditions, and below only peptides and 
proteins who revealed differences in phosphorylation after chemokine stimulation. Pie charts in panel B show the amount of 
phosphopeptides (and their proportion over total identified phosphopeptides) not modified (in blue), up-regulated (in red) and 
down-regulated (in green) by CCL3L1 stimulation found only in ACKR2 (on the left) and CCR5 (on the right) datasets, while 
panel C shows receptor-specific differences in protein phosphorylation regulation. 
 
 
Taken together, these results indicate differences between ACKR2 and CCR5 activation in terms 
of kinetics, with CCR5 rapidly mediating changes in protein phosphorylation that are maintaned up to 30 
minutes, that mainly consist in phosphorylation events, while ACKR2 has a delayed kinetic activation, 
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with changes in protein phosphorylation that can increase in time up to doubling at 30 minutes, and 
changes in terms of modification, since a prominent portion of the modifications are residue 
dephosphorylation, indicative of a significant activation of phosphatases and not only of kinases.  
 
4.3.4-GENE ONTOLOGY ANALYSIS OF DATABASES 
To make a general distinction of the functions regulated by ACKR2 and CCR5 signaling events 
elicited upon their expression and activation we performed a gene ontology analysis, to group 
differently phosphorylated proteins between different conditions in classes depending on their 
biological functions. This allowed us to obtain an indications on the biological meaning of receptors 
signaling, identifying functional classes that were more represented in modificated proteins.  
After induction of receptor expression, are modulated proteins involved in the regulation of 
cytoskeleton activity, cell organization and transcription (Figure 25 A). In particular, the most different 
class between ACKR2 and CCR5 is the one involved in the regulation of transcriptional processes. 
Interestingly this class of proteins are most abundantly regulated by both ACKR2 and CCR5 after CCL3L1 
stimulation, but in the case of ACKR2 represent the 68% and 70% of total modified proteins at 3 and 30 
minutes, respectively (Figure 25 B and C), while in the case of CCR5 increase over time going from 53% 
to 65% of total regulated proteins. The second most regulated class is the one including proteins 
involved in cell organization, required to promote cell adaptation functional to cell response. These 
proteins are the double in terms of percentage in CCR5 compared to ACKR2, which may represent the 
reorganization cells incur to support CCR5 induced cell migration. Of notice, there are differences in 
terms of kinetics in regulation of ontology classes, in example in the case of CCR5 proteins associated to 
chemokine receptor signaling belonging to the MAP kinase family are mainly regulated at 3 minutes 
after stimulation, and disappear at 30, while downstream ACKR2 are present as a small percentage after 
3 minutes and increase at 30 minutes after stimulation, possibly underlying a delay in activation of the 
same molecules. In the case of ACKR2 instead a component of signaling functions related to 
macromolecules organization appears at 3 minutes and disappears at 30, possibly indicating an 
undergoing preparation of the signalosome required by ACKR2 to generate stronger signals at later time 
points. 
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Figure 25: Gene ontology of phosphoproteins modulated by ACKR2 and CCR5. Pie charts show the distribution among gene 
ontology classes of differently phosphorylated proteins between datasets analyzed, with datasets generated with HEK T-Rex 
ACKR2 on the left and CCR5 on the right. Panel A shows distribution of regulated proteins between cells in which receptor 
expression was induced and cells where it has not (Basal), in panels B and C are grouped proteins differentially phosphorylated 
in cells stimulated with 100 nM CCL3L1 for 3 minutes (T3, B) or 30 minutes (T30, C) compared to unstimulated cells. Gene 
ontology classes are reported in the legend. 
 
4.3.5-REGULATED KINASE MOTIFS DIFFER BETWEEN ACKR2 AND CCR5 
Trying to understand what are the signaling events more proximal to the receptors, the ones 
regulated upstream all the signaling cascades that regulate cell function, we analized the 
phosphorylation sites regulated in all the conditions, looking at recurring motifs recognized by kinases 
and phosphatases on target proteins, to find possible proteins responsible for ACKR2 or CCR5 distinct 
signaling events. Since phosphorylation domains are not univocally defined but are more addressed by 
conserved residues positions, it could happen that one phosphosite can be recognized by more than one 
kinase or phosphatase, therefore we measured the fold enrichment of each kinase domain in each 
dataset and compared it abundance with the ones found in the corresponding dataset of CCR5 by 
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subtraction, obtaining values representative of kinase motif more abundantly regulated by ACKR2 and 
by CCR5. 
Figure 26: Kinase motifs distribution between ACKR2 and CCR5. Histograms show the distribution of relative enrichment of 
ACKR2 (left) and CCR5 (right) specific kinase motifs in phosphosites modulated in T0 (A, induction of receptor expression by 
tetracycline), T3 (B, 3 minutes stimulation with 100 nM CCL3L1) and T30 (C, 30 minutes stimulation with 100 nM CCL3L1), 
expressed as differences between ACKR2 fold enrichment and CCR5 fold enrichment (ACKR2 F.E.-CCR5 F.E). Motifs were 
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distributed from the left, with motifs more abundant in HEK T-Rex ACKR2 cells, decrease towards right with motifs similarly 
recurring between ACKR2 and CCR5 datasets, and end on the right with motifs more specific for CCR5.  
 
As it can be observed in Figure 26 A, in basal conditions ACKR2 and CCR5 show activation of 
pretty distinct kinases and phosphatases, that regulate proteome phosphorylation acting on different 
motifs between ACKR2 and CCR5, since most of the motifs have a fold increases higher than 1, 
compared to the other receptor, indicating that constitutive receptor activity regulates most of the 
phosphoproteome residues differentially between HEK T-Rex ACKR2 and CCR5 cells. After 3 minutes of 
stimulation with CCL3L1 the distribution of regulated phosphomotifs shows that motifs specifically 
regulated by CCR5 are more abundant than for ACKR2 (Figure 26 B), resembling the differential kinetic 
of phosphosites enrichment observed by signaling activation in Figure 23. Conversely specific 
phosphomotifs tend to converge to the center and be regulated similarly at 30 minutes, possibly 
indicating that even if at 30 minutes can be found most phosphorylated peptides and proteins 
differentially regulated between analyzed conditions (Figures R14, R15 and R16 panels A. 1067 
regulated phosphosites in T30 versus 496 and 280 sites in T3 and T0, respectively), most of the 
differences between ACKR2 and CCR5 occurring in terms of proteome phosphorylation occur at shorter 
timepoints. Interestingly, among kinase motifs specifically regulated by ACKR2 can be found bot in basal 
conditions and after stimulation the β-adrenergic receptor kinase motif and casein kinase 1 and 2 
motifs, possibly indicating strong interactors with ACKR2, mediating receptor signaling in both 
constitutive conditions and after ligand stimulation.  
 
4.4-CXCR1 AND CXCR2 SIGNAL MODULATION BY NONCOMPETITIVE ALLOSTERIC INHIBITORS 
Among inflammatory chemokines, CXCL8 is a ELR+ CXC chemokine whose expression is induced 
by inflammatory stimuli as LPS, TNF-α and IL-1β [335] and exerts its functions recruiting several 
leukocyte populations to inflamed tissues acting on CXCR1 and CXCR2 receptors [3]. In particular these 
two receptors are highly expressed on neutrophils and monocytes, the most important players of innate 
immunity and acute inflammation, regulating their influx in damaged tissues in many models of 
inflammatory diseases, not only during acute inflammation but also in auto-immune diseases, 
transplantation and cancer-related inflammation [10, 11]. Therefore, since chemokine system 
characterization, chemokine receptors as CXCR1 and CXCR2 have been considered an ideal therapeutic 
target to block leukocyte infiltration and inflammation, not only because they are expressed with a cell 
specific pattern and they drive leukocyte recruitment within tissues, but also because of their GPCR 
structure, which allows them to be targeted by orally deliverable small molecules [10, 11]. Over the 
years, many drugs have been developed and described to be specific and effective in vitro on chemokine 
receptors, but only two compounds are actually available on the market, since most of them failed to 
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progress over all the clinical trials, due to adverse side effects as immune deficiency [146] or therapy 
inefficacy due to the complexity and redundancy of the chemokine system, since the same cell can be 
recruited through different overlapping stimuli this system is hard to be tackled by conventional 
pharmacological antagonists [10, 11, 55]. Drug development is now taking into account all the 
possibilities given by biased agonism to generate molecules able to activate only distinct signals and 
activities of a given GPCR. As well drug development addressed to chemokine receptors is considering 
the option of molecules that can bind receptors in their minor hydrophobic binding pocket to allow the 
receptor to bind its ligands reducing the risk of cross activation of other receptors but block chemotaxis 
[11, 145, 147]. In particular, the Italian company Dompé developed small molecules that are allosteric 
inhibitors which have already been shown to block leukocyte infiltration in various models of 
inflammation. These molecules bind to CXCR1 and CXCR2 without displacing CXCL8, that despite binding 
to the receptors no longer mediates its migratory activity [194]. Unfortunately these molecules effects 
on CXCR1 signaling have been investigated only to functional cell aspects, as cell migration or adhesion 
molecules activation, and at the molecular level only by their ability to block GTPγS binding to cell 
membrane, Ca2+ fluxes generation and chemokine binding displacement. To better understand how 
these inhibitors interfere with the conventional CXCR1 signaling activities elicited by CXCL8, and 
whether this better therapeutic efficacy underlies a modulation of receptor signaling towards a biased 
signaling, we decided to investigate different receptor activities induced by CXCL8 on CXCR1 after the 
treatment with Reparixin (DF1681Y), an allosteric modulator that is actually in phase 3 clinical 
evaluation, which has a higher specificity for CXCR1 compared to CXCR2, and DF3053Y, an orthosteric 
inhibitor designed by Dompé that occupies chemokine binding site impeding CXCL8 binding to CXCR1. 
4.4.1-REPARIXIN DOES NOT BLOCK CXCR1 INTERNALIZATION 
To understand the mechanism by which Reparixin blocks cell migration even if allows CXCR1 to 
bind CXCL8, we wondered what macroscopically happens to CXCR1 expressed in HEK293 cells upon 
CXCL8 binding together with Reparixin, measuring CXCL8 ability to induce HA-tagged CXCR1 
internalization over time after stimulation, looking by flow cytometry at cell-associated fluorescence. 
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Figure 27: CXCL8-induced internalization of CXCR1 is not affected by Reparixin. Graphs show variations over time of HA-CXCR1 
expression on HEK293 cells surface after cell stimulation with 100 nM CXCL8, measured by flow cytometry after cell staining 
with a mouse anti-HA antibody and a secondary goat anti-mouse IgG conjugated to APC. Treatment with vehicle (DMSO) is 
plotted with empty squares and thick dotted line (, - -), while concentrations of DF3053Y (A) and Reparixin-DF1681Y (B) are 
represented as follows: 0.1 μM (), 1 μM () and 10 μM (). Variations in fluorescence of each sample are reported as 
percentage of mean cell fluorescence over basal fluorescence at the initial time point of each treatment. Statistical analysis of 
three independent experiments was performed by two-way Anova with Bonferroni post-hoc test, with *=p<0.05, **=p<0.01 
and ***=p<0.001 compared to DMSO-treated cells. 
 
Results indicate that CXCL8 induces a decrease over time in CXCR1 expression on the cells 
surface, as expected, in cells treated with vehicle (DMSO) (Figure 27) and receptor internalization is 
blocked when cells are treated with at least 1 μM DF3053Y (Figure 27 A), that avoid CXCL8 binding and 
activation of CXCR1. This effect is more prominent at 10 μM, which significantly blocks CXCR1 
internalization even at 5 minutes after stimulation. On the contrary, HEK293 CXCR1 cells treatment with 
Reparixin does not block receptor internalization, resulting in a similar behavior of the receptor in cells 
treated with DMSO (Figure 27 B). Apparently Reparixin even induces on CXCR1 a trend to be internalized 
faster, compared to vehicle treatment. 
 
4.4.2-REPARIXIN DOES NOT BLOCK CXCR1 INTERACTION WITH Β-ARRESTINS AFTER AGONIST STIMULATION 
Since CXCR1 is internalized after ligand exposure in a β-arrestin-dependent manner [176], we 
decided to assess the effect of these inhibitors on CXCL8-induced β-arrestin recruitment to CXCR1.  
Our results indicate that the orthosteric inhibitor DF3053Y efficiently blocks β-arrestin recruitment to 
CXCR1 in a dose-dependent manner, since 0.1 μM treatment still allows CXCR1 to partially recruit both 
β-arrestin 1 and 2 (Figure 28 C and D) even if significantly reducing CXCL8 efficacy (Figure 28 A and G), 
but already at 1 μM DF3053Y completely blocks receptor response compared to vehicle-treated cells 
(Figure 28 A, C and D). On the opposite Reparixin did not induce any significant modification to agonist-
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induced β-arrestin interaction with CXCR1, and even at the highest dose there is no reduction in CXCL8 
potency or efficacy (Figure 28 B, E, F and G). 
 
 
 
Figure 28: Effects of Reparixin on CXCL8-induced β-arrestin recruitment to CXCR1. Treatments are indicated as DMSO (, 
black circle), 0.1 μM of drug (, green square), 1 μM of drug (, blue facing down triangle) and 10 μM of drug (, red 
triangle). Prior to each experiment cells were pretreated for 30 minutes with the indicated concentration of inhibitor or the 
corresponding dilution of DMSO. A-B) Measurement of different concentration of inhibitors on dose-response curves of β-
arrestin 2 recruitment to CXCR1 in living HEK293 cells by BRET. Results are expressed as Net BRET calculated subtracting the 
BRET ratio obtained by cells expressing only CXCR1-RLuc preincubated with DMSO and stimulated for 30 minutes with different 
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concentrations of commercial CXCL8, from the BRET ratio obtained from cells co-transfected with CXCR1-RLuc and β-arrestin 2-
EYFP and stimulated for 30 minutes with corresponding concentrations of CXCL8 in presence of vehicle or different 
concentrations of DF3053Y (A) or DF1681Y (B) ±SEM; N=5. C-F) Effect of inhibitors on CXCL8-induced β-arrestin 1 (panel C, E) 
and β-arrestin 2 (panel D, F) recruitment to CXCR1 monitored over 15 minutes time in presence of PBS or 100 nM of CXCL8 
variants and different concentrations of inhibitors or DMSO. One representative experiment out of 3 performed is shown for 
each condition. G) Table reports the mean LogEC50 and BRETmax ±SEM obtained by nonlinear regression curve fitting  in the 
cAMP and β-arrestin 2 recruitment assays, with values statistically different reported in bold, calculated by one-way Anova with 
Dunnett’s multiple comparison with ***=p<0.001 compared to DMSO-treated cells. 
 
4.4.3-REPARIXIN DOES NOT BLOCK CXCR1 ADENYLYL CYCLASE INHIBITION 
Reparixin has already been described as able to block efficently G protein activation, generation 
of Ca2+ fluxes and phosphorylation of focal adhesion kinases on CXCL8-stimulated polymorphonuclear 
leukocytes (PMN) [194]. Given our results indicating that CXCR1 treatment with this inhibitor still results 
in receptor internalization and β-arrestin recruitment after CXCL8 stimulation, we wanted to assess its 
ability to block CXCR1-dependent G protein signaling, therefore we measured the ability of increasing 
concentrations of CXCL8, in presence of different concentrations of Reparixin and DF3053Y, to reduce 
forskolin-induced intracellular cAMP increase in HEK293 CXCR1 cells. 
Our results confirm the inhibitory effect of DF3053Y, that is able to significantly reduce CXCL8 
activity in terms of potency and efficacy, avoiding chemokine binding to CXCR1 (Figure 29 A, D), but also 
show that Reparixin treatment of HEK293 CXCR1 cells is ineffective in blocking adenylyl cyclase 
inhibition by CXCL8 (Figure 29 B, D). This result is unexpected since intracellular cAMP decrease is 
considered to be mainly mediated by α inhibitory subunits of G proteins, whose activation downstream 
CXCL8 stimulation of CXCR1 was demonstrated to be inhibited by Reparixin [194]. This raises open 
questions that require more investigations to confirm the ability to block in HEK293 cells CXCR1 
signaling activities that have already been described in other cell types as PMN, to verify the reliability of 
HEK293 cells to assess Reparixin inhibition of CXCR1 and eventually confirm our data regarding receptor 
internalization and β-arrestin association. 
We performed bias calculation to compare signaling modulation of at least DF3053Y, on which 
inhibition we can rely, to vehicle treated cells and it reported no significant changes in CXCR1 activation 
balance (Figure 29 C). 
Taken together, these results indicate that inhibition of CXCR1 by occupation of its orthosteric 
binding pocket is an effective method to prevent CXCR1 activation by CXCL8 in vitro, while on Reparixin 
we can only say that it does not block CXCL8-induced CXCR1 G protein activation, β-arrestin recruitment 
or internalization in HEK293 cells, pending on the confirmation of inhibitor activity in at least one assay 
already reported in literature to be blocked by this inhibitor.  
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Figure 29: Effects of Reparixin on CXCL8-induced CXCR1 inhibition of forskolin. Treatments with inhibitors are indicated as 
DMSO (, black circle), 0.1 μM of drug (, green square), 1 μM of drug (, blue facing down triangle) and 10 μM of drug (, 
red triangle). A-B) Alphascreen measurement of intracellular cAMP in HEK293 CXCR1 cells pretreated for 30 minutes with the 
indicated concentration of inhibitor before being stimulated with 10 μM forskolin and different concentrations of CXCL8, with 
the result reported as percentage of inhibition of forskolin-induced cAMP increase normalized over DMSO treatment ±SEM; 
N=3. C) Bias plot indicates the ΔΔlog(τ/KA) ±SE for cAMP signaling over β-arrestin 2 recruitment. D) Table reports the mean 
LogEC50 and cAMPmax ±SEM obtained by nonlinear regression curve fitting in the cAMP assay. Values statistically different 
from DMSO-treated cells are reported in bold, with *=p<0.05 and **=p<0.01 calculated by one-way Anova with Dunnett’s 
multiple comparison.  
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Chemokine system is a highly complex system comprising about 50 ligands that can interact 
more or less promiscuously with about 20 chemokine receptors, that inducing cell migration towards 
chemical gradients of chemokines sustain accumulation of cells on which receptors are expressed at 
sites where cognate chemokine is more abundant [1, 5]. Specific cell positioning regulated by 
chemokines is a fundamental process to coordinate different biological functions, among which in adult 
organisms are leukocyte trafficking within peripheral tissues and their homing in lymphoid organs in 
homeostatic conditions [7]. Due to their abundance of expression on leukocytes, chemokine receptors 
also drive immune cells recruitment to inflamed tissues in response to pathological processes [1-5, 7], 
dependent on the fact that chemokines expression is usually induced upon inflammatory stimuli, with 
many different chemokines up-regulated at once to warn about a dangerous situation and recruit 
leukocytes in inflamed tissues to face the offense [1, 7]. This mechanism of chemokine activity 
regulation is generally devoid of stringent control, since most chemokine receptors can be expressed by 
more than one leukocyte, respond to different chemokines and most chemokines can activate more 
than only one receptor, giving rise to a redundant and complex system that can be hardly regulated by 
an on/off mechanism simply based on gene expression [55]. In the case of immune response control, 
misleading signals can result in immune deficiency, for defective leukocyte recruitment to inflamed 
tissues or maintenance of hematopoietic progenitors in bone marrow niches, or on the opposite can 
result in excessive immune response that causes tissue injury, auto-immunity, inflammation related 
diseases and even support cancer development [1, 9-11]. Therefore, given the relevance of chemokine 
system regulation, fine tuning of chemokine activity is exerted at multiple levels, with different steps of 
regulation that determine chemokine fate, modulating their activity and controlling leukocyte 
recruitment to prevent immune system dysregulation [7]. Chemokine activity on target cells is mediated 
by chemokine receptors, that belong to the superfamily of 7 TM GPCRs, and upon chemokine 
recognition receptors undergo a conformational rearrangement that activates heterotrimeric pertussis 
toxin-sensitive Gαi proteins [23, 28, 69, 171] leading to the activation of many intracellular signaling 
events, among which occur also receptor phosphorylation and β-arrestins recruitment, that desensitize 
the receptor, mediate its internalization and simultaneously support the activation of many other 
signaling cascades [74, 336]. A relatively new concept in pharmacology has provided the idea and 
evidences that GPCRs do not act as bimodal switches that shift from an inactive to an active state, but 
they can be activated with different grades to activate in particular circumstances only selected signaling 
pathways and not indiscriminately all the signals they can conventionally elicit, on the basis of which 
agonist they bind, the cellular type in which they are expressed [84] or their structural properties that 
regulate receptor conformation [24, 221]. These evidences have been found to apply also to the 
chemokine system, with receptors like CXCR3, CCR2, CCR5 and CCR7 that can generate different 
responses upon binding of different ligands or by manipulation of their structure [24, 99, 101, 102, 135, 
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136, 221], that impact on their chemotactic ability, inducing a preferential signaling towards signaling 
pathways mainly involved in the regulation of other biological functions of chemokines rather than 
promoting cell migration [77, 114]. To this point one of the aim of this thesis has been to investigate the 
existence of bias signaling in two key components of the chemokine system regulation, post-
translational modifications of chemokines and the regulatory activity of atypical chemokine receptors. 
Post-translational modifications are enzymatic reactions that modify proteins, regulating their 
structure, stability and activity. Several evidences demonstrated that post-translational modification 
naturally occur also on the chemokine system, affecting both receptors [337] and chemokines [226]. In 
particular these enzymes can be released during infection, deriving from bacterial origin to support 
infection establishment interfering with host immune system, but can also be released by immune cells 
of the host itself to achieve pathogen or host pathologic cells degradation and clearance. These enzymes 
act on the most different proteins, among which chemokines, that have been identified in vivo to be 
occurring with post-translational modifications, that can be generated by pathogens or by host response 
to pathogens [226]. Most of the modifications on chemokines are made by proteases, that cleave 
chemokines affecting their biological activity that either reducing it, by chemokine inactivation and 
degradation, or on the opposite increasing it, depending on the chemokine modified and on the 
modifications exerted [16, 226]. In this thesis the attention was focused on the post-translational 
modifications occurring on two ELR+ CXC chemokines, CXCL5 and CXCL8, that acting on CXCR1 and 
CXCR2 constitute an important signal for the activation and recruitment to inflamed sites of neutrophils, 
a key component of innate immune response. Both CXCL5 and CXCL8 can be cleaved by different 
proteases on their NH2-terminus, generating chemokine variants differing in the exposure of their ELR
+ 
motif, fundamental for receptor activation and chemotaxis [186, 226]. Another modification occurring 
on these two chemokines is substitution of NH2-terminal arginine with citrulline, by the removal of the 
imino moiety present on arginine and its replacement with an oxygen. All these modifications have been 
described to appear on CXCL5 and CXCL8 in different immune models and diseases [226]. Proteases 
cleaving CXCL8 and CXCL5 NH2-terminal residues have already been shown to improve their chemotactic 
activity, increasing it in the case of CXCL8 and activating CXCL5 which is a poor chemoattractant in its 
intact form [240, 243-245, 338, 339]. These modification enhance CXCL8 and CXCL5 signaling activity 
measured by induction of Ca2+, increase receptor desensitization and improve chemotaxis both in vitro 
and in vivo, proving themselves as strong regulators of the chemokine system by amplifying chemokine 
activity in the first phases of inflammation, where neutrophils begin to accumulate and release these 
enzymes in inflamed tissue where have been recruited by chemokines, that are modified to recruit more 
and more immune cells at the inflammatory site [226, 228]. Citrullination has been shown to be able to 
generate in the case of CXCL8 a more potent agonist compared to intact CXCL8 in in vitro assays, but in 
vivo, even if it is still able to induce stronger neutrophil mobilization within the blood, it lacks 
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chemotactic ability within the tissue due to its deficient binding to GAGs that retain chemokines close to 
inflamed tissues [340, 341]. In the case of CXCL5, citrullination dampens its activity, reducing CXCL5 
signaling and chemotactic ability. 
In our experiments, aimed at evaluating the ability of these post-translational modification to 
induce CXCL8 and CXCL5 biased agonism, we tested different chemokine variants on their ability to 
activate Gαi proteins and to recruit β-arrestins to CXCR1 and CXCR2. We observed that in the case of 
CXCL8 no bias occurs after chemokine modification, compared to the signaling induced by intact CXCL8 
on both CXCR1 and CXCR2 receptors in HEK293 cells, in terms of selectivity between receptor inhibition 
of adenylyl cyclase and β-arrestins recruitment. Anyway, we have been able to reproduce evidences 
already published on the behavior of these chemokine variants, with truncation of NH2-terminal 
residues that progressively increases chemokine potency in signal activation on both CXCR1 and CXCR2. 
In our hands citrullination of arginine 5 of CXCL8 increases chemokine potency assayed on HEK293 cell 
transfectants, in part different with published data reporting that this modification only affects receptor 
binding [340] and not its signaling properties [341] on neutrophils, possibly due to differences in the 
cellular system. We also evaluated the effects of post-translational modifications acting on CXCL5 NH2-
terminus, recording that these modifications alter chemokine potency, with progressive cleavage that 
increases chemokine potency and citrullination of arginine in position 9 that reduces it signaling ability, 
in agreement with previously published data [245]. We also calculated the ability of these modifications 
to bias CXCL5 agonism, resulting in no reliable data due to the poor ability of CXCL5 to induce β-arrestin 
recruitment to CXCR2 at the concentration we tested, limited by the amount of variants availability and 
partly by the reflection of a biological relevant setting, in which is almost impossible to find elevated 
concentrations of chemokines. Therefore we can only conclude that these modifications for sure 
modulate CXCL5 potency, but their ability to bias CXCL5 signaling have still to be assessed as soon as 
new amounts of different variants will be synthesized. Taken together, these results allow us to 
conclude that NH2-terminal truncation mediated by different proteases acting on both CXCL8 and CXCL5 
increase chemokine activity, while citrullination has divergent effects on CXCL8 and CXCL5, where 
increases and decreases chemokine potency, respectively. Therefore we can say that chemokine system 
regulation by post-translational modifications occurring on CXCL8 do not induce any selective activation 
between G proteins and β-arrestins recruitment on CXCR1 and CXCR2 in HEK293 cells, but only have a 
role in globally regulating chemokine potency. On CXCL5 modifications instead more experimental 
evidences are needed before accounting any effect on functional selectivity, while it can be said that 
truncation and citrullination of CXCL5 NH2-terminal residues act in opposition to modulate chemokine 
activity. 
Chemokine system regulation is mediated also by atypical chemokine receptors, that despite 
sharing conserved sequence and structural homology to chemotactic chemokine receptors [3], possess 
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several differences in structural motifs involved in GPCR conformational change that underlies receptor 
activation and coupling to signal transducers [23, 33, 143] that allows them to regulate the chemokine 
system rather than promoting cell migration. These receptors therefore are thought to have evolved 
from chemokine receptors by modifying structural features important to activate migratory signals into 
motifs that still regulate their activation but induce structurally biased signaling activities that allow 
them to control chemokine functions by transport, present or degrade their ligands in barrier tissues, 
where they are preferentially expressed compared to conventional chemokine receptors [3, 143, 225, 
246, 282, 292, 294]. ACKR2 is one of the most characterized ACKRs and due to its ability to efficiently 
mediate degradation of its ligands, it dampens inflammation and reduces leukocyte recruitment [142]. 
Its activity relies on both a constitutive trafficking, by which ACKR2 is continuously internalized and 
recycled back to the plasma membrane, and on its G protein independent and β-arrestin dependent 
signaling activity, induced after agonist binding to increase receptor recycling rate improving its 
degradative performance [292, 312]. To better elucidate this ACKR2 structurally biased signaling activity 
and to understand the relevance of this bias in the regulation of chemokine system activity, we decided 
to assess different aspects of ACKR2 signaling properties, comparing them to the signals elicited by the 
conventional chemokine receptor CCR5, which mediates chemotaxis upon recognition of many ACKR2 
ligands. Therefore we first assessed the ability of these receptors to interact with β-arrestins and after 
that we investigated the most relevant signaling activities elicited by these receptors in constitutive 
conditions and after chemokine stimulation by quantitative measurement of modifications in the 
phosphorylation status of HEK293 cell transfectants whole proteome. 
Previously published evidences obtained by confocal microscopy, which only allows to measure 
colocalization of proteins, indicated that ACKR2 can drive β-arrestins relocalization in basal conditions, 
and that this association regulates receptor intracellular localization [292, 309, 324]. Our results 
obtained by BRET, that allows to monitor physically interacting molecules, are in agreement with these 
data and indicate that ACKR2 is able to associate both β-arrestin 1 and β-arrestin 2 in basal conditions, 
with β-arrestin 1 preferentially associated to molecules expressed on the cell surface, rather than to 
ACKR2 present in intracellular stores, and this is in contrast to CCR5 that is only weakly associated to β-
arrestins in basal conditions. ACKR2 binds different inflammatory CC chemokines, that are degraded by 
ACKR2 with different efficacy, depending on the presence of a proline in position 2 from the NH2-
terminus of the chemokine, and can be distinguished between active ligands, the ones efficiently 
degraded, and neutral ligands, the ones bound but poorly or not degraded [310]. Active ligands are 
considered as ACKR2 agonists, since we already published our evidences indicating that these active 
ligands induce the activation by ACKR2 of a G protein-independent and β-arrestin 1-dependent signaling 
pathway. This pathway, impacting on Cofilin phosphorylation, regulates actin cytoskeleton 
rearrangement necessary to improve ACKR2 scavenging ability, increasing its recyling rate and its 
5-Discussion 
99 
expression on the cell surface [292, 313]. To link this agonist-induced signaling activity to β-arrestin 
interaction, we assessed by BRET the ability of chemokines to modify ACKR2 association to β-arrestins. 
Our results demonstrate that, regardless of ACKR2 subcellular localization, agonist stimulation induces 
an increase of β-arrestin 1 recruitment to ACKR2, but not of β-arrestin 2, which remains associated to 
the receptor with only minimal differences between agonist and PBS stimulation. Furthermore, this 
ACKR2 preference occurs not only in HEK293 cells but also in a choriocarcinoma cell line originated from 
throphoblasts, that endogenously express ACKR2, indicating that this preferential recruitment of β-
arrestin 1 compared to β-arrestin 2 is a specific characteristic of the receptor and not of cell type used 
for the experiment. On the opposite, CCR5 stimulation induces recruitment of both β-arrestin 1 and 2, 
as previously reported [86, 100], and in our hands this occurs preferentially on the plasma membrane 
after 20 minutes stimulation. These results indicate that agonist-induced β-arrestin recruitment occurs 
differentially between CCR5 and ACKR2, and in the case of CCR5 the association with both β-arrestin 1  
and 2 is initially mainly induced on cell surface and at later time points increases also in the intracellular 
compartments, possibly due to the fact that CCR5 is internalized after ligand exposure, resulting in a 
cytosolic localization of endocytic vesicles in which CCR5 remains associated to β-arrestins. CCL3L1 
stimulation instead increases ACKR2 interactions preferentially with β-arrestin 1, and since these 
proteins regulate receptor trafficking [309, 324], and is β-arrestin 1 the essential regulator of ACKR2 up-
regulation on the plasma membrane in response to active ligands [292], we can speculate that after 
agonist exposure ACKR2 increases its association preferentially to β-arrestin 1 because this protein and 
not β-arrestin 2 may be more suited to associate ACKR2 molecules present in intracellular stores and 
direct their mobilization to plasma membrane. In addition, this preferential increase in ACKR2 
association to β-arrestin 1 occurs only in presence of agonists and not with neutral ligands, meaning that 
ACKR2 is a chemokine receptor structurally biased to signal through β-arrestins and not G proteins, but 
is also biased in the selective association of β-arrestin 1 for modulating its agonist-induced signaling 
activity. To explore the signaling implications of such a great ability of ACKR2 to interact with β-arrestins 
in basal conditions and after ligand stimulation, we decided to analyze the signaling activities that 
ACKR2 regulates and the differences with CCR5-mediated signals, in terms of phosphorylation 
modifications on the whole proteome, assessed by SILAC. Our analysis describes that ACKR2 expression 
is sufficient to modify expression levels of different proteins inside the whole proteome, and to 
modulate their phosphorylation more than occurring after CCR5 expression. In addition, stimulation 
with the same agonist induces in the whole proteome very different changes between CCR5 and ACKR2 
both in terms of activation kinetics, with ACKR2 that is more prone to induce changes in 
phosphorylation at later time points, and signal transducers, since ACKR2 is modulates a significant 
quote of phosphorylations and also dephosphorylations, that in the case of CCR5 represent only a minor 
portion of the modifications. These differences are also reflected by the kinase motifs regulated, 
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indicative of the fact that ACKR2 and CCR5 exploit different kinases to modulate proteome 
phosphorylation, which is reflected by the classification of these modifications by gene ontology, that 
describe ACKR2 as able to induce stronger modulation of proteins whose functions are involved in the 
regulation of transcription and macromolecular complex formation, compared to CCR5. 
These results tell us that signaling activities elicited by ACKR2 are extremely different compared 
to CCR5, in terms of both kinetics of regulation of the same molecules, as MAP kinases, and in the 
regulation of proteins with different functions by the activation of different sets of kinases. Differences 
in functions and association to β-arrestin 1 or β-arrestin 2 have already been reported to occur for other 
GPCRs [342] and also for ACKR3 [281], therefore in our opinion ACKR2 evolved to constitutively interact 
with both β-arrestins, that can eventually regulate its constitutive trafficking ability and support its 
constitutive signaling, but to respond to agonist stimulation ACKR2 is able to increase its association 
preferentially to β-arrestin 1 rather than β-arrestin 2. Up to date, needing a direct experimental 
demonstration, we can only speculate that this preferential association results in the differences we 
observed in proteome phosphorylation, but for sure it is possible that these differences can underlie the 
regulation of different activities downstream ACKR2 regulated by the two β-arrestins. To this point we 
consider that a deeper investigation of ACKR2 signaling activities could help unveiling not only the 
mechanisms involved in chemokine system regulation exerted by ACKRs, but could also improve the 
current knowledge existing on GPCRs and biased signaling, defining ACKR2 as a structurally biased 
receptor that can selectively engage β-arrestins to regulate its functions. 
We consider that a better understanding of the mechanisms underlying biased signaling in 
chemokine receptors, and on how this occurs due to structural modifications in ACKRs, would help drug 
design aimed at targeting the chemokine system, that up to now, despite all the efforts invested, lead 
only to three commercialized drugs targeting the chemokine system [10, 11, 55]. In detail, since in the 
case of ACKRs the lack of G protein activation but the retained interaction with β-arrestins allow these 
receptors to internalize chemokines and dampen inflammation, we tried to characterize the migration 
inhibitory activity of Reparixin, a small molecule inhibitor of CXCR1 that does not inhibit CXCL8 binding 
to the receptor, but prevents leukocytes migration within inflamed tissues in different preclinical model 
of inflammatory diseases [194, 197-199]. This inhibitor showed promising results in advanced clinical 
trials for the prevention of rejection of transplanted pancreatic islets [201]. In particular our aim has 
been to characterize if this promising chemokine receptor drug relies on the modulation of CXCR1 
signaling towards a biased activity, blocking G protein signaling and maintaining β-arrestins  recruitment 
as ACKRs do, mediating chemokine degradation, since it could represent a more effective therapeutic 
approach compared to conventional antagonistic approaches [10, 11, 119]. 
Our results indicate that differently from an ortosteric inhibitor, that preventing CXCL8 binding 
to CXCR1 prevents its activation and signaling on all the functional readouts observed, by binding CXCR1 
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at the level of an allosteric binding site Reparixin allows CXCL8 to induce receptor internalization, β-
arrestins recruitment and adenylyl cyclase inhibition, assessed on HEK293 cells. These results are, at 
least regarding the adenylyl cyclase inhibition, unexpected in our mind and contradictory to what has 
already been published on this inhibitor, since it is able to block G proteins activation in PMN, that are 
considered to be the main responsible for cAMP decrease observed after chemokine receptors 
activation. This results therefore raise different possibilities, the most valuable of which is that this 
inhibitor, assayed on HEK293 cells, is not effective, and therefore the activity of this inhibitor should be 
assayed in our HEK293 cell model reproducing data obtained on other signaling pathways in other cell 
types as PMN, such as GTPγS binding to membrane preparations, focal adhesion kinases activation or 
Ca2+ fluxes generation [194, 343], to verify that HEK293 cells represent a reliable model to study 
allosteric modulators activity. 
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